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Summary
Summary
There is a substantial clinical need for improved therapeutic systems for the treatment 
of arthritis. This thesis concerns the development of a novel medication that is applied 
to the skin directly overlying the areas affected. The system comprises the co-3 
polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA), plus a non-steroidal anti-inflammatory (NSAID) drug. The source of EPA and 
DHA is fish oil which contains high proportions of these compounds and, although still 
largely considered a ‘neutraceutical’, its therapeutic value is supported by an ever 
increasing body o f evidence, both scientific and anecdotal. The NSAID examined was 
ketoprofen, a widely used drug, found in a number o f topical preparations. Synergistic 
action involving the two substances would be expected to provide a multi-faceted attack 
on the aetiology o f arthritis. Ketoprofen and EPA/DHA were successfully delivered 
across full-thickness porcine ear skin in-vitro, although the presence o f thickening agent 
retarded permeation of the latter. The successful delivery o f these compounds into the 
joint capsule o f a porcine forelimb was also demonstrated in-vitro. A novel 
transcutaneous delivery model was developed and used to provide preliminary data for 
the uptake o f EPA into an ex-vivo cartilage ex-plant post transcutaneous permeation. 
The last three chapters can be considered collectively as an investigation into the 
unexpected phenomenon o f enhancement o f EPA/DHA by ketoprofen and two main 
hypotheses were tested; firstly, the formation o f a jt-jc ketoprofen / EPA complex -  the 
existence o f which was strongly supported by the NMR/molecular modelling work of 
Chapter 8 ; secondly, the ketoprofen inhibition o f epidermal enzymes active upon EPA, 
discussed in Chapters 7 and 9. In summary, the development of a novel dual-action, 
transcutaneous anti-arthritic formulation is possible and has been supported by this 
work. Furthermore, a hitherto unknown topical delivery mechanism has been 
elucidated.
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Introduction
Chapter 1 Introduction
1. Overview
There is a substantial clinical need for improved therapeutic systems for the treatment of 
arthritis. This thesis concerns the development of a novel medication that is applied to 
the skin directly overlying the areas affected. The system comprises the co-3 
polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA), plus a non-steroidal anti-inflammatory (NSAID) drug. The source of EPA and 
DHA is fish oil which contains high proportions of these compounds and, although still 
largely considered as a ‘neutraceutical’, its therapeutic value is supported by an ever 
increasing body of evidence, both scientific and anecdotal (Calder, 2006, Curtis et al., 
2004, Fortin et al., 1995). The NSAID examined was ketoprofen, a widely used drug, 
used in a number of topical preparations. Synergistic action involving the two 
substances would be expected to provide a multi-faceted attack on the aetiology of 
arthritis.
1.1 Arthritis
The term arthritis covers many different disease states all associated with inflammation 
of one or more joints. The most common forms of arthritis are rheumatoid arthritis 
(RA) and osteoarthritis (OA). The estimated cost of rheumatoid arthritis alone to the 
National Health Service is £240-600 million per year. The social cost of both diseases 
is also considerable, with significant numbers of patients being unable to work, 
requiring residential home care and having reduced life expectancy (Scott et al., 1998). 
The type of treatment an arthritic patient receives depends on several factors including 
the type of arthritis. Treatment programs can include combinations of rest, exercise, 
methods of protecting the joints and medication.
1.1.1 Rheumatoid Arthritis
Rheumatoid arthritis (RA) is one of the commonest autoimmune diseases. It is a 
chronic, progressive, systemic inflammatory disorder affecting the synovial joints and
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typically producing symmetrical arthritis. If left untreated it leads to joint destruction 
which is ultimately responsible for the deformity and disability seen in this disease.
The prevalence of rheumatoid arthritis is consistent worldwide, affecting about 0.5-1% 
of the population (Buch and Emery, 2002). Although the disease affects people all over 
the world, certain populations exhibit particularly low or high prevalence, for example 
the Inuit population and native Americans respectively. Studies of the Inuit population 
revealed a low incidence of a number of disease states common in Western society, 
including rheumatoid arthritis. This is believed to be linked to their diet and due to their 
high consumption of oily fish (Belch, 1990)
Pain and swelling are the main clinical symptoms seen in the early stages of rheumatoid 
arthritis and are caused by two factors. Firstly, inflammation of the synovium 
membrane that lines the joint capsule, referred to as synovitis, and, secondly, effusion of 
fluid into the cavity of the joint. Disease progression leads to cartilage degradation due 
to lysosomal enzymes and polymorphonuclear leukocytes present in the effusion fluid. 
Sustained inflammation leads to further erosion of cartilage and eventually bone. The 
management of rheumatoid arthritis aims to relieve pain, limit inflammation and 
improve mobility and function.
1.1.2 Osteoarthritis
Osteoarthritis (OA) is the most common disabling condition in the Western world. 
(Aigner et al., 2006) Osteoarthritis is the degeneration of, most commonly, the weight 
bearing joints of the body i.e. hips and knees and is most frequent and symptomatic in 
middle aged and older people. Once a patient has developed OA they will suffer with 
the disease for the rest of their lives with the severity and pain of the condition generally 
becoming progressively worse.
Primary or idiopathic OA occurs in the absence of a known cause of joint degeneration, 
age and general wear on the joints is the primary cause. Less frequently, infection or 
neurological disorders or damage to the joint for example, via mechanical stress, results
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in secondary OA (Buckwalter and Martin, 2006). The World Health Organisation 
(WHO) estimates that 9.6% of the world’s male population and 18% of women over the 
age of 60 suffer from OA. Due to the correlation between age and OA the prevalence 
of the disease is rising as the average age of the population increases (Buckwalter et al., 
2003).
OA can affect any synovial joint although OA rarely occurs in the ankle, wrist, elbow 
and shoulder, however it is common in the hand, foot, knee, spine and hip joints. Of 
these the most common occurrence is in the knee joint. The main clinical symptoms of 
OA are similar to those of RA in that pain and stiffness are usually the symptoms 
experienced at the onset and throughout the disease. These symptoms are caused by 
pathological changes in and around the OA joint. Increased pressure within the joint 
capsule and surrounding bone, inflammation of the synovial lining and alteration in the 
function of the surrounding musculature are some of these changes. Current therapy 
aims to combat the pain caused by OA and in doing so increase the patient’s ability to 
use the joint. There are no proven treatments currently available to slow or stop the 
progression of the disease.
The link between RA and OA lies with inflammation. RA is caused by the body over­
producing inflammatory mediators and OA is potentiated by these same inflammatory 
mediators. If this inflammation could be inhibited then both disease states may be 
treated more effectively. Inflammatory processes must first be examined to allow 
identification of potential inhibitory mechanisms.
1.2 Inflammation
Inflammation is the body’s response to tissue damage by a wide range of harmful 
stimuli, including mechanical trauma, tissue necrosis and infection. The purpose of 
inflammation is to eradicate the damaging agent, initiate repair processes and return the 
damaged tissue to normality. The body’s initial reaction is to increase blood flow to the 
area and to increase permeability across blood capillaries. This allows larger molecules, 
antibodies and cytokines, to cross the endothelial wall and increases the movement of
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leukocytes from the bloodstream into the surrounding tissues. The cells most prevalent 
at the onset of inflammation are granulocytes followed by monocytes / macrophages 
and lymphocytes. These cells are then triggered to produce inflammatory mediators 
which are involved in further processes including pathogen elimination, clearing 
cellular and tissue debris and tissue repair. The inflammation process is an essential 
function of the body and is usually well controlled via negative feedback loops and 
production of compounds which help to terminate the inflammatory process. In certain 
cases however termination does not occur and the inflammation process continues and 
propagates itself in an inflammatory cascade. High levels of cytokines, can lead to 
muscle wastage and bone and tissue loss. These cytokines are also responsible for the 
induction of other pro-inflammatory mediators as discussed below.
1.2.1 Cytokines
Cytokines are a group of proteinaceous signalling compounds that are used extensively 
for inter-cell communication, and are critical to the function of both innate and adaptive 
responses. Produced by a variety of cell types they can exert effects on both nearby 
cells or throughout an organism. The main inflammatory cytokines are detailed in 
section 1 .2 .1 . 1  and 1 .2 . 1 .2 .
1.2.LI Interleukin 1 (IL-1)
The IL family contains two agonists (IL -la  and IL-1 P) and one antagonist (IL-lra). IL- 
ip  is produced in response to injury, infection, or by induction from other cytokines and 
is mainly generated by monocytes and activated macrophages, but can also be generated 
by endothelial cells, fibroblasts and epidermal cells (Horai et al., 1998). IL-1 p is 
important in systemic inflammatory responses and acts synergistically with tumour 
necrosis factor a  (TNF-a). IL-la, which is intracellular and not secreted from cells, and 
IL-1 p have been implicated in the pathogenesis of several diseases including RA, 
inflammatory bowel syndrome, sepsis and several autoimmune diseases. Diseases 
associated with IL-1 may be caused by an imbalance between IL-1 agonists and the 
antagonist IL-lra. IL-1 is responsible for the production of other cytokines, prostanoids
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and nitric oxide, and also regulates extra-cellular matrices and causes cartilage and bone 
resorption (Stylianou and Saklatvala, 1998). IL-1 has also been shown to induce its 
own expression and that of cyclooxygenase-2 (COX-2), a pro-inflammatory mediator, 
in the brain (Horai et al., 1998).
1.2.L2 Tumour necrosis factor (TNF)
Two types of TNF are known to exist namely TNF-a and -(3. The two are structurally 
related but appear to have distinct three-dimensional structures as they differ in their 
sensitivity to various proteases and chemical agents, however, both are potent inducers 
of similar biological responses (Porter, 1990). TNF is responsible for the production of 
many systemic inflammatory responses including fever, mobilization / activation of 
polymorphonuclear leukocytes and induction of both COX-2 and lipoxygenase 
enzymes.
1.2.2 Cyclooxygenase (COX), lipoxygenase (LOX) and eicosanoids
The mechanism for the propagation of inflammation lies with cell membrane-bound 
fatty acids and the formation of eicosanoids: a group of biologically active lipids that 
act as chemical messengers within the immune system. They are synthesised from 
polyunsaturated fatty acids (PUFAs), in particular from arachidonic acid (AA), but also 
from dihomo-ylinolenic acid (DGLA) and eicosapentaenoic acid (EPA). The 
membranes of most immune cells contain large amounts of AA, compared to DGLA 
and EPA. AA therefore, is usually the principal precursor for eicosanoid synthesis. 
Three major classes of eicosanoids are formed from these compounds: prostaglandins 
(PG), formed via the cyclooxygenase (COX) pathway, leukotrienes (LT), produced by 
the lipoxygenase (LOX) pathway (in particular 5-lipoxygenase (5-LOX)) and lipoxins 
(LX), the enzymatic products of 5-, 12-, and 15-LOX. (Penrose, 2006)
There are two iso-forms of the enzyme COX: COX-1 and COX-2. COX-1 is the 
constitutive form and is responsible for regulating homeostatic processes such as 
platelet aggregation and gastric cytoprotection. COX-2 is thought of as the inducible 
iso-form and is involved principally in inflammatory conditions (Solomon, 2006).
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COX-2 is induced by multiple inflammatory stimuli including cytokines such as IL-1 
and TNF-a. Metabolism of AA by COX gives rise to the 2-series prostaglandin, e.g. 
PGE2 . (See Figure 1.1)
ARACHIDONIC
ACID
ICyclo-oxygenase
ENDOPEROXIDE
PGH,
PROSTAGLANDIN PGE2 I PROSTACYCLIN PGI2 
THROMBOXANE TXA2
Figure 1.1 Prostanoid synthesis from AA precursor (Adapted from Calder, 2001))
PGE2 acts synergistically with other inflammatory mediators such as leukotrienes 
(below) to cause hyperalgesia and increase venopermeability (Sperling, 1995). PGE2 is 
produced in rheumatoid synovium where it stimulates osteoclastic (help to break down 
bone) activity and inhibits bone cell proliferation. (Paisz et al., 1993) It has also been 
demonstrated (Abramson and Yazici 2006) that the RA synovium can produce 
approximately ten times the concentration of PGE2 compared to a normal healthy joint, 
indicating the importance of PGE2 in the disease state. Table 1 . 1  indicates some of the 
roles of the prostanoids produced via the COX pathway.
Table 1.1 Prostanoids and the inflammatory process
The Role of Prostanoids in Inflammatory Processes
Prostanoid Effects
p g e 2 Dilates and increases permeability of microvasculature
Hyperalgesia
Pyrogenic
Stimulates osteoclastic activity and bone resorption
Inhibits bone cell proliferation
t x a 2 Bronchoconstricts
Constricts miocrovasculature
p g i2 Vasodilates
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Release of AA from the cell membrane caused by phospholipase A2 can also result in 
the production of LTs catalysed by the 5-LOX enzyme. 5-LOX has been found in 
granulocytes, monocytes, macrophages and mast cells. Metabolism of AA by 5-LOX 
first produces 5-hydroperoxyeicosatetraenoic acid (5-HPETE) which is dehydrated in 
the presence of 5-lipoxygenase activating protein (FLAP) to form leukotriene A4 
(LTA4 ). This in turn is converted to leukotriene B4 (LTB4 ) by LTA4  hydrolase (see 
Figure 1.2). LTB4 is then exported from the cell to exert its inflammatory effects which 
include increased IL-1 and IL - 6  production by monocytes and increased IL-1 p in 
synovial cells. (Lewis et al., 1990) Table 1.2 lists some of the effects of LTs. LTB4 not 
only initiates and amplifies an inflammatory response but may also initiate its own 
production (Devchand et al., 1996) as well as stimulating cytokine release and 
proliferation. LTB4 concentrations have been shown to be in high in the synovial fluid 
and peripheral blood of patients with rheumatoid arthritis.
M em bra** phespfcelipM s
Cytosolic 
phospholipase A2J
A racfcM eaic aeM
15-lipoxygenase /  5-NpoxJgenase 1 lipoxygenase
15-HPETE 5-HPETE FLAP 12-HPETE
1 I I15-lipoxygenase 5 - lipoxygenase -*#—I 12-lipoxygenase
* i
LTA4 12-HETE
LTA4 hydrolase
15-HETE
LTC4 synthase
LTC4 LTB4
Figure 1.2 Leukotriene synthesis from AA precursor (adapted from Penrose, 2006) 
Table 1.2 Effects of LTs on inflammation
Proinflaminatory, Inflammatory and Immunomodulating Effects of Lipoxygenase Products
Lipoxygenase Product Effect
l t b 4 Hyperalgesia
Stimulates monocyte and macrophage IL-1 and TNF-a production
l t c 4 Dilates and increases permeability of microvasculature
15-HETE Hyperalgesia
Inhibits PGH Synthase
15-HPETE Suppresses T lymphocyte function
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1.3 R A  an d  O A  th e rap ie s
Figure 1.3 illustrates the targets for inflammation therapy for the prostanoid pathway 
and the treatments used for those targets. The severity of inflammatory disease dictates 
the treatment, e.g. mild analgesics and complementary therapies such as acupuncture for 
mild cases or artificial joint replacement for more severe cases. Many drugs are 
currently used to treat the symptoms of both RA and OA and the choice depends on the 
stage and severity of the disease. These range from the commonly prescribed non­
steroidal anti-inflammatory drugs (NSAID) such as ibuprofen, to disease modifying 
anti-rheumatic drugs (DMARDs), e.g. methotrexate. For the LT pathway, (1) in Figure
1.3 can be replaced with a LOX inhibitor such as Licofelone which would inhibit the 
production of the inflammatory mediator LTB4 . However, replacement of AA with a 
different fatty acid substrate allows (2) to be a potential target for treatment.
P h y sio lo g ic  stim u lu s
P latele ts, endothelial cells, 
most tissues
A rachidonic acid
I C o n stitu tiv e  
I (C O X -1)
TXA2, PGC, PGE2
P latele ts, kidney, 
endothelium, and 
stomach mucosa
N orm al p h y s io lo g ic  
fu n c tio n s
Inflam m atory stim u lu s
Macrophages, fft>roblasts,
synoviocytes
A rachidonic acid
I Inducible •
^  (C O X -2) •  •
PGE2
I
P ro teases, nitric oxide 
synthase, 
histamine, bradykmin, and 
other mediators
Neutrophils, fibroblasts, 
macrophages, synoviocytes
N orm al p h y sio lo g ic  
fu nct ions
Figure 1.3 Representation o f prostanoid synthesis and potential levels o f inhibition, (1) Aspirin and 
other NSAIDs, (2) Alternative fatty acid substrates, (3) Selective COX-2 inhibitors, (4) Receptor 
antagonists, (5) Nitric oxide synthase inhibitors, antihistam ines (edited from Solom on, 2006)
The following sections cover some of the current treatments used for the symptoms of 
RA and OA and include drug therapies, natural products and supplements.
Chapter 1 Introduction
1.3.1 NSAIDs
NSAIDs are the most commonly prescribed drugs for the treatment of rheumatic 
disease. Table 1.3 lists some of the commonly prescribed NSAIDs which are available 
in a range of formulations including oral, topical and injectable preparations. Their 
pharmacological action lies in their ability to inhibit the COX enzyme (Buchanan, 
1997).
The main limitation to the use of NSAIDs is their side effect profile with 
gastrointestinal toxicity by far the most common adverse effect, although generally of a 
mild degree. Less frequent, but potentially serious, is renal toxicity. Renal 
complications fall into six categories; acute renal failure, interstitial nephritis and 
nephrotic syndrome, papillary necrosis, water retention and hyperkalemia. Acute renal 
failure is the most common renal complication described with NSAID therapy but is 
generally reversible within 24 to 72 hours.
Patients with interstitial nephritis / nephrotic syndrome did not necessarily have any 
former renal disease and by discontinuing NSAID use clinical manifestations are 
usually resolved. This syndrome is usually associated with propionic acid derivatives 
such as ibuprofen and ketoprofen. Sodium retention represents a universal side effect of 
NSAID therapy and essentially all NSAIDs have been implicated. Allergic reactions 
are also associated with the use of NSAIDs and aspirin. The clinicl symptoms can 
include anaphylactic shock, angiodema and types of skin eruptions (Stevenson, 1984). 
Also of significance is the effect of these drugs in asthma patients. A distinct clinical 
syndrome called aspirin-induced asthma can be caused by the use of aspirin and other 
NSAIDs (Szczeklik and Stevenson, 2003) In approximately 10% of asthma sufferers 
this condition can be induced after taking these medications (Szczeklik 1987). Topical 
treatment using NSAIDs can also cause reactions and this is discussed in detail by 
Ophaswongse and Maibach; (1993). Overall, NSAID therapy carries a low incidence of 
significant complications.
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Table 1.3 Com m only prescribed NSAIDs
NSAIDs and usual doses
NSAID Trade Name Usual Oral Dose
Aspirin (acetylsalicylic acid) Multiple 2.4 -  6 g / 24 hours (divided doses)
Ibuprofen Brufen, Nurofen 3.2g /24 hours
Ketoprofen Orudis, Oruvail 75mg three times daily
Diclofenac Voltarol 50 -  75mg twice daily
Celecoxib Celebrex® 1 0 0  -  2 0 0 mg four times daily
Rofecoxib Vioxx® 12.5 -  25mg four times daily
1.3.2 COX-2 inhibitors
The ideal aim for an NSAID would be to inhibit the trauma induced COX-2 enzyme and 
thus decrease inflammation, whilst having very little or no effect upon the constitutive 
COX-1 enzyme and normal physiological processes. Such a compound would 
maximize efficacy, without the associated toxicity, in particular, gastroduodenal 
erosions and renal effects. Two such selective COX-2 inhibitors, celecoxib 
(Celebrex®) and rofecoxib (Vioxx®) received approval from the Food and Drug 
Administration (FDA) in the United States. Both were approved for use in RA and OA. 
The selective COX-2 inhibitors demonstrate at least a 200 to 300-fold selectivity for 
inhibition of COX-2 over COX-1 at the defined therapeutic doses. Studies have shown 
that they are comparable to non specific NSAIDs in their analgesic effect for both RA 
and OA without the unwanted gastroduodenal toxicity (Emery et al., 1999; Silverstein 
et al., 2000). However, rofecoxib was recently withdrawn worldwide by the 
manufacturer due to an increased risk of adverse cardiovascular events. Celecoxib was 
also withdrawn for similar reasons.
1.3.3 Disease modifying anti-rheumatic drugs (DMARDs)
The class of drugs known as DMARDs, yield their action in their ability to affect the 
immune system and so stop disease progression. Generally these drugs are effective, 
but they take time to show positive results. For example, hydroxychloroquine
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(.Plaquenil™), used mainly in psoriatic arthritis, may take three or four months before a 
patient notices a significant effect. Other drugs, such as methotrexate, work more 
quickly, but often not quickly enough if the patient is suffering severe pain. For this 
reason, physicians often prescribe an additional drug such as an NSAID to help control 
pain and inflammation while the DMARD starts to work. DMARDs are most 
commonly used for RA, but some of the drugs are also used for juvenile RA, ankylosing 
spondylitis, psoriatic arthritis and lupus. The dosages of these drugs range from 200- 
600mg per day for hydroxychlorquine up to 7.5-20mg per week for methotrexate, 
usually given as one dose either orally or via injection. However depending on the 
specific condition and other factors including age, body weight and other medications, 
the dosages may vary.
1.3.4 Natural products
A number of natural products have received attention, all claiming to ease the pain of 
RA and OA and even in some cases stop the progression of the disease. Listed here are 
some of the more widely used natural products currently available.
1.3.4.1 Capsaicin
Capsaicin, Figure 1.4, is the active compound found in hot chilli pepper and is 
administered via a topical formulation. It exerts its biological effect by retarding the 
release of substance P, a polypeptide involved in the transmission of pain impulses from 
peripheral receptors to the central nervous system, from unmyelinated C nerve fibres. 
(Winter et al., 1995)
,CH>
HO-
H>C
Figure 1.4 Capsaicin structure
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The efficacy of capsaicin was assessed in a randomized, double-blind, placebo- 
controlled trial where both RA and OA patients demonstrated mean pain reduction of 
57 and 33% respectively after four weeks treatment with a 0.0025% topical capsaicin 
formulation. Side effects reported were local irritation (burning, stinging, and erythema) 
which occurred in approximately 40% of patients. (Deal et al., 1991) The efficacy of 
this capsaicin formulation appeared good, however this study involved an application of 
the formulation four times daily. This would prove very expensive for patients for long 
term use and patient compliance would also be difficult to obtain.
1.3.4.2 Glucosamine and chondroilin
Glucosamine is an amino sugar which is a pre-cursor to proteoglycan which in turn is a 
major component of cartilage (Figure 1.5). Glucosamine is important for the repair and 
maintenance of cartilage and is usually delivered orally as the sulphate or chloride salt. 
It has been suggested from animal model studies that glucosamine sulphate may slow 
cartilage breakdown through the stimulation of cartilage to synthesize 
glycosaminoglycans (GAGs) and proteoglycans, and the inhibition of proteolytic 
enzymes (McAlindon et al., 2000).
OHOH
NH
Figure 1.5 Glucosamine structure
Oral glucosamine is an increasingly popular supplement for the symptoms of OA. 
Some patients have reported glucosamine having a greater pain reducing effect in knee 
OA than NSAIDs (Dodge and Poole, 1989). Several studies have concluded that the 
addition of glucosamine into a cartilage culture system led to less matrix 
metalloproteinase (MMP) and aggrecanase activity within the cartilage extra-cellular
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matrix (ECM). Both compounds cause breakdown of the ECM and further destruction 
of the cartilage (Poole, 1993). Cartilage degradation is discussed in detail in Chapter 6 . 
However, promising as these results seem, the experiments were carried out ex -vivo and 
glucosamine is intrinsically difficult to deliver to joints due to its poor bioavailability 
from oral dosing. Persiani et al., (2005) found that an oral dose of 3000mg glucosamine 
sulphate only increased blood plasma levels by approximately 250ng ml' 1 from baseline 
plasma levels. Studies have also revealed that the reported benefit in joint space 
narrowing is only limited and may have been due to overall pain relief and thus use of 
the affected joint (Reginster et al., 2001). A patch form of glucosamine is also available 
but with un-reported value.
Chondroitin sulphate (CS), (Figure 1.6), is a major structural component of the cartilage 
and is composed of repeating units of galactosamine sulfate and glucuronic acid. It is 
the predominant glycosaminoglycan found in articular cartilage. Chondroitin is 
believed to help stimulate the production of new healthy cartilage, block enzymes that 
break down cartilage, and normalize joint fluids to reduce friction. Oral availability of 
this compound is once again poor (Volpi, 2002) relying on intra-articular (into the joint) 
administration to ensure delivery to the site of action.
coo*
OH
Figure 1.6 A Chondroitin Sulphate sub-unit
A 2000 meta-analysis involving 7 studies compared the pain relieving effects of CS 
with those of a placebo and found it to be significantly more effective. However 
patients were still allowed analgesic and anti-inflammatory medications and no dose 
effect of CS was observed (Leeb et al., 2000). It was also found that the efficacy of 
chondroitin sulphate was similar to that of glucosamine. Chondroitin sulphate used 
alone appears to provide little benefit among those with osteoarthritis. There is a
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possibility that it is more effective when used in combination with glucosamine in those 
with more severe pain. However, the glucosamine/chondroitin arthritis intervention 
trial (GAIT) did not show glucosamine and CS to be significantly more efficacious than 
placebo for pain relief or functional improvement in patients with OA of the knee.
1.3.4.3 Hyaluronans /Hyaluronic Acid
Several studies have examined the effects of intra-articular hyaluronans in OA. 
Hyaluronan is a form of glycosaminoglycan (GAG) and one of the primary components 
of cartilage ECM. It is thought that intra-articular injections of hyaluronans can lead to 
decreased OA symptoms as these compounds are deficient in degenerating cartilage. 
Replacement of these missing hyaluronans leads to their beneficial effect. Commercial 
hyaluronan formulations are currently available in the US. The main limitation with 
this form of treatment comes from the patient as intra-articular injections can prove 
painful and lead to infection.
A 2003 meta-analysis examined the results of 22 trials of hyaluronan injections 
compared to intra-articular placebo injections. It concluded that hyaluronan injections 
were more beneficial than the placebo but had a relatively small effect (Lo et al., 2003). 
A similar study in 1998 compared the effects of hyaluronans with placebo and oral 
naproxen. They found the hyaluronans improved the symptoms of knee pain compared 
to placebo but found no significant difference against naproxen (Altman and 
Moskowitz, 1998).
In summary, the available evidence suggests that intra-articular hyaluronans have a 
small pain relieving advantage when compared to intra-articular placebo injections with 
little or no advantage over oral NSAID therapy.
1.3.4.4 Polyunsaturated fatty acids (PUFAs)
A polyunsaturated fatty acid is a carboxylic acid with a hydrocarbon chain of 4-36 
carbons with multiple regions of unsaturation, i.e. double bonds. Three fatty acids
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bonded as esters to a glycerol backbone form a triglyceride, and the hydrolysis of this 
triglyceride yields free fatty acids. The triglyceride can contain the same or a mix of 
fatty acids. Fatty acids are the main constituent of cell membranes and different types 
of fatty acids including saturated, mono or poly-unsaturated exhibit different 
characteristics when bound in cell membranes. Several fatty acids are classed as 
essential (see section 1.3.4.4.2) because the human body cannot produce them and they 
must therefore be obtained from the diet.
1.3.4.4.1 Nomenclature ofpolyunsaturated fatty acids (PUFAs)
Fatty acids have systematic names but most also have trivial names and are described 
by a standard shorthand nomenclature (British Nutrition Foundation, 1992 and 1999) 
This nomenclature indicates the number of carbon atoms in the chain, the number of 
double bonds in the chain and the position of the first double bond from the methyl 
terminus. There are rules regarding the position of double bonds in unsaturated fatty 
acids; these are determined by the specificity of the enzymes that insert those bonds into 
the hydrocarbon chain. It is the position of the first double bond in the hydrocarbon 
chain which is indicated by the n-7, n-6, part of the shorthand notation for a fatty acid. 
An n-3 fatty acid, therefore has the first double bond on the third carbon from the 
methyl terminus. Another notation replaces the n with the Greek letter co (omega) as 
this is the last letter of the Greek alphabet, it is indicative of the last carbon in the chain, 
thus co-3 notates a fatty acid with the first double bond three carbons from the methyl 
terminus. This is illustrated in Figure 1.7 below.
0
Figure 1.7 EPA -  cis- 5 ,8 ,1 1 ,1 4 ,17-eicosapentaenoic acid (20:5/1-5)
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1.3.4.4.2 Biosynthesis ofpolyunsaturated fatty acids
Saturated fatty acids and most monounsaturated fatty acids can be biosynthesised in 
mammalian tissues from non-fat precursors like glucose or amino acids, but this does 
not usually occur in humans eating a Western diet since the consumption of fat in 
general, and of saturated and monounsaturated fatty acids in particular, is high. 
Mammals cannot convert oleic acid (OAc) (18:1h-9) into linoleic acid (LA) (18:2«-6) 
as mammals are unable to chemically introduce double bonds before the ninth carbon in 
OAc. The enzyme responsible for this, A12-desaturase is found only in plants. 
Similarly, the conversion of LA to a-linolenic acid (ALNA) carried out by the A15-  
desaturase enzyme, also responsible for the interconversion of n- 6  and n-3 fatty acids, 
can only be achieved by plants, as shown in Figure 1.8. As these fatty acids cannot be 
made by mammals, they are deemed essential. Table 1.4 lists some of the most 
prevalent fatty acids.
Table 1.4 Common fatty acids
Carbon notation Common Name
12 Laurie acid
16 Palmitic acid
18 Stearic acid
18:2 Linoleic acid
18:3 Linolenic acid
20:4 Arachidonic acid
20:5 Eicosapentaenoic acid
22:6 Docosahexaenoic acid
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18:l«-9
]
A1 2 -desaturase
f
Al 5-desaturase
18:2/7-6 ------------------- ► 18:3/7-3
Figure 1.8 Plant metabolism of oleic acid
Once consumed in the diet LA can be converted via y-linolenic (GLA 18:3/?-6) and 
DGLA; 2 0 :3 /7 - 6  acids to arachidonic acid AA; 2 0 :4 /7-6 . Using the same pathway 
dietary ALNA can be converted into EPA; 2 0 :5 /7 - 3  and then to DHA; 2 2 :6 /7-3 , but this 
process is inefficient in the physiology of the Western society. Many marine plants also 
carry out fatty acid carbon chain elongation, and further desaturation of ALNA to 
produce EPA and DHA. It is the formation of these long chain n-3 PUFAs by marine 
algae and their transfer through the food chain that accounts for their abundance in the 
tissues of some marine mammals and fish (e.g. herring, tuna and mackerel; known as 
“oily fish”). EPA and DHA are found in relatively high proportions in the commercial 
products known as “fish oils” which are a preparation of the body oils of cold water fish 
e.g. salmon and tuna. EPA and DHA are also found in high proportions in the oils 
extracted from the livers of other species of fish which live in warmer waters e.g. cod 
(Calder, 2001).
1.4 Fish oil and inflammation
With increased bioavailability of EPA and DHA the production of the 2-series PGs and 
the 4-series LTs from AA is diminished as cell membranes incorporate a larger 
proportion of these fatty acids at the expense of AA. As a result the severity of the 
inflammatory response is modulated as EPA and DHA also act as substrates for COX 
and LOX enzymes and produce a different class of PGs and LTs (Figure 1.9). The 3- 
series PGs and the 5-series LTs are comparably less potent than their AA relatives. It 
has been found by Goldman et al., (1983) that LTB5 is 10 to 100 fold less potent as a 
neutrophil chemotactic agent than the equivalent LTB4 . Similarly, prostaglandin E3
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(PGE3) has been shown to be a less potent inhibitor of COX-2 gene expression in 
fibroblasts and of IL- 6  production by macrophages compared to PGE2 (Calder, 2006).
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Figure 1.9 Prostanoid and leukotriene synthesis from EPA
Long chain n-3 PUFAs have also been shown to effect the synthesis of inflammatory 
cytokines. The mechanism of this is thought to lie with the reduction of the cytokine 
regulating PGE2 and 4-series LTs. Cell studies have demonstrated that both EPA and 
DHA can inhibit the production of TNF-a and IL-ip by monocytes (Calder, 2006). 
Several studies have also shown EPA and DHA to inhibit the expression of COX-2, IL- 
la , IL-ip, TNF-a, 5-LOX, 5-LOX activating protein and MMP genes in OA cartilage 
cultures and bovine chondrocytes (Curtis et al., 2000). Figure 1.10 is a summary of the 
differences between the products of AA and EPA via the COX and LOX inflammatory 
pathways.
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Figure 1.10 Summary of COX and LOX mediated metabolism of AA and EPA (Adapted form 
Shapiro, 2003)
1.5 Delivery of fish oil into the body
Several studies have been carried out concerning the effect of an EPA enriched diet on 
the symptoms and progression of RA and OA. James et al. (2000), showed that after 4 
weeks of 9 g day' 1 fish oil supplementation both the TNF-a and IL-1 p concentrations 
within human peripheral blood mononuclear cells were significantly reduced. Marsen 
et al. (1992), found a concentration of 19.9 ±3 .3  mg L*1 in plasma after 28 days after 
receiving a 12g day' 1 fish oil formulation. A different study by Fortin et al. (1995) 
looked at the efficacy of fish oil in relation to joint tenderness and morning stiffness 
associated with rheumatoid arthritis. This study concluded “a statistically significant 
improvement in tender joint count and morning stiffness” in those treated for three 
months with fish oil compared to a placebo. All studies carried out involve the patient 
taking approximately 3-12g day'1, a large dose to achieve a relatively low plasma 
concentration. If EPA could be delivered straight to the site of action i.e. the joint, it 
would eliminate the need for such high oral doses.
Drug delivery into the body is a fundamental research area in the pharmaceutical 
industry. Most drugs are administered orally or intravenously and enter the systemic 
circulation to exert their activity after transport to their site of action. Some drugs
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however are not suited to this form of delivery, either due to the high metabolic activity 
and consequential breakdown within the stomach or liver (first pass effect) or due to 
their incompatibility with the oral route of administration. The concentration of a drug 
within the body is also of importance as when an oral dose is given there is an initial 
increase in the plasma concentration and these peaks can cause undesirable effects. 
Troughs associated with this dosing, post administration, may be sub therapeutic. Pulse 
dosing (see Figure 1.11) is common with oral drug delivery but can be avoided by the 
delivery of drugs via the skin.
trans dermal 
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♦ TD offers: consistent dosing, no peaks or troughs 
Figure 1.11 Pulse effect o f oral dosing
Localised topical delivery has several advantages over other routes. It allows specific 
targeting of drugs to their site of action and minimises the side effects that can be seen 
after oral administration and reduces the frequency of dosing. This is particularly 
beneficial in diseases such as RA and OA as the pain and inflammation associated with 
the diseases are localised at individual joints. Topical drug delivery ensures that the 
drug enters the systemic circulation directly, eliminating the first pass metabolism of the 
liver. Direct delivery of both an anti-inflammatory drug and an alternate fatty acid 
substrate to compete with AA, to the site of the inflammation would provide a two­
pronged attack on the inflammatory mediators and thus progression of RA and OA. 
With the combination of an NSAID and alternate fatty acid substrate both the main 
inflammatory mechanisms will be modulated and lead to a diminished inflammatory 
response. While the NSAID acts on the COX pathway the fatty acid can also act on the
21
Chapter 1 Introduction
COX and LOX pathways as well as inhibiting further inflammatory cytokines and 
mediators from being expressed by relevant cells.
The action of applying a topical formulation also has its benefits, primarily the 
psychological effect of applying a treatment to the site where pain is felt and the 
rubbing action when applying the formulation may help absorption of the drug into the 
skin. Particularly in arthritic conditions the massaging of the affected area has the effect 
of increasing blood flow, thus providing warmth and a soothing feeling during 
application. Many elderly patients are now subject to taking large quantities of oral 
medications and are averse to the constant swallowing of tablets / capsules. Combining 
this with the soothing effect of massaging, many patients would prefer to apply a 
medication to an arthritic joint as opposed to taking further oral medication.
Drug delivery through skin is not simplistic and many considerations must first be taken 
into account concerning the barrier function of skin and possible delivery mode of the 
chosen compounds.
1.6 The structure and function of the skin
Skin is a complex organ that has many functions including protection; a barrier to 
physical and biological threats from the external environment as well as ultra violet 
(UV) light and the regulation of water loss, body temperature and synthesis of vitamin 
D with UV absorption. The heaviest organ of the body, the skin comprises 
approximately 16% of total body weight, is in constant regeneration and is 
metabolically active in its immunological and histological response to trauma 
(Williams, 2003). The skin is composed of three histologically distinct layers known as 
the epidermis, dermis and hypodermis or subcutaneous tissue layer (see Figure 1.12).
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Figure 1.12 Diagram m atic representation o f the skin structure (Am erican M edical Association, 
1998)
1.6.1 The hypodermis (subcutaneous layer)
The hypodermis is the bridge between the dermis and underlying body constituents (its 
principal function is body insulation and resistance to mechanical shock). This layer of 
adipose tissue provides the body with readily available energy-providing molecules and 
carries the principal blood vessels and nerves to the skin. (Williams, 2003)
1.6.2 The dermis
The dermis is the major component of skin at 3-5mm thick. The hydrophilic nature of 
the dermis, composed of a network of collagen fibrils and elastic tissue embedded in a 
mucopolysaccharide gel (Williams, 2003), poses the minimal barrier to hydrophilic 
compounds but may limit the permeation of lipophilic molecules such as fatty acids / 
triglycerides to a higher degree. The dermis lies below the epidermis and contains 
sweat glands, hair follicles, lymphatic vessels, nerve endings, and blood capillaries.
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1.6.3 The viable epidermis
This is the live epithelial tissue overlying the dermis and can itself be divided into 
distinct sections and can differ in thickness from 0.06 mm on the eyes to 0.08 mm on 
the palms and soles of the hands and feet. The epidermis is devoid of blood vessels and 
all nutrients are obtained from the underlying dermis via passive diffusion through the 
dermo-epidermal layer (Figure 1.13). Similarly waste products and permeating 
compounds must diffuse through the epidermis and cross the dermo-epidermal layer 
before being taken into the systemic circulation or permeating to deeper regions (Elias, 
1989).
¥Dermis
E p id e rm is
Figure 1.13 Skin section highlighting derm is, epiderm is, derm o-epiderm al layer (DE) and stratum  
corneum (SC)
The epidermis is made up of four histologically distinct layers: the stratum basale (the 
layer closest to the dermis), stratum spinosum, stratum granulosum, with the uppermost 
layer comprising of the stratum lucidum the stratum corneum (outermost layer). These 
last layers can generally be thought of as one layer as the stratum lucidum is thought of 
as the first layer of the stratum corneum. The main cells present in the epidermis are 
keratinocytes and these cells differentiate as they progress from the basal layer to the 
SC where they terminally differentiate to dead comeocytes.
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1,6.3A Enzyme activity of the viable epidermis
The enzyme activity within the viable epidermis has been estimated at approximately 
<10% of the specific enzymes found in the liver (Hotchkiss, 1998). Nevertheless 
metabolism of compounds permeating the skin does take place. For example Mavon et 
al. (2004) reported that 20% of the applied dose of 8 -tocopherol glucoside was 
bioconverted to free tocopherol. Miller and Ziboh, (1988) found that the human 
epidermis metabolised EPA to 15-hydroxyeicosapentaenoic acid via the 15-LOX 
pathway. It is therefore important to consider the possible metabolism when delivering 
drugs through the skin. In many permeation experiments the skin membrane used has 
been frozen / stored for some period. This may not have been found to effect the 
permeation rates of certain compounds (Sintov and Botner, 2006), but little 
investigation to the enzyme viability of the frozen skin has been undertaken. The 
viability of the skin during permeation process is studied in Chapter 7; Chapter 9 
investigates the action of EPA and ketoprofen on two epidermal enzymes associated 
with inflammation, namely COX-2 and LOX.
1.6.3.2 Stratum basale (basal layer)
The basal layer represents the most metabolically active layer of the epidermis. It 
contains typical organelles such as mitochondria and ribosomes as found in other tissues 
in the body. The keratinocytes present in the basal layer are the only cells within the 
epidermis that undergo continual mitosis. Half of these cells progress upwards to 
differentiate while the other half remain behind to continue mitosis. The keratinocytes 
present in the basal layer also produce pro-inflammatory cytokines such as IL-1. The 
basal layer also contains melanocytes which produce the pigment melanin. This is 
transferred to keratinocytes and eventually reaches the SC where they are uniformly 
distributed to form a UV absorbing cover reducing the UV absorption deeper into the 
skin. Other cells present in the basal layer include, Langerhans cells, the major antigen- 
presenting cells of the skin, and the Merkel cell, associated with nerve endings beneath 
the dermis they are found in greater numbers in touch-sensitive areas of the body 
(Williams, 2003).
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1.6.3.3 Stratum spinosum
In this layer of the skin the shape of the keratinocytes begins to change from columnar 
to polygonal and this represents the earliest stage of comification. The synthesis of 
keratins, that aggregate and eventually form desmosomes which connect the cell 
membranes of adjacent keratinocytes, are formed by the evolving cells. The 
desmosomes are responsible for the maintenance of an approximately 2 0 nm distance 
between the keratinocytes.
1.6.3.4 Stratum granulosum
Here the keratinocytes begin to mature further and membrane-coating granules are 
synthesised which form the precursors for the inter-cellular lipid lamellae seen in the 
SC.
1.6.3 The stratum corneum (SC)
The SC is the outermost layer of the skin and is a between 10 and 20 pm thick, 
consisting of terminally differentiated keratinocytes, now referred to as comeocytes, 2 0  
to 40 pm long and approximately 0.5 pm thick (Schaefer and Redelmeier 1996). The 
comeocytes of the stratum corneum are considered largely impenetrable and are 
arranged in a tight interlocking fashion surrounded by complex lipoidal domains, 
composed of lipids, mainly cholesterol, free fatty acids and ceramides. The cells of the 
stratum corneum are continually shed and renewed from the underlying epidermal 
layers (Walters, 1990). The comeocytes embedded in the lipoidal domains have been 
compared to a brick wall with the comeocytes representing the bricks, and the 
intercellular lipids the mortar (Elias, 1983). The intercellular lipid matrix found 
between the comeocytes is arranged into bilayers and is formed from the exocytosis of 
lamellar bodies during terminal differentiation of keratinocytes. It is believed that these 
bilayers provide the SC its formidable barrier properties and may form the only 
continuous domain of the SC.
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1.7 Routes of drug permeation across the skin
There are three main modes of delivery to be considered when applying a formulation 
to the skin. Diseases associated with the skin require the drug to be held within the skin 
and so exert their effect with minimal transdermal or transcutaneous permeation. Drugs 
with poor oral bioavailability are required to permeate through the epidermis and be 
carried from the dermis into systemic circulation. Tissues underlying the skin that 
require treatment need drugs to permeate through the dermis and hypodermis. These 
three modes of delivery are discussed in detail in the following sections.
1.7.1 Dermatological
Dermatological formulations produce a localised drug effect either on or in the skin. 
Besides the specific therapeutic action of incorporated active drugs, the formulations 
can also serve as lubricants or emollients. Treatments using dermatological 
formulations can help with minor skin infections, itching, bums, athlete's foot (e.g. 
Canesten® containing clotrimazole), acne (e.g. Oxy 10 containing benzoyl peroxide), 
psoriasis, and eczema are but a few examples. Such treatment requires the drug or 
compound of action to be retained within the skin and not pass through into the 
systemic circulation. In many cases the skin barrier is compromised and retaining the 
drug in the upper layers of the skin becomes difficult. Certain methodologies can be 
applied to maintain the concentration of drug within the skin, including the use of 
liposomes which are spherical vesicle with a membrane composed of a phospholipid 
bilayer used to encapsulate drugs or genes for delivery. The liposomes permeate the SC 
relatively easily but cannot permeate the more hydrophilic regions of the viable 
epidermis and so are retained in the SC where they can release the encapsulated drug. 
The formation of a reservoir within the SC by a rapidly permeating solvent alters the 
properties of the tissue into which the drug can partition and help to maintain a large 
drug concentration within the skin.
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1.7.2 Transdermal
Transdermal delivery requires the drug of interest to permeate through the SC and the 
epidermis, reaching the blood vessels or lymphocytes in the dermis and consequential 
uptake into the systemic circulation and get transported to their site of action. Such 
treatments include nicotine replacement therapies and hormonal replacements.
1.7.3 Transcutaneous
Transcutaneous delivery involves the permeation of the drug across the complete skin 
membrane to underlying tissues. The drug must be able to permeate the lipophilic SC, 
then the hydrophilic viable epidermis before by-passing the blood vessels within the 
dermis and permeating through to the underlying tissue. This is particularly important 
in the case of arthritis as the inflammation process is occurring beneath the skin, within 
the joints e.g. Oruvail. This is an example of a formulation that that has been designed 
to deliver drug in this way. The main limitation to this mode of delivery through the 
skin is the clearance of the drugs into the systemic circulation. The rate of permeation 
of the compounds must out-weigh the rate of clearance to allow further permeation. 
Cutaneous dialysis is a method of determining the clearance rate of hydrophilic 
molecules but has had little success with molecules of a lipophilic nature (Morgan et al. 
2003). This technique has also been used by Church (1997) to follow inflammatory 
reactions within the skin.
1.7.4 Crossing the stratum corneum
The three modes of topical delivery detailed above all share a common factor; the active 
agent must first cross the SC. Three main routes of entry into the skin from an applied 
formulation have been proposed (see Figure 1.14). The permeation of drugs via routes 
1 and 3 also called the shunt route is an area of great scrutiny. Although the sweat 
glands and hair follicles only occupy approximately 0 .1 % of the total skin surface 
(Scheuplein, 1967) they have been shown to play a significant part in drug permeation. 
Illel et al. (1991) showed that appendage free rat skin produced four-fold lower
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permeation values of several drugs. Barry (2002) provides many examples of 
formulations utilising this route including liposomes and naked DNA molecules and 
Williams. (2003) discusses how this route of permeation may be important for large 
polar molecules and ions that would have difficulty it permeating through the SC.
Hair shaft
Routes of penetration
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Sub-epidermal 
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Figure 1.14 Diagram of skin structure and routes of drug penetration (Barry, 2002). Route 1, via 
the sweat ducts; route 2, across the continuous stratum corneum; route 3, through the hair follicles 
with their associated sebaceous glands
Route 2 can be sub-divided into two further permeation routes; transcellular, through 
the cell and intercellular, around the cells through the lipid bilayers. Figure 1.15 
illustrates these two routes of permeation through the SC.
29
Chapter 1 Introduction
Transee Ma? routeintercellular route
Plasma Cel!
membrane cvtootasm Fatty ac.<l Ceramide
tntercelular
space
Liprd Aqueous Cbotestert>i/  TnGvconrJe Mmmalfcpid 
Cholesterol sulphate
Figure 1.15 Diagrammatic representation of SC membrane (Barry, 2001)
1.7.4.1 Transcellular permeation
The transcellular route represents the most direct route through the SC. The molecule 
crossing the SC in this way is however presented with several challenges. The molecule 
must first partition into the top layer keratinocyte followed by diffusion through the 
hydrated keratin within the cell (Hadgraft et al., 1992). When delivering a compound 
such as a fatty acid the diffusion of such a compound into the cell may also lead to 
incorporation of the fatty acids within the cell membranes. This is more likely within 
the lower cell layers of the SC as the upper layers are terminally differentiated. It is 
generally assumed therefore that this route is likely to be avoided by most drugs. 
However, evidence supporting transcellular permeation has been found and is discussed 
in Williams (2003) and Perkins and Heard, (1999).
1.7.4.2 Intercellular permeation
This involves the diffusion of compounds through the lipid bilayers that surround the 
comeocytes. The lipid bilayers make up approximately 1 % of the SC diffusional area 
and represent the best permeation route for a lipophilic molecule although not a 
complete uninterrupted route. The diffusional pathlength that the molecule must travel
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is significantly greater than the 15-20}im thickness of the SC and can be up to 350pm 
for methyl nicotinate (Albery and Hadgraft, 1979) and the pathlength for the diffusion 
of water was found by Potts and Francoeur (1991) to be 500pm. The actual pathlength 
of a molecule would heavily depend upon its physico-chemical characteristics and as 
such the diffusional pathlength differs from molecule to molecule. The composition of 
the lipid bilayers in the skin are unique, in that they lack phospholipids and contain a 
variety of ceramides.
The route of drugs through the skin is therefore arduous at best, and physicochemical 
characteristics of the drugs also play a large part in the permeation route. Ideal factors 
including molecular weight (not greater than 700Da), pKa (compatable with skin pH) 
and log P (the octanol / water partition, generally required to be between 2 and 5) all 
add to the complications of delivery through the skin. Ways of enhancing the 
permeation of compounds have been examined in great detail and Section 1.8 presents 
some of the enhancement techniques commonly studied.
1.8 Permeation enhancement strategies
To enhance the permeation of drugs through the skin, several possible strategies can be 
employed. Some techniques involve the disruption of the SC barrier, another involves 
the by pass of this barrier completely. The sections that follow summarise some of the 
common enhancement strategies.
1.8.1 Physical Modulation
1.8.1.1 Microneedles
A traditional solution to avoiding the SC is to use a hypodermic needle; however patient 
compliance due to the fear of needles, the pain caused and possible cross-contamination 
lead to the development of microneedles. When applied to the skin they puncture 
through the stratum corneum and into the viable epidermis. The heights of the needles 
are such that the pain receptors deeper in the skin are not triggered. The microneedle
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device has recently been found to allow DNA delivery and subsequent gene expression 
within the viable epidermis (Coulman et al. 2005). The use of microneedles does pose 
certain problems. Breakage of the silicon needles can occur and these fragments may 
remain in and irritate the skin. Needle-less injection employs a gas powered gun to fire 
small particles into the skin in an attempt to avoid pain receptors. This strategy does 
have its benefits such as localised delivery but also its disadvantages as SC variation 
between subjects would vary the depth to which the particles could penetrate. Damage 
to the SC is also of concern as leaving “holes” in the SC would lead to reduced barrier 
function and possibly infection (Williams, 2003).
1.8.1.2 Iontophoresis
Other physical techniques include iontophoresis, employing an electrical potential 
gradient to aid drug delivery. The action of iontophoresis lies in the ability to repel 
charged molecules from two electrodes, with positively charged molecules being 
repelled by the anode and negative molecules by the cathode. The majority of 
molecules permeate via appendageal routes although some via paracellular pathways. 
Factors including skin pH, molecular weight and ionic competition affect the usefulness 
of this technique but it has found uses for the delivery of anti-inflammatory agents. 
Mathy et al., (2005) found that iontophoresis was efficient in delivering high 
concentrations of flurbiprofen to the dermis and underlying tissues of hairless rats. 
Similarly Curdy et al., (2001) found that iontophoresis improved the delivery of 
piroxicam into the SC of human volunteers compared to passive diffusion alone. Both 
results could be due to the increased permeation via appendageal routes when using 
inotophoresis. The use of iontophoresis in delivering drugs for the treatment of arthritic 
conditions is discussed in detail by Rosenstein, 1999.
A similar method is ultrasound or sonophoresis, using ultrasound with a frequency 
beyond 20kHz to facilitate the drug through the skin with an ultrasound probe.
32
Chapter 1 Introduction
1.8.2 Chemical enhancement
This thesis is focused on delivering a fatty acid / triglyceride with ketoprofen through 
porcine skin in-vitro and so these physical methods would be impractical and so were 
not considered. The second strategy of enhancement uses chemical enhancement, 
studied in Chapter 4. It is important to evaluate the possible chemical enhancers to 
demonstrate that the correct method was employed for the proposed application.
1.8.2.1 Dimethyls ulfoxide (DMSO)
DMSO is a powerful aprotic solvent and is one of the earliest and most widely studied 
enhancers. Barry and Williams (2003) discuss the use of DMSO as an enhancer and 
conclude that it enhances both hydrophilic and lipophilic drugs. They also state that the 
levels required to attain the greatest enhancing effects are >60% DMSO which at that 
concentration causes erythema and damage to the skin.
1.8.2.2 Fatty acids
Fatty acid permeation enhancement using oleic acid has been well studied. (Barry and 
Williams, 2003) but like several other mechanisms of enhancement, the compound 
acting as the enhancer is assumed to do no more than temporarily effect the skin before 
being washed out of the stratum corneum. Fatty acids as enhancers are discussed in 
detail in Chapters 3, 4 and 7.
1.8.2.3 Alcohols
Ethanol is a common solvent for many formulations as not only does it act as a solvent 
but enhances the permeability of the drug within the formulation. Recently Kung et al. 
(2006) have shown the flux of mefenamic acid to be proportional to the flux of ethanol. 
As the concentration of ethanol increased in the formulation a corresponding increase 
was seen in the concentrations of permeated mefenamic acid and ethanol. This novel 
work has indicated the possibility of co-permeation related to the enhancers ability to 
solvate the permeating drug.
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1.8.2.4 Pro-drugs
A form of chemical enhancement is the use of pro-drugs. These are compounds which 
typically aren’t suitable for transdermal / transcutaneous delivery and are chemically 
modified to allow permeation through the skin. The most common form of 
modification is the formation of ester linkages. This allows greater permeation of drugs 
through the lipophilic SC. Once the pro-drugs reach the viable epidermis the esterases 
present within these skin layers can break this ester linkage and thus return the drug to 
its original, active form.
1.8.2.5 Terpenes
Terpenes are a group of non aromatic compounds comprising of carbon, hydrogen and 
oxygen and found in essential oils including menthol and limonene. 1 ,8 -cineole is the 
major terpenoid of eucalyptus oil and has found application in a number of 
enhancement studies (Thomas and Heard, 2005; Feminia-Font et al. 2005; Yamane et 
al. 1995). 1,8-cineole was also found to have a concentration dependent effect on 
mefenamic acid and again implies a co-permeation or drag effect upon the drug by the 
enhancer. The action of 1,8-cineole is discussed in Chapter 4.
1.9 Objectives and Aims
The objectives of this project was to test the hypothesis that a dual action formulation 
containing ketoprofen and fish oil could be efficacious in the treatment of symptoms 
associated with arthritic conditions, in particular RA and OA.
The associated aims were:
i. To develop a formulation capable of transcutaneously delivering 
ketoprofen and EPA from fish oil
ii. To investigate the delivery of the active compounds into a joint capsule 
and diffusion into synovial fluid
iii. To determine the efficacy of the formulation against the biological 
symptoms of arthritis within cartilage
iv. To investigate the fate of the compounds during skin permeation
v. To probe complexation issues of formulation components
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2.1 In-vitro permeation experiments
2.1.1 Skin preparation
Porcine ears were obtained from a local abattoir, cleaned under running water and the 
hair shaved using electric clippers. Full thickness dorsal skin was removed from the 
underlying cartilage using a scalpel, cut into approximately 2 cm x 2 cm and stored at 
-20°C until required. Porcine skin was used as it has been shown to be one the best 
in-vitro models for human skin available (Simon and Maibach, 2000). As this thesis is 
studying transcutaneous delivery full thickness skin was used.
2.1.2 Franz cell diffusion
The standard tool for determining in-vitro skin penetration and permeation is the Franz 
diffusion cell or variants thereof (Williams, 2003). All in-vitro permeation experiments 
throughout this thesis were carried out using all glass Franz diffusion cells, of the type 
illustrated in Figure 2.1. The complete cell consists of two chambers, the lower 
(receptor) and the upper (donor). The nominal receptor volume and diffusional area was
3.5 ml and 1.5cm2 respectively -  these are important parameters for the accurate 
quantitative determination of permeation parameters. To limit leakage the mating 
flanges of both halves were pre-cleaned and greased with high vacuum grease (Dow 
Coming, Barry, UK). The square skin sections were placed between the two chambers 
with the SC uppermost and the chambers clamped together. The appropriate receptor 
phase (de-gassed beforehand) was then added to the receptor chamber ensuring no 
bubbles were present beneath the underside of the skin. To assist mixing (regarding 
stagnant diffusion layers) a micro-stirrer bar was added and the complete cell placed on 
a magnetic stirrer plate (Variomag, Daytona Beach, USA) in a water bath (Clifton, 
Fisher, UK) set at 37°C (to provide a skin surface temperature of 32°C via heat 
dissipation) (Figure 2.2). The sampling arm of the receptor compartment was occluded 
using a cap to ensure no loss of receptor phase. After a pre-determined equilibration 
time (typically 1 0  minutes) the cell was dosed via the donor chamber which was
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occluded using laboratory film. Each bath can accommodate up to 15 cells. All other 
details for specific experiments are detailed in individual chapters.
onor chamber
|Skin section
eceptor compartment
Sampling arm
Figure 2.1 Glass Franz-type diffusion cell
Figure 2.2 Set o f  12 diffusion cells in water bath
2.1.3 Receptor phase
The choice of receptor phase in any membrane permeation/penetration experiment is of 
major importance. The primary function of a receptor phase is to provide a sink for the 
permeated compounds and thus an optimum receptor phase should be one in which the 
amount of permeated drug contained should never exceed 2 0 % of its solubility in that 
liquid (Williams, 2003). This is particularly an issue for lipophilic permeants. A 
further requirement of a receptor phase is that it does not adversely affect the membrane
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by reverse diffusion, thus those with high alcohol content should be avoided as, e.g. 
ethanol is capable of leaching lipids of the stratum corneum (Barry, 1987).
In this work the receptor phase used for EPA / DHA and ketoprofen was cetrimide. 
Cetrimide solution (30 mg ml'1) containing 0.05% butylated hydroxyanisole (BHA) as a 
standard reagent to inhibit decomposition of the polyunsaturated fatty acids was found 
to provide an effective sink for ketoprofen and fish oil. In this solution, ketoprofen was 
freely soluble and fish oil solubility was estimated at 5.1 ± 0.3pl ml' 1 (5.2 ± 0.3mg ml"1), 
approximating to 1.73 ±0.1 mg (5.72 ± 0.33pmol) EPA ml’1, by adding sequential 
aliquots of the oil to receptor phase at 37°C until a clear solution was no longer 
attainable. Furthermore, a preliminary study indicated that this receptor phase 
performed in a similar manner to the more ubiquitous alcohol-in-water system, giving 
rise to no perceptible deleterious effects on the skin (Heard et al, 2002). The optimum 
receptor phase would be to use the phase that the compounds would eventually 
permeate i.e. blood or specifically in this case synovial fluid. For the purposes of the 
initial permeation experiments it was thought that the use of cetrimide would be an 
acceptable receptor phase, offering a suitable sink, as the acquisition of large quantities 
of blood and synovial fluid is difficult due to regulatory implications. Chapter 5 uses 
the whole joint of a porcine forelimb and therefore provides the best receptor phase 
available, synovial fluid.
2.2 Quantitative determination of EPA and DHA
Several methods were investigated to determine the concentration of fish oil 
(EPA/DHA) from the receptor phase samples during a permeation experiment. The 
usual analysis method for fatty acids is gas chromatography (GC), due to the 
unavailability of this instrument HPLC analysis was used. As the concentrations of 
individual fatty acids present in the fish oil was to be determined by HPLC, it was 
thought that they must first be liberated from the triacylglycerols as which, they are 
bound. To accomplish this, the fatty acids were derivatised. The derivatised sample 
must be highly UV active in order to analyse the samples using an HPLC with UV 
detection and the conditions harsh enough to allow the derivatisation of each individual
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fatty acid present as triacylglycerols. The first derivitisation method used was the 
formation of fatty acid phenacyl esters.
2.2.1 Preparation of fatty acid phenacyl esters
2-bromoacetophenone in acetone (lOmg/ml) (10ml) and triethylamine in acetone 
(lOmg/ml) (10ml) were added to a sample of fish oil (50mg) prior to heating under 
reflux at 70°C for 30 minutes. The reaction was kept under nitrogen throughout. Acetic 
acid (7ml) was then added and the reaction mixture heated to reflux for a further 5 
minutes (Nichols and Davies, 2002). The solvent was then evaporated under vacuum 
and a pale yellow liquid remained. The sample was then dissolved in acetonitrile / 
water, 95/5 for HPLC analysis.
Triacylglycerols 2-bromoacetophenone Fatty acid phenacyl ester
Figure 2.3 Reaction scheme for polynunsaturated fatty acid phenacyl ester preparation
Note: As this reaction must be free of water to go to completion, the receptor phase 
samples were freeze dried to remove any traces of water which would compete with the 
2 -bromoacetophenone.
2.2. LI HPLC analysis offatty acid phenacyl esters (FAPE)
FAPE samples were analysed on a Hewlett Packard 1100 HPLC system with a variable 
wavelength detector. LC separations were carried out on a Phenomenex Kingsorb C l 8  
column (150 x 4.6mm, 5pm) fitted with a Phenomenex Securiguard guard column. The 
mobile phase conditions were acetonitrile / water (95:5; v/v) run, isocratically, for 20
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minutes at a flow rate of 1.5ml/min. UV detection was set at 240nm. Retention times 
of EPA and DHA were 6.0 minutes and 6.7 minutes respectively.
2.2.1.1.1 Liquid Chromatography -  Mass Spectrometry (LC-MS) analysis o f FAPE 
samples
FAPE samples were analysed on a Finnigan SN 4000 series with a diode array detector 
in series with a Finnigan LCQ mass spectrometer. HPLC separations were as above. 
The mobile phase conditions were acetonitrile / water (95:5; v/v) run, isocratically, for 
20 minutes at a flow rate of 1.5ml/min. Wavelengths from 190 to 300nm were 
monitored on the diode array detector. The LC-MS was run under the following 
conditions: APCI (atmospheric pressure chemical ionisation) source, vaporiser 
temperature 450°C, capillary temperature 150°C, discharge current lO.OOpA, sheath gas 
80 psi, auxiliary gas 10 psi, capillary voltage -24.00V. The range from m/z 150-1000 
was scanned. EPA and DHA eluted at 7.4 and 8.3 minutes respectively. Their 
corresponding m/z ions were 421 and 447 respectively.
The mass spectrometry validated the FAPE HPLC analysis in that the peaks identified 
in the HPLC chromatogram were indeed the FAPEs of EPA and DHA. Quantification 
of EPA or DHA present in the fish oil was not carried out as the method provided 
suitable results but proved very time consuming. The preparation of fatty acid methyl 
esters (FAMEs) was therefore investigated.
2.2.2 Preparation of fatty acid methyl esters (FAMEs)
An improved method of derivatisation was found and validated involving the formation 
or fatty acid methyl esters (Heard et al., 2002)
PUFAs were transmethylated (see Figure 2.4) by heating under reflux in a sealed 
methylating tube with anhydrous methanol (10ml) in the presence of acid catalyst (2.5% 
v/v H2 SO4 ) for 2  hours at 70°C. After this time the solution was allowed to cool to 
room temperature and the reaction quenched by the addition of aqueous NaCl (5% w/v)
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(2.5mls). The FAMEs were then extracted with 3 x 30mls petroleum ether (60 -  80°C 
b.p.), the ether phases pooled and evaporated to dryness under vacuum. The remaining 
product was dissolved in methanol (2 ml), bubbled with nitrogen, sealed and stored 
under light exclusion prior to HPLC analysis.
MeOH
Triacylglycerols * * *  301(1 meth5'1 ester
Figure 2.4 Transmethylation of a triacylglycerol
2.2.2.1 HPLC analysis of FAMEs
FAMEs were again analysed on a Hewlett Packard 1100 HPLC. Separations were 
carried out on a Phenomenex Kingsorb C l 8  column (150 x 4.6mm, 5pm) fitted with a 
Phenomenex securiguard guard column. The mobile phase conditions were methanol / 
water (95:5; v/v) run, isocratically, for 20 minutes at a flow rate of 1.0 ml min'1. UV 
detection was set at 210nm. EPA and DHA eluted at 10.8 minutes and 12.8 minutes 
respectively.
2.2.2.1.1 LC-MS analysis of FAMEs
FAMEs were analysed on a Finnigan LC SN 4000 series with a diode array detector in 
series with a Finnigan LCQ mass spectrometer. LC separations were carried out on a 
Phenomenex Kingsorb C l 8  column (150 x 4.6mm, 5pm) fitted with a Phenomenex 
securiguard guard column. The mobile phase conditions were methanol / water (95:5; 
v/v) run, isocratically, for 20 minutes at a flow rate of l.Oml/min. Wavelengths from 
190 to 300nm were monitored on the diode array detector. The LC-MS was run under 
the following conditions: APCI source, vaporiser temperature 450°C, capillary
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temperature 150°C, discharge current 5.00pA, sheath gas 80 psi, auxiliary gas 10 psi, 
capillary voltage 26.00V. The range from m/z 150-1000 was scanned.
The LC-MS analysis validated the FAME HPLC method. The values quoted by Boots 
PLC for the concentration of EPA and DHA were 330 mg per 1000 mg and 21 mg per 
1000 mg respectively. The results from this method of analysis were found to correlate 
with the values quoted by Boots PLC. Therefore this method was used for the analysis 
of EPA and DHA in Chapters 3, 4 and 6 .
2.2.3 HPLC analysis of free fatty acids
During the work carried out in Chapters 5 and 7 it was discovered that the analysis of 
free fatty acid of EPA could be analysed in the same HPLC method as stated in Section
2.2.2.1. Under these conditions EPA free fatty acid eluted at 6.9 minutes. A standard 
calibration curve, prepared in methanol (extraction solvent), was constructed over the
1 7range 1-250 pg ml' and provided r values of > 0.99. This was again validated by LC- 
MS, as Section 2.2.2.1.1, and the values of EPA present in the fish oil were found to 
correlate with values quoted by the supplier.
2.3 HPLC analysis of 15-HEPE
The HPLC conditions for the analysis of 15-HEPE are as Section 2.2.2.1. Under these 
conditions 15-HEPE eluted at approximately 4 minutes. A standard calibration curve, 
prepared in methanol (extraction solvent), was constructed over the range 1-250 pg ml' 1 
and provided r2 values of > 0.99. The LOD of 15-HEPE was 0.7 pg ml'1.
2.4 HPLC analysis of ketoprofen
Ketoprofen samples were analysed on a Hewlett Packard 1100 HPLC system with a 
variable wavelength detector. Separations were carried out on a Phenomenex Kingsorb 
C l 8  column (150 x 4.6mm, 5pm) fitted with a Phenomenex Securiguard guard column. 
The mobile phase was acetonitrile / potassium phosphate buffer (pH 1.5) (55:45; v/v)
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run isocratically for 10 minutes at a flow rate of 1.0 ml/min. UV detection was set at 
258nm. The retention time of ketoprofen was 6 . 8  minutes and the limit of detection 
(LOD) was 0.03 pg m l'1. A standard calibration curve was constructed over the range 
1-120 pg ml'1, prepared in receptor phase, which provided an r2 of 0.99
2.5 HPLC data analysis and construction of permeation profile
The standard calibration curve along with the sample peak area was used to calculate 
the concentration of compound in the receptor phase. To avoid solvatochromatic 
effects, calibration curves were always prepared using the same medium as the test 
samples. Cumulative ketoprofen, EPA and DHA concentrations (pg cm' ), corrected 
for sampling were plotted against time, ± the standard error of the mean (s.e.m). S.E.M 
was used instead of SD as replicates were performed over 2 or more occasions. Steady 
state flux, Jss, was determined from the gradient of the linear portion of the plots. Lag 
time, where applicable, was determined by extrapolation to the x axis from the linear 
portion of the graphs. The partition coefficient kp was determined by the division of the 
steady state flux Jss by the concentration of drug in the formulation applied to the skin.
2.6 Depth profiles by tape stripping
Whereas permeation parameters can provide information concerning the transport of 
molecules across skin membranes it tells us little about the deposition or localisation of 
drug within the skin. Tape stripping is a technique which allows the concentration of a 
drug to be determined as a function of depth through the layers of the skin.
2.6.1 Depth profile methodology
A D-Squame® adhesive disc (1cm in diameter) was placed firmly over the diffused area 
of the skin sample. The strip was then removed using tweezers and placed in a clean 
glass vial. This was repeated using 30 individual strips which were grouped three per 
vial before methanol (2ml) was added and the vial left for approximately 24 hours under 
light exclusion on a laboratory shaker. The remaining epidermis was heat separated
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from the dermis by placing the skin section epidermis side down onto a glass plate 
maintained at 55°C for approximately 30 seconds. The remainder of the epidermis was 
removed and both the dermal and epidermal tissue placed in separate glass vials with 
methanol (4ml) and extracted as above.
2.7 Immunocytochemistry (ICC) methodology
Immunocytochemistry is a method used extensively to probe the activity of enzymes 
within tissues and cells. It has previously found use for the analysis of COX, in UVB 
induced skin inflammation, (Athar et al. 2001) and for LOX in lung tumours in a study 
carried out by Gonzalez et al. (2004).
Stage 1 of any staining process is the fixing and dehydration of the skin samples. After 
the appointed time within the Franz cell apparatus, the skin is removed and the donor 
phase / formulation is removed from the surface of the skin with distilled water and 
wiped with a fresh tissue. The skin is then cut into approximately 2mm thick strips 
using a clean surgical blade, ensuring that the strips are taken from the area on which 
the formulation was applied. Following this, the skin is placed into 7 x 5 cm cassettes 
and the cassettes are snapped shut. The skin within the cassettes then undergoes the 
procedure as detailed in Table 2.1. The formaldehyde treatment fixes the skin while the 
ethanol treatment removes water. The xylene steps then displace the ethanol for further 
treatment.
Table 2.1 Procedure of fixation and dehydration of skin samples for ICC analysis
I Solvent Time of Treatment
4% Formaldehyde 24 hours
70% Ethanol -16 hours
70% Ethanol 30 minutes
90% Ethanol 2 x 30 minutes*
100% Ethanol 2 x 30 minutes*
100% Xylene 60 minutes
100% Xylene 3 x 30 minutes*
*Each treatment carried out using fresh solvent
44
Chapter 2 Analytical Methods
Once the fixation and dehydration procedure has been carried out the skin is ready to be 
embedded in paraffin to enable accurate sectioning. Before the embedding can take 
place the removal of xylene must first occur. This is achieved by placing the cassettes 
into 3 equivalent molten wax baths and applying a vacuum for a specified interval (see 
Table 2.2).
Table 2.2 Removal of xylene
Wax bath no. Vacuum off (min) Vacuum on (min) Vacuum off (min)
1 15 1 0 5
2 1 0 15 5
3 1 0 15 25
The lid of the storage cassette is then removed and molten paraffin wax is poured over 
the skin and allowed to cool. The embedded skin is now in such an orientation as to 
allow cross sections from SC to dermis to be taken. The sections are cut using a 
Shandon Finesse microtome to a thickness of 5pm and are placed onto 2.5 cm x 7.5 cm 
x 1mm Surgipath pre-cleaned microslides.
The skin is then heated at 37°C for one hour and undergoes the following set of 
procedures to de-wax and re-hydrate the skin (Table 2.3).
Table 2.3 De-waxing and re-hydrating
Solvent Treatment Time (mins)
Xylene 2 x 7
100% Ethanol 2 x 3
90% Ethanol 2 x 3
70% Ethanol 2 x 3
Distilled H2O 1 x 5
PBS* 1 x 5
♦Phosphate buffered saline
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Xylene is used to remove any wax within the skin and present on the slide. Ethanol 
displaces the xylene from the cells and the skin is gradually re-hydrated.
2.7.1 Staining Procedure
To block endogenous peroxidases that would interfere with the staining process, an 
aqueous solution of hydrogen peroxide (3%) was applied to each section and left for 5 
minutes. Excess solution was then removed by 2 x 3 minute washes in PBS.
2.7.2 Antigen unmasking
The sections were then micro-waved in 1L sodium citrate buffer (0.01M), adjusted to 
pH 6  with HC1 for 30 minutes at 560 Watts. The slides were then cooled for ten 
minutes under running water and then washed twice for three minutes using PBS.
2.7.3 Application of primary antibody
Unspecified proteins were blocked by applying a PBS plus 0.2% Tween solution to the 
sections for 15 minutes. The excess blocking reagent was then removed and the 
primary antibody for the specific enzyme was applied to the sections and left at 23°C 
overnight. See Chapter 9 for details of primary antibody.
2.7.4 Application of secondary antibody and label
Slides were first pre-washed using a 1 x 3 minute PBS wash and then 2 x 5  minute 
PBS/Tween washes. A Dako Corporation horse radish peroxidase (HRP) labelled 
rabbit EnVision detection system was applied and the slides incubated for 2 hours at 
23°C. The detection system contains both secondary antibody and label. The slides 
were then placed into a 1 x 3 minute PBS wash and then 2 x 5  minute PBS/Tween 
washes. Dako DAB was then applied to the sections and left for 10 minutes. The slides 
were then rinsed in distilled water for 3 x 2 minutes.
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2.7.5 Counterstaining
An aqueous solution of 0.5% methyl green was applied to the sections for 5 minutes and 
was then rinsed off with distilled water for 2 x 3 minutes. The sections were then 
dehydrated at 37°C and Menzel-Glaser 22 x 40 mm cover-slips fixed over the sections 
using a distyrene, plasticizer, xylene (DPX) mix. The sections were then oberserved 
and photographed using an Olympus BH-2 microscope with Olympus digital camera.
2.8 Nuclear Magnetic Resonance (NMR) Spectral Modulation
lH NMR spectra were obtained using a Bruker Avance DPX400 spectrometer operating 
at 400MHz and 27°C. Sub-saturated solutions of ketoprofen (2.5% w/w) in fish oil, 
mixtures of fish oil and Miglyol 812N, 1:10, 1:20, 1:1, 10:1 and 20: and pure Miglyol 
812N were prepared and used as a control vehicle. A fixed volume of formulation 
(25pi) was added to separate NMR tubes and CDCI3 (475pi) was added as solvent. 
These volumes were found to produce suitability strong NMR signals. The differences 
in shifts of the aromatic protons compared to a ketoprofen control were calculated and 
the individual proton shifts were plotted. These experiments were repeated using EPA 
and DHA free fatty acid standards. Due to the small amount of material available, serial 
dilutions of a 25mg ml' 1 solution in Miglyol 812N were prepared and saturated with 
ketoprofen. Control experiments were carried out using ketoprofen in CDCI3 .
2.9 Molecular modelling and binding energy calculation
In collaboration with Dr. Jamie Platts, Chemistry Department, Cardiff University, 
individual molecules of ketoprofen, EPA and the triglyceride of this fatty acid, were 
built using the Molecular Builder function of the MOE package 
(http://www.chemcomp.com/), and minimised using the MMFF-94 force-field (Halgren, 
1996) until no force on any nucleus exceeded 0.05 kcal / (Ang mol).
Complexes between ketoprofen and EPA constructed by bringing together optimised 
structures and re-optimising using the same force-field and force cut-off. This resulted
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in little or no change to the conformation of either drug or fatty acid. The 
conformational energy landscape of these complexes was explored by randomly altering 
the mutual orientation of drug and fatty acid as well as the dihedral angles of any 
rotatable bonds. This was followed by full energy minimisation. Throughout this 
procedure, the cis orientation of the C=C bonds in fatty acids was maintained using 
harmonic restraints, which were subsequently removed in the final minimisation. These 
stochastic searches proceeded until either 1 0 0 0  conformations were found, or no new 
low-energy conformations were found after 1 0 0 0  searches.
Binding energies were calculated by subtracting the energies of the individual 
molecules from the total energy of the complex, all calculated using the MMFF-94 
force-field. In all cases the contribution to binding energy from bond length, 
angle and dihedral terms was effectively zero, such that binding was a 
combination solely of electrostatic and Van der Waals forces.
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Chapter 3 In-vitro transcutaneous delivery o f ketoprofen, EPA and DHA from simple gel formulations
3.1 Introduction
It has previously been demonstrated that the simultaneous transcutaneous permeation of 
NSAID and essential fatty acids from fish oil across excised porcine skin using a 
saturated fish oil vehicle is possible (Heard et al., 2003). Solanki et al, (2005) have also 
shown that topically applied safflower oil (rich in linolenic and arachidonic fatty acids) 
can be absorbed in neonates and may be available for nutritional purposes. They also 
concluded that the fatty acid constituents of topically applied oil can “influence the 
changes in the fatty acid profile of the massaged babies.” A transcutaneous system 
containing fish oil as a source of EPA and DHA therefore also represents a potentially 
useful vehicle for the delivery of these essential fatty acids and thereby treatment of 
inflammatory conditions.
This chapter studies three basic formulations containing fish oil and ketoprofen. 
Ketoprofen was selected as the NSAID of choice as Hadgraft et al., (2000) showed 
ketoprofen to provide the best predicted bio-effectiveness when considering maximum 
flux and IC50 values (Cordero et al., 2001). The formulations prepared in this chapter 
are the first stage in the development of a commercial formulation as previous work 
(Heard et al., 2003) employed saturated solutions of fish oil and NSAID but this does 
not represent commercially available NSAID products. In most available products this 
is 5% w/w for ibuprofen formulations (e.g. Ibuleve™) and 2.5% w/w for ketoprofen 
(e.g. Oruvail™). For this reason 2.5% w/w ketoprofen is used throughout the work. 
Furthermore, as it has already been demonstrated that significant amounts of ketoprofen 
and fish oil permeate skin (Heard et al., 2003a), and thermodynamic activity 
considerations were considered to be of less relevance. In this case the pull / drag effect 
is thought to be of more importance due to the solvation effects that may be seen within 
a formulation of this kind (Heard et al., 2006). BHA antioxidant was added to limit 
PUFA oxidation.
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3.2 Materials and methods
3.2.1 Materials
Boots Super Strength concentrated fish oil capsules lOOOmg (Batch number: BE09) 
were used as a source of EPA and DHA. Ketoprofen, polyethylene glycol 400N (PEG 
400), hydroxypropyl cellulose (HPC), cetrimide and butylated hydroxyanisole (BHA) 
were obtained from Sigma -  Aldrich Company Ltd., Poole, UK.
3.2.2 Gel preparation
Four gels were prepared for the initial skin permeation experiments with the 
compositions shown in Table 3.1. PEG 400 was heated to approximately 40°C on a 
temperature controlled heating mantle and the required mass of BHA was then added 
and allowed to dissolve at 40°C. The required mass of ketoprofen was added and 
allowed to dissolve followed by the fish oil. HPC was then added and the gels were 
allowed to mix overnight using a blood serum rotator. This produced a clear, bubble- 
free gel of appropriate (although arbitrary) viscosity.
Table 3.1 Gel formulations
Formulation Fish Oil (%) Ketoprofen (%) PEG (%) HPC (%) BHA (%)
I 0 2.50 89.50 8 . 0 0 0.05
II 5.00 2.50 84.50 8 . 0 0 0.05
III 1 0 . 0 0 2.50 79.50 8 . 0 0 0.05
IV 2 0 . 0 0 2.50 69.50 8 . 0 0 0.05
3.2.3 Skin preparation
Skin was prepared as in Chapter 2, section 2.1.1.
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3.2.4 Skin permeation experiments
Skin permeation experiments were carried out as in Chapter 2, Section 2.1.2. Porcine 
ear specimens were equally distributed between the gels to eliminate donor variability. 
The receptor phase chamber was filled with a cetrimide solution (30 mg/ml) and BHA 
(0.05% w/v) receptor phase and a micro stirrer bar added. After 10 minutes temperature 
equilibration time an infinite dose of 0.7g (approximately 1ml) gel and was added to the 
donor chamber. A total of three replicates were carried out on four occasions. At 3, 6 , 
12, 24, 36 and 48 hours the entire receptor phase was removed with 500|xl transferred to 
a HPLC auto-sampler vial for the analysis o f ketoprofen and the remainder of the 
receptor phase transferred to a larger screw-capped vial for the analysis of the fish oil. 
The Franz cell was replenished with fresh receptor phase after each point.
3.2.5 HPLC Analysis
Fish oil and ketoprofen were assayed as outlined in Chapter 2 Section 2.2.2 and 2.4 
respectively.
3.2.6 Data Analysis
The activity o f fish oil as an enhancer was expressed as an enhancement ratio for the 
flux o f ketoprofen (ERfiux), where ERflUX = Drug flux no fish oil/ Drug flux with fish oil.
Statistical analyses were carried out using Instat 3 for Macintosh (GraphPad Software, 
Inc), where non-parametric Kruskal-Wallis ANOVA and Dunn’s multiple comparison 
tests were employed to determine differences between data sets and specific pairs 
respectively. These tests are used due to the no Gaussian population within and 
between data sets.
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3.3 Results
3.3.1 Ketoprofen
Figure 3.1 shows the cumulative permeation profiles for ketoprofen across porcine skin 
from the four gels. Typical profiles were obtained, although steady state flux may not 
have been attained in all cases as the rate continued to increase by the end of the 
experiment. However a trend is clear in that there was a concentration-dependent 
relationship between ketoprofen permeation and fish oil content.
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Figure 3.1 Cum ulative permeation o f ketoprofen across porcine skin from 4 gels (n=5 ± s.e.m)
The apparent steady state flux and permeability coefficient (Kp) for ketoprofen from 
each of the gels is shown in Table 3.2, where steady state flux was taken between 24-48 
hours. All gels produced significantly different flux values from control, (p= < 0.001 
for gels III and IV compared to control and p= < 0.05 for gel I compared to control). 
The steady state flux for ketoprofen from the control gel I was 4.72 x 10"2 pg cm’2 h '1.
Gels, II, III and IV showed a ketoprofen steady state flux of 20.07 x 10"2 pg cm"2 h"1,
2\ 2 1 2 2 151.32 x 10" pg cm" h" and 62.03 x 10" pg cm" h" respectively. This equates to an
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increase of steady state flux of ketoprofen in gel II, III and IV of 425%, 1087% and 
1314% respectively compared to gel I.
Table 3.2 Mean apparant steady state flux, KP and enhancement ratio of ketoprofen from fish oil 
gels (n = 12 ± s.e.m.)
Formulation App. Jss (pg c m 'V 1) KP (cm h 1) (xlO-6) ERfiux
I 0.0472 ±0.0103 2.70 -
II 0.2007 ±0.0444 11.47 4.25
III 0.5132 ±0.0856 29.33 10.87
IV 0.6203 ±0.0711 35.45 13.14
3.3.2 EPA and DHA
No EPA or DHA was detected in any of the receptor phase samples which is surprising 
given the results obtained by Heard et al. (2003).
3.4 Discussion
The results obtained from this short study clearly showed that in the presence of fish oil 
the permeation of ketoprofen is greatly increased. Numerous studies have previously 
shown that the presence of fatty acids significantly augments the permeation of certain 
drugs these are expertly summarised by Williams and Barry (2004) and detailed below. 
However, the anticipated (and desired) permeation of EPA and DHA from the fish oil 
appeared not to occur in these experiments. Had significant quantities of EPA and 
DHA been found to permeate the skin in proportion to fish oil content the ketoprofen 
data could have been attributed to the pull effect (Bowen and Heard, 2006) i.e. 
ketoprofen permeation was aided by the “pull” of EPA / DHA as they permeated the 
skin. Indeed, it has recently been proposed that the pull effect alone is sufficient to 
account for the enhanced permeation of mefenamic acid by ethanol and 1 ,8 -cineole 
(Heard et al., 2006). It seems, therefore that the pull effect was not responsible for the 
ketoprofen permeation enhancement results in this study and a more traditional 
explanation seems appropriate.
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Considering the fish oil as a penetration enhancer, a possible mechanism of 
enhancement concerns the reduction of skin resistance as a permeability barrier by 
disruption of tightly packed lipid regions of the stratum comeum. The disruption of 
these lipids allow molecules to flow through the intercellular space with greater ease 
than when these regions are present. This is well documented as leading to increased 
permeation across the intercellular lipid matrix (Barry, 1987). One study showed that 
the permeation of naphazoline was increased by the addition of fatty acids (Green et al., 
1988). It was hypothesised that this could be further influenced by ion pair formation 
between drug and fatty acids, resulting in increased skin/vehicle partitioning of the 
drug. This mechanism could be in action in this investigation. The disruption of the 
lipid domains by the fish oil allows ketoprofen, already solubilised in the fish oil, to 
flow freely between cells and continue to permeate through into the receptor phase.
Electron microscope studies after treatment with oleic acid revealed discreet lipid 
domains within the stratum comeum. (Vavrova et al., 2005). The formation of such 
domains provides defects within the bilayer lipids and has been shown to aid the 
permeation of hydrophilic molecules (Williams and Barry, 2004). The “kink” in the 
chain of this cis isomer of oleic acid (Figure 3.2) was believed to be the main factor in 
this enhancement (Vavrova et al., 2005). EPA may act in a similar way as it is mainly 
present as the cis isomer, although the multiple double bond system may limit this 
effect. However, if EPA is present as the free fatty acid then the kink in the chain could 
provide a further explanation for the enhancement seen, if it is present as the 
triacylglycerol, then the formation of fish oil pools within the SC could allow increased 
ketoprofen permeation as discussed earlier. Both mechanisms acting simultaneously 
could then explain the magnitude of enhancement and the permeation pattern exhibited 
by the formulations studied may have been predicted.
The flux data from the permeation experiments also shows an interesting pattern. The 
flux enhancement ratio (ERflux), Table 3.1, for gel II is 4.25 times that of gel I, and gel 
III at 10.87 is more than double that of gel II. Following this, gel IV would be expected 
to have approximately double the ERflux of gel III but this is not the case. One study 
looking at the effects of fatty acids as penetration enhancers found that using 3 % oleic
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acid as an enhancer in propylene glycol (PG1) had very high enhancing effects on 
tenoxicam, yet when the concentration was increased to 5% OAc, the enhancing effect 
on tenoxicam permeation decreased (Gwak and Chun, 2002). A similar phenomenon 
could have been taking place here, in that the presence of 20% fish oil / fatty acids 
could be reaching a plateau of enhancement and any more could cause a decrease in the 
permeation of ketoprofen possibly via saturation of the SC and consequent reduction in 
the available routes for ketoprofen permeation.
Fatty Acids
Trans Cis
Saturated unsaturated unsaturated
Figure 3.2 Depiction o f a “kink” within a cis unsaturated fatty acid (oleic acid)
Given the permeation of EPA and DHA reported previously (Heard et al., 2003), the 
absence of EPA or DHA present in the receptor phases in the current work was 
surprising. It appears that there was some interaction between the fish oil in the gel and 
the stratum comeum as indicated by the pattern of ketoprofen enhancement. It has 
become a convention in skin permeation experiments to ensure test formulations are 
prepared at equal thermodynamic activities (Williams, 2003). This consideration was 
deemed less relevant to the current study as it was expected that the vehicle (i.e. fish oil) 
would permeate skin alongside the ketoprofen. As no EPA or DHA were found to 
permeate skin it may be contended that the results obtained were influenced by 
thermodynamic activity. However, at 2.5% w/w, ketoprofen is substantially below 
solubility (>320 mg m f1) therefore thermodynamic effects are less likely to be of 
relevance.
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It is possible that the concentration of oil that penetrated was sufficient to form a 
reservoir within the stratum comeum, but insufficient to overcome the barrier presented 
by the hydrophilic areas of the epidermis and dermis. The resident oil could then be 
further subjected to metabolism, a topic explored in Chapter 7.
However, it is known that a simple solution of ketoprofen in fish oil does produce a 
steady state flux of EPA and DHA. The primary difference between the formulations 
used by Heard et al., (2003) and the current work was the use of a thickening agent, 
HPC, and it seems that its presence resulted in substantial retention of the fish oil within 
the vehicle, retarding its partition into the skin and subsequent permeation. However, 
ketoprofen appears not to be subject to similar retentive processes.
Furthermore, as release of fish oil from the gel seems to have been limited by the HPC, 
modulations to the skin barrier may still have been in progress at 48 hours. This could 
explain the lack of attainment of steady state (Figure 3.1). For future formulations 
different thickeners could be employed and their effect on permeation studied.
3.5 Conclusions
From this preliminary gel formulation study it would appear that the formulations 
prepared may be suitable for ketoprofen delivery (where fish oil content produced 
concentration dependent enhancement) but not for EPA and DHA. The principle cause 
for the lack of EPA and DHA permeation appears to be use of the thickening agent, 
HPC as previous work (Heard et al. 2002) used non-thickened formulations to obtain 
permeation.
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Chapter 4 In-vitro transcutaneous delivery o f  ketoprofen, EPA and DHA from fish oil containing 1,8-
cineole
4.1 Introduction
The results obtained in Chapter 3 suggest that the use of HPC as a thickening agent was 
detrimental in the development of a transcutaneous system for the delivery of EPA and 
DHA from fish oil. Thus a simple solution would appear to be a better option, despite 
its low viscosity. However, in order to achieve a useable transcutaneous system, the 
modest rates of permeation observed previously (Heard et al., 2003) would need to be 
optimised. The ClogP of EPA and DHA are 6.71 and 7.70 respectively, (ChemDraw) 
suggesting less-than-ideal permeation candidates and the potential benefit of employing 
penetration enhancement. As outlined in Chapter 1 penetration enhancement strategies 
generally fall in to one of two categories: physical and chemical, the latter the simplest 
and most patient friendly.
This chapter describes the effort to enhance the simultaneous transcutaneous delivery of 
EPA, DHA and ketoprofen via chemical enhancement using 1,8-cineole (eucalyptol), 
the major terpenoid of eucalyptus oil, which also fulfilled a secondary role of 
addressing the issue of odour arising from the use of this natural product, in particular 
oxidised PUFAs. 1,8-cineole, Figure 4.1, possesses a pleasant ‘medicinal’ odour, which 
was found to have a long acting odour-masking effect on the fish oil when applied to 
skin, has previously demonstrated to be a highly effective permeation enhancer 
(Yamane et al., 1995).
CH
CH
Figure 4.1 Structure of 1,8-cineole
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This chapter aimed to address the issue of negligible EPA and DHA permeation as 
found in Chapter 3. The exclusion of the permeation inhibiting HPC should allow 
permeation of EPA and DHA. The effect of the proportion of 1,8-cineole on the 
delivery of ketoprofen, EPA and DHA was also investigated.
4.2 Materials and Methods
4.2.1. Materials
Boots Super Strength concentrated fish oil capsules lOOOmg (Batch number: 100673) 
were purchased from a local store. Ketoprofen and BHA and cetrimide were obtained 
from Sigma -  Aldrich Company Ltd., Poole, UK. Methanol (HPLC grade) and 
petroleum ether 60-80°C were obtained from Fisher Chemicals, UK. All other reagents 
were of analytical grade or equivalent.
4.2.2 Preparation of formulations
A fixed sub-saturated dose of ketoprofen (2.5% w/w) was used in each formulation as 
described in Chapter 3. The appropriate masses of ketoprofen and fish oil were 
combined and the formulation vortex mixed, followed by the drop-wise incorporation of 
1,8-cineole in the quantities stated in Table 4.1. The formulations were thoroughly 
vortex mixed and stored at 2-4°C until required (< 24 hours). In addition, three control 
formulations were employed: 2.5% ketoprofen in fish oil (enhancer-free) (I), 2.5% 
ketoprofen in de-ionised water (V) and fish oil without ketoprofen (VI).
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Table 4.1 Percentage of components within formulations
Formulation Fish Oil* (%) Ketoprofen 1,8-cineole h 2o
I 97.5 2.5 0 . 0 0 . 0
II 92.5 2.5 5.0 0 . 0
III 87.5 2.5 1 0 . 0 0 . 0
IV 77.5 2.5 2 0 . 0 0 . 0
V 0 . 0 2.5 0 . 0 97.5
VI 1 0 0 . 0 0 . 0 0 . 0 0 . 0
*Fish oil containing 0.05% BHA
4.2.3 In vitro transcutaneous delivery
Permeation experiments were carried out as described in Chapter 2, Section 2.1.1. A 
total of six replicates were carried out for each formulation.
4.2.4 HPLC analysis
HPLC analysis of EPA / DHA and ketoprofen was carried out as Chapter 2, section
2.2.2.1 and section 2.4 respectively.
4.2.5 Data analysis
Statistical analyses were carried out using Instat 3 for Macintosh (GraphPad Software, 
Inc), where non-parametric Mann-Whitney tests were employed to determine 
differences between specific pairs of formulations. This test was used as the data was 
of non-Gaussian distribution.
4.3 Results and Discussion
4.3.1 Transcutaneous delivery of ketoprofen
Figure 4.2 shows that steady state flux of ketoprofen was attained for each formulation 
between approximately 12 and 48 hours.
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Figure 4.2 Permeation profiles o f ketoprofen from form ulations I - V
Permeation data is summarised in Table 4.2, where ketoprofen in water served as 
control and formulation VI is not shown as this was fish oil alone. The lowest flux was 
from the water vehicle control (V) and it is apparent once again that a fish oil vehicle 
alone (I) enhanced the permeation of ketoprofen relative to water, by a factor of 1.72; 
however this flux difference is deemed not significant (p=0.1775). The solubility of 
ketoprofen is 37.6 mg ml’ 1 which is significantly higher than in the water vehicle, 
however both solutions are prepared as 2.5% ketoprofen solutions and so once again 
thermodynamic activity is of less relevance.
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Table 4.2 Summary of permeation data for transcutaneous delivery of ketoprofen (n=6 , ± s.e.m.)
Formulation Lag Time (h) 
± s.e.m
Jss (pg cm 2 h 1) 
± s.e.m
ERflUX 
Form./Keto H2O
ERflux 
Form./Keto FO
I 11.65 ±0.51 11.54 ± 1.84 1.72 -
II 10.82 ± 1.05 13.87 ±2.50 2.06 1.20
III 9.54 ± 0.87 18.51 ±2.19 2.75 1.60
IV 8.55 ±1.13 24.31 ±3.18 3.62 2.11
V 11.0 ± 1.26 6.72 ± 1.78 - 0.58
This enhancement of ketoprofen is probably due to greater absorption of the oil vehicle, 
incorporating the ketoprofen solute, into the lipoidal domains of the stratum comeum, 
followed by diffusion across the viable epidermis and dermis. This was discussed in 
Chapter 3. The presence of the more hydrophilic layers of the epidermis appears not to 
have presented a major obstacle to the permeation of ketoprofen under these conditions.
The enhancement of ketoprofen by fish oil / fatty acids has been discussed in Chapter 3 
and appears to be in action once again. The mechanism of enhancement by fatty acids 
is believed to be by reduction of skin resistance as a permeability barrier by disruption 
of tightly packed lipid regions of the stratum comeum (see Chapter 3). Perturbation has 
the effect of increasing the partitioning of a permeant molecule into the intercellular 
lipid matrix (Barry, 1987; Wang et al, 2003). However, within the fish oil the fatty 
acids are predominantly triacylglycerols, rather than free fatty acids. Therefore uptake 
of oil and ketoprofen would be more likely to be a consequence of absorption due to the 
miscibility between the skin lipids and the oil. In this case ketoprofen permeation in the 
oil would have been enhanced by the “drag” effect of the absorbing oil into the SC.
The enhancement potential of another PUFA, linolenic acid, has previously been 
studied in the transdermal delivery of melatonin across rat and porcine skin (Kandimalla 
et al, 1999) and for luteinizing hormone release hormone across human epidermis 
(Bhatia and Singh, 1999). As is typical in such reports the fate of the fatty acids and 
vehicle were not reported, although the effects of occlusion on the percutaneous 
penetration of linoleic acid was reported (Taylor et al., 2002). A major difference in
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formulations is that this work involved triacylglycerols enhanced to incorporate greater 
proportions of EPA with a small amount of fatty acid ethyl esters, rather than free fatty 
acids -  the latter being more amphiphilic and less liable to absorption by the stratum 
comeum lipids than the more lipophilic fish oil.
Figure 4.2 and Table 4.2 clearly show that there was a dose-dependent increase in the 
permeation of ketoprofen relative to the proportion of 1,8-cineole. The greatest flux of 
ketoprofen, 24.31 ± 3.18 pg cm' 2 h"1, was obtained with formulation IV which contained 
20% w/w 1,8-cineole and was significantly different from both controls (p=0.0043 and 
0.0152 compared to formulation V and I respectively). Terpenoids such as 1,8-cineole 
are believed to act by disruption of lipid bilayers and increasing diffusivity (Yamane et 
al, 1995). When EPA and DHA were present in the formulation a dual action mode of 
enhancement appeared to operate. The Q2 4 and Q48 data also express the same dose 
dependent relationship between ketoprofen and 1 ,8 -cineole flux data with the highest 
Q24 and Q48 values, 355.78 ± 50.73 pg cm' 2 and 963.29 ± 136.69 pg cm' 2 respectively, 
being observed in formulation IV containing 20% 1,8-cineole.
Heard et al. (2003) showed the flux of ketoprofen through full thickness porcine skin
0 1from a saturated fish oil vehicle to be 6.12 ± 2.39 pg cm' h' . This study demonstrated
7 1a flux of 6.72 ± 1.78 pg cm' h' from a 2 .5% w/w aqueous solution (formulation V). 
However the flux of ketoprofen from a 2.5% w/w fish oil vehicle (formulation I) was
n 1
11.54 ± 1.84 pg cm' h' demonstrating a significant improvement compared to either an 
aqueous or saturated fish oil vehicle. This difference may be explained by the dosing 
regime of both studies with the former, although using a saturated solution, dosed a 
finite 2 0 0 pl indicating that the use of a saturated formulation appears to have a 
detrimental effect on ketoprofen permeation.
Loden et al. (2004) achieved a flux of 0.2pg cm ' 2 h' 1 when using a 2.5% ketoprofen 
formulation with 30% ethanol. Ethanol is commonly used as an enhancer and has been 
shown to be very effective in this role. (Williams, 2003) When comparing this study 
with Loden et al. the presence of fish oil and 1,8-cineole appear to have a much greater 
effect than ethanol on the permeation of ketoprofen.
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In a study by Rhee et al. (2001) the flux of a 3% ketoprofen / oleic acid micro-emulsion 
containing 5% cineole was shown to be 11.36 ± 2.17 pg cm2 h'1. This flux is very 
similar to the flux obtained in this study and indicates the presence of EPA and DHA 
had a similar if not slightly greater enhancing effect upon ketoprofen permeation.
4.3.2 Transcutaneous delivery of EPA and DHA
In contrast to the results using thickened (gelled) fish oil, transcutaneous delivery of fish 
oil was confirmed by the cumulative permeation EPA and DHA (Figures 4.3 and 4.4).
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Figure 4.3 Permeation profile o f EPA from formulations I - IV
65
Chapter 4 In-vitro transcutaneous delivery o f  ketoprofen, EPA and DHA from fish oil containing 1,8-
cineole
16 -
E
o>3
COO
30 36 42 480 6 12 18 24
Time (hours)
Figure 4.4 Permeation profile o f DHA from form ulations I - IV
The most surprising observation was that the general shape of the permeation profiles 
was dissimilar to those obtained for ketoprofen and, unlike ketoprofen, the presence of
1,8-cineole had no discernible enhancing effect on EPA and DHA which were both in 
much greater excess than ketoprofen and therefore have a greater possibility of 
interaction. This suggests that the enhancer was acting solely on ketoprofen, possibly as 
the 1,8-cineole may have solvated the ketoprofen in preference to the oil 
triacylglycerols. Furthermore, it is apparent that fluxes of EPA and DHA were not at 
steady state at any time throughout the 48 hour period, instead there was initially more 
rapid permeation followed by an approximately linear secondary permeation phase. 
Reasons for this behaviour are not clear although, breakdown of the barrier may be 
discounted, as ketoprofen provided classical permeation profiles. Saturation of the 
receptor phase can also be discounted as the entire receptor phase was sampled and the 
levels of EPA in the receptor samples were some three orders of magnitude below their 
maximum solubility level (see Chapter 2, Section 2.1.3). It is possible the morphology 
of the skin was altering in response to the permeating oil in a manner that restricted the 
permeation process. Seemingly, this response did not affect permeation of ketoprofen, 
the smaller molecule. The receptor phase itself could be the cause of the difference in 
permeation profiles. The receptor phase should act as a non invasive sink for the
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permeating compounds and therefore produce a standard permeation profile as did 
ketoprofen. If the receptor phase was in some way encouraging the permeation of fish 
oil by provided a more than adequate sink, this may explain the initial rapid flux. 
However, if this was the case then the permeation profile would be expected to increase 
with time in a uniform manner following the pattern of the initial rapid flux, as the dose 
is infinite and at each time point the complete receptor phase is sampled. This does not 
happen and the permeation profile tails off as it would with a finite dose of formulation. 
Further explanations and possible experimentation for this must therefore be considered.
Table 4.3 summarises the permeation data. Formulation I, containing no 1,8-cineole,
9 1 <gave the highest first and second phase fluxes of EPA at 1.89 pg cm* h* (67.20 x 10* 
% of dose) and 0.36 pg cm* h* (8.44 x 10* % of dose) respectively. Surprisingly the 
inclusion of 10% 1,8-cineole (formulation III) produced the lowest first phase flux. 
Unexpectedly the lowest second state flux was seen with formulation IV containing the 
highest percentage of the enhancer, 20% w/w.
Table 4.3 Summary of the flux data for the in vitro transcutaneous delivery of EPA and DHA
Formulation Dose SSF 1st Phase (pg cm 2 h*1) SSF 2nd Phase (pg cm 2 h *)
EPA DHA EPA DHA
I Keto FO 1.89 ±0.26 1.03 ±0.06 0.36 ± 0.06 0.24 ± 0.03
II 5% 1,8-cineole 1.38 + 0.14 0.93 ±0.18 0.34 ± 0.04 0.21 ±0.01
III 10% 1,8-cineole 0.74 ± 0.20 0.71 ±0.11 0.25 ± 0.03 0.22 ± 0.02
IV 20% 1,8-cineole 0.96 ±0.14 0.93 ± 0.08 0.24 ± 0.03 0.21 ±0.03
V Keto H20 - - - -
VI Fish oil 0 0 0 0
Statistical analysis showed there to be a significant difference in the first phase flux of 
EPA in formulations IV (p=0.0087) and III (0.0173) compared to formulation I. No 
significant difference was observed in the second phase fluxes of formulations II, III, IV 
relative to formulation I (p = >0.25 for each formulation). Lag times were too short to 
be measured.
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No significant effect of 1,8-cineole was seen on the permeation of DHA. The greatest 
first phase flux, 1.03 p,g cm'2 h '1 (57.50 x 10'5 % of dose), was once again seen in
'y i
formulation I which contained no 1,8-cineole. The lowest flux, 0.21 p,g cm' h' (12.74 
x 10'5 % of dose), was seen in the second steady state in formulation IV containing 20% 
w/w 1,8-cineole. Statistical analysis showed no significant difference between either 
first or second phase fluxes of formulations II, III and IV relative to I (p = >0.10 in each 
case).
Neither EPA nor DHA were detected for formulations V and VI. As permeation of 
EPA and DHA was seen in formulations I, II, III and IV and the common component in 
these formulations was ketoprofen, it can be hypothesised that ketoprofen has a 
permeation enhancing effect on EPA and DHA. This is a subject studied in Chapters 7, 
8 and 9.
The first phase flux data for both EPA and DHA show no clear pattern of the effect of
1,8-cineole. The second phase of steady state however shows an inverse dose 
dependent relationship between the concentration of 1,8-cineole and the flux of both 
EPA and DHA i.e. as the concentration of 1,8-cineole increases the second phase flux of 
both EPA and DHA decreased.
The very low permeation percentages (Table 4.4) are due in part to the high lipophilicity 
of the oil and its inefficiency in permeation (Taylor et al., 2002) and also reflect the fact 
that when infinite doses of EPA and DHA are applied, high absolute values may appear 
low when reported as a percentage of that infinite dose.
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Table 4.4 Percentage of the applied dose of EPA and DHA
Formulation Dose Percentage of applied dose 
1st Phase (10 5)
Percentage of applied dose 
2nd Phase (10 s)
EPA DHA EPA DHA
I Keto FO 67.20 57.50 8.44 25.33
II 5% 1,8-cineole 51.55 54.60 7.87 20.17
III 10% 1,8-cineole 28.41 43.08 8.38 14.93
IV 20% 1,8-cineole 42.09 64.08 7.16 12.74
V Keto H20 - - - -
VI Fish oil - - - -
The Q24 and Q48 data (Table 4.5) do not show a clear relationship between the 
permeation of EPA or DHA and concentration of 1,8-cineole, reflecting the pattern 
shown in Figures 4.3 and 4.4. There appeared to be an inverse dose dependent 
relationship until formulation IV where the permeation increased slightly.
Table 4.5 Amount permeated (Q2 4 and Q48) values for EPA and DHA
Formulation Dose Q 24 Values (pg cm'2) 
± SEM
Q 48 Values (pg cm'2) 
± SEM
EPA DHA EPA DHA
I Keto FO 20.19 ± 2.18 11.14 ± 1.31 28.87 ±2.97 15.61 ±2.24
II 5% 1,8-cineole 15.17 ±2.26 8.89 ±1.56 23.42 ± 1.83 14.27 ± 1.55
III 10% 1,8-cineole 10.30 ± 1.44 8.88 ±0.87 17.00 ±0.95 13.11 ± 1.36
IV 20% 1,8-cineole 11.47 ±0.92 10.75 ±0.98 16.11 ±0.79 15.13 ±1.32
V Keto H20 - - - -
VI Fish oil - - - -
The importance of vehicle formulation is well established. For example, it was recently 
demonstrated that it is possible to disturb SC lipids using fatty acids with short chains in 
a lipophilic mineral oil formulation, but not with formulations based on propylene
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glycol (Wang et al., 2003). It is a basic physicochemical concept that solutes exist in 
discrete solvation cages, although a less well-probed phenomenon is that of differential 
solvation (Duffy and Jorgensen, 2000; Diaz and Berger, 2001) within a vehicle and its 
consequences in topical drug delivery (Heard et al., 2003: Karia et al., 2004). The 
nature of solvated permeant molecules depends on the mutual interactions between all 
species present within the formulation. It is feasible then, that the differences seen in 
enhancement between the PUFAs and ketoprofen were due to selective solvation by
1,8-cineole. Solvation of the smaller, more functionalised ketoprofen molecule is likely 
to have been preferential to the solvation of the large sterically hindered triacylglycerol 
units and therefore ketoprofen permeation may be expected to be relatively greater.
As EPA and DHA were both administered principally as triacylglycerols the main 
barrier to transcutaneous permeation would have been the aqueous domains of the 
viable epidermis and the dermis which are substantially more polar than the lipoidal 
domains of the stratum comeum. This may explain the very low levels of EPA and 
DHA in the receptor solutions. The lack of direct correlation between the concentration 
of 1,8-cineole and the permeation of EPA and DHA may be explained by the method of 
enhancement of 1,8-cineole. Terpenoids act as enhancers by the unpredictable 
disruption of lipid bilayers within the stratum comeum, although the dose dependency 
of such effects is less well documented.
Williams et al. (2006) have recently changed the common opinion of terpenoid 
enhancement by investigating the molecular interactions between 1,8-cineole and 
human skin using Raman spectroscopy. They concluded that 1,8-cineole causes both 
disruption of SC lipids and an increase of the order of these lipids. The difference 
between the areas of order and disorder allows the increased dmg delivery seen after 
application of 1,8-cineole. At levels up to 10% 1,8-cineole the integrity of the skin may 
be intact and the balance between the ordered and disordered areas of the stratum 
comeum lipids may lie in the favour of ordered lipid domains, maybe incorporating a 
certain amount of the permeating lipids, i.e. EPA and DHA. However, at 20% 1,8- 
cineole far greater disruption to the integrity of the skin may have occurred and more 
disorder of the skin lipids takes place, allowing greater permeation of ketoprofen and
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fish oil. This could explain the increase in the first phase flux of EPA and DHA in 
formulation IV. Formulation I has no interference from an increase or decrease in the 
order of SC lipids and so greater concentrations of EPA and DHA can permeate without 
uptake into cell bilayers.
Negligible amounts of EPA or DHA permeated from formulation VI which consisted of 
100% fish oil. The main barrier to the transcutaneous permeation of a highly lipophilic 
substance would have been the dermis, which is substantially more polar than the 
lipoidal domains of the stratum comeum. With no other compound present it is possible 
that no oil could permeate as it may need to complex with another compound in order to 
permeate via the “drag” effect. The surprising inference from this chapter was that 
ketoprofen enhanced the permeation of EPA and DHA in the other formulations 
suggesting the need for a co-permeant. This phenomenon is studied in greater depth in 
Chapters 7, 8 and 9.
Differences in the permeation of EPA and DHA were expected due to the different 
concentrations of the two within the fish oil, although no distinct pattern in the 
permeation of the two fatty acids was observed. This could be explained by differential 
metabolism within the freshly excised skin.
4.5 Conclusions
Simultaneous permeation of ketoprofen and EPA/DHA has been confirmed. The 
permeation of ketoprofen from a fish oil vehicle increased by a factor of 1.72 compared 
to an aqueous solution of the drug. A concentration dependent relationship was found 
between the flux of ketoprofen and the concentration of 1,8-cineole, although no clear 
effects were seen on the permeation of EPA and DHA as fish oil. However, 
explanations of resulting patterns of permeation have presented themselves through 
recent findings concerning the action of 1,8-cineole (Williams et al., 2006). This may 
also have been due to differential solvation effects in the vehicle or in the permeation 
process, or modulation of the barrier which affected the permeation of oil but not
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ketoprofen. 1,8-cineole has recently been shown to permeate full thickness porcine skin 
in a concentration dependent manner (Heard et al., 2006). The preferential solvation of 
ketoprofen by 1,8-cineole and the resulting drag effect could explain the concentration 
dependent enhancement seen throughout this chapter. The combination of both fish oil, 
aiding the permeation through the lipophilic SC, and 1,8-cineole, aiding permeation 
through the remainder of the epidermis and dermis via complexation, leads to the very 
large flux values of ketoprofen. The loss of this solvent from the formulation could 
cause an alteration to the thermodynamic activity of ketoprofen and act as another 
enhancement mechanism. If developing a formulation containing 1,8-cineole this must 
be studied further and toxicity and the fate of 1,8-cineole after leaving the formulation 
must also be determined.
The maximum flux of ketoprofen achieved in Chapter 3 was 0.6203 ± 0.071 lpg cm'2 h '1 
when using the 20% fish oil gel. This is ten fold less than formulation V and again 
indicates the severe retardation affect of the HPC thickening agent upon permeation.
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Chapter 5 Delivery of EPA and Ketoprofen to Excised Porcine Joint Capsule
5.1 Introduction
With the knowledge gained in the previous chapter concerning the delivery of EPA and 
ketoprofen through skin, this chapter investigated permeation deeper into the underlying 
joint capsule. All articular joint capsules are similar in nature comprising of two bones, 
with their ends covered in articular cartilage converging and held in place by tendons 
and ligaments. The joint is covered by a membrane called the synovium which 
produces synovial fluid. Synovial fluid is the main source of nutrients to the cartilage 
and contains hyaluronan to act as a shock absorber to the joint and to allow smooth 
movement between the limbs. The synovium outer layer is a fibrous joint capsule. See 
Figure 5.1.
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Figure 5.1 Anatom y o f the knee 
(http://www.healthsystem .virginia.edu/)
Intra-articular drug delivery is currently under great scrutiny. As RA is an 
inflammatory disorder, treatment of the external areas of the joint, the swollen joint
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capsule and synovium is paramount. The link between this and OA is discussed in 
detail in Chapter 6, where the synovium and external areas of the joint contribute to the 
destruction of cartilage and overall progression of the disease. In OA, cartilage also 
releases pro-inflammatory mediators and cytokines and to treat this type of arthritis 
requires the delivery of drugs into the synovial fluid. When delivering EPA in either 
disease, RA or OA, the passage of EPA is the same. EPA must first permeate through 
the external joint, followed by the joint capsule, synovium, then into the synovial fluid 
and ECM of cartilage followed by incorporation into the chondrocytes. As EPA 
permeates these tissues its effect can be exerted on the inflammation process occurring 
in each tissue. The permeation process in itself has obvious benefits, not just the 
incorporation into cartilage, as by permeating each inflamed tissue it can help in the 
treatment of the symptoms and progression of the disease states. There are currently 
several DMARDs available for use in RA and these can slow the progression of this 
disease. OA has no such treatment available and current medical therapies are of 
limited effectiveness (Abramson, 2006). These treatments rely on the use of NSAIDs 
and nutraceuticals such as glucosamine given orally. Intra-articular therapies for OA 
and RA include injections of corticosteroids and the hyaluronans. The intra-articular 
route offers the possibility of delivering high concentrations at the site of action and 
also the delivery of drugs with low oral bioavailability. Intra-articular drug delivery 
does pose significant disadvantages. Multiple injections into the joint are very 
inconvenient and painful for patients and drugs injected into the joint space may also be 
cleared relatively quickly by the synovium. Transcutaneous delivery of a natural 
product which would be used in every part of the joint and if in excess likely to be 
incorporated into surrounding chondrocytes and synoviocytes, presents an ideal 
mechanism for the treatment and symptomatic relief and of both RA and OA. The sub­
cutaneous approach has been used to deliver the anti IL-ip receptor antibody, AMG108, 
offering advantages by accessing all areas of the joint in both disease states (Abramson, 
2006).
The delivery of ketoprofen into the joint space also has clear benefits as inhibition of 
COX has been well documented to assist with the inflammation and pain associated 
with both RA and OA. It has been reported, when using a multi-chamber distribution
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dialysis system, that a non-stereoselective affinity of ketoprofen enantiomers for 
articular tissues is observed, with ketoprofen becoming more concentrated in solutions 
of synovial membrane, joint capsule and ligament compared to much lower 
concentrations achieved within those of articular cartilage (Lagrange et al., 2001). This 
may be due to the inability of ketoprofen to traverse the negatively charged ECM. 
However, when multiple topical applications of ketoprofen were employed, a 6 -  10 
fold concentration increase in cartilage and menisci compared to synovial tissue was 
observed (Rolf et al., 1999). This again shows promise as the combined delivery of 
ketoprofen and EPA would help all areas of inflammation.
The concentration within the joint post application will be fundamental to the efficacy 
of an EPA / ketoprofen formulation.
The aim of this chapter is to determine the extent to which EPA and ketoprofen may 
permeate the joint capsule and become bioavailable within synovial fluid in a joint. 
This was achieved by using a porcine hock model. Clearly, the most appropriate model 
would have been a freshly excised joint complete with skin prior to steam cleaning. 
However, this was impossible to obtain due to food regulations. Furthermore, 
permeation data already exists for permeation of EPA and ketoprofen through skin, 
which would be expected to constitute the rate-limiting barrier.
All further work focused on EPA alone as Volker et al. (2000) found an EPA based diet 
to be more effective in the suppression of inflammation than a DHA diet in their rat 
model of streptococcal cell wall arthritis.
5.2 Materials and methods
5.2.1 Materials
Fish oil capsules lOOOmg (Boots Super Strength, batch number: 30446M) were 
purchased from a local store. Ketoprofen, butylated hydroxyanisole (BHA) and 
cetrimide and HPC were obtained from Sigma -  Aldrich Company Ltd., Poole, UK.
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Methanol (HPLC grade) was obtained from Fisher Chemicals, Loughborough, UK. All 
other reagents were of analytical grade or equivalent. Porcine carpal joints were 
obtained from a local abattoir post steam cleaning and refrigeration for approximately 
24 hours. The skin was then removed from the joint avoiding the removal of tendon 
and ligaments and used immediately.
5.2.2 Preparation of formulations
A fixed sub-saturated dose of ketoprofen (2.5% w/w) in fish oil was used as in previous 
chapters. The appropriate masses of ketoprofen and fish oil were combined, in addition 
to BHA (0.05% w/w) to inhibit PUFA degradation, and the formulation vortex mixed. 
Due to the difficulty of application of a liquid (fish oil) onto curvature of the porcine 
joint, it was necessary to thicken the formulation to stop the liquid running off the joint 
and was acheived by the addition of HPC, approximately 8%. In Chapter 3 it was found 
that this retarded the permeation of EPA. In this study however the vehicle itself was 
fish oil and not limited to a maximum of 20% and therefore the need for thickening of 
the formulation was thought to out-weigh the possible retardation affects. The 
formulations were stored at 2-4°C until required (< 24 hours).
5.2.3 In-vitro joint capsule permeation experiments
Joint capsule permeation experiments were carried out using the carpal joint of the 
forelimb of the pig (Figure 5.2). A donor chamber was pre-greased and placed onto the 
skinless joint over the carpometacarpal compartment and secured in place using 
adhesive tape. The formulation (1ml) was then added into the donor chamber and 
occluded. After the required time the donor cell was removed, the joint cleaned 
thoroughly and washed several times with MeOH then wiped using paper tissues until 
no visible traces of formulation remained. The underlying synovial fluid was then 
extracted using a sterile 5 cm hypodermic needle and 5ml syringe and samples were 
stored at -20°C prior to analysis. A total of four replicates were carried out for each 
time point.
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Figure 5.2 Carpo-m etacarpal joint (highlighted) o f a porcine forelim b
5.3 Analytical Methods
5.3.1 Extraction of ketoprofen and EPA from synovial fluid
The EPA within a fixed volume of synovial fluid (200pl) was extracted by the addition 
of methanol (4ml) to the synovial fluid and sonication for 10 minutes. The resulting 
solution was then centrifuged at 9000 rpm for 10 minutes. The supernatant was then 
sampled with EPA and ketoprofen concentrations determined by HPLC analysis as 
described in Chapter 2, Sections 2.2.3 and 2.2.4 respectively.
5.4 Results and Discussion
Figure 5.3 illustrates the cumulative permeation of both EPA and ketoprofen in the joint 
capsule synovial fluid. It must be noted at this stage that the concentrations shown are 
calculated from the sampling of 200pl of synovial fluid. This is due to the variations in 
the volume of synovial fluid removed from the joints, which is related to the size of the 
forelimb itself. To keep consistency between the different limbs a value of 200pl was 
chosen as this was the minimum volume of fluid that could be removed.
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Figure 5.3 Delivery o f EPA and ketoprofen into porcine joint capsule (n = 4, ± s.e.m.)
5.4.1 Permeation of EPA
Approximately 30-40pg of EPA permeated into the synovial fluid within the joint space 
after 24 hours. Interestingly there seems to be a plateau of delivery after only 3 hours. 
EPA is very lipophilic both as the triglyceride and free fatty acid and it is possible that 
the synovial fluid can become saturated with fats / fatty acids. If the majority of 
permeated EPA can become incorporated within the cartilage then this will dramatically 
reduce the inflammation cascade seen with RA and OA. The permeation through a 
swollen synovium will also be beneficial in both disease states as it is the synovium 
which contributes a large proportion of inflammatory cytokines and the presence of 
EPA will reduce the induction of these mediators. If this production can be reduced at 
the source then the benefits are obvious.
It is worthy of note that throughout the literature it is very difficult to find a therapeutic 
dose for EPA. Curtis et al., (2000) used an EPA dose of 70pg ml’1 when conducting 
their experiments with ex-vivo cartilage ex-plants, to mimic human plasma fatty acid
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levels. In these experiments, detailed in Chapter 6, they found this to be a suitable dose 
to inhibit the inflammatory cascade.
The skin permeation seen in Chapter 4 indicated that only approximately 20pg EPA had 
permeated the full thickness porcine skin after 24 hours. This result suggests that the 
best use of an EPA topical formulation to treat arthritis would be repeated applications 
to accumulate EPA within the synovial fluid up to a concentration of approximately 
70pg ml"1. This repeated application would also serve to keep a constant concentration 
within the inflamed tissues surrounding the joint and help balance out the removal of 
these fatty acids into the systemic circulation. The percentage of EPA permeated from 
the applied dose is shown in Figure 5.4. The percentage values are small which is 
expected given the infinite dose regime. These values follow the permeation trend of a 
seemingly steady state and plateau of permeation.
0.35
- • —% of ketoprfoen from dose
0.3
0.25
0.2
o 0.15
0.1
0.05
0 3 6 9 12 15 18 21 24
Time (hours)
Figure 5.4 Percentage o f EPA from applied formulation (± s.e.m.)
5.4.2 Permeation of ketoprofen
Figure 5.3 shows the permeation profile for ketoprofen. The synovial fluid solubility 
for ketoprofen appears to be higher than that of EPA which explains the greater
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concentration of ketoprofen present after 24 hours. Comparing this to the skin 
permeation however shows that a lower concentration of ketoprofen permeated. The 
maximum ketoprofen concentration through skin after 24 hours was approximately 
144pg as opposed to approximately 55pg through into the joint capsule. This difference 
could be explained by the difference in the type of membrane i.e. joint capsule versus 
full thickness skin. These results still show promise, as if 144pg permeates through the 
skin after 24 hours then this allows the 55pg (38% of the mass that can permeate full 
thickness porcine skin) to permeate into the synovial fluid in the same period. The 
bioavailability from an oral dose of 150mg can reach a plasma concentration of 15-25pg 
ml"1 which is much higher than the therapeutically active concentration (Upton et al., 
1981). Roda et al. (2002) have studied a sustained release formulation of ketoprofen 
(lOOmg) and found plasma levels to reach 4pg ml'1 two hours after oral dosing and 
remain constant for up to twelve hours. In this chapter twelve hours after topical dosing 
onto the skinless joint allows a concentration of approximately 21pg m f1 to be 
delivered into the synovial fluid. This would be less with the skin membrane present 
but should still deliver a therapeutic dose.
It is interesting to note that both EPA and ketoprofen show a similar delivery profile. In 
Chapter 4 it was noted that the two profiles were substantially different and showed that 
EPA appeared to have an initial rapid flux followed by a period of steady state. 
Ketoprofen showed a classic permeation profile. The similarity in profiles seen in this 
experiment might be due to the difference in the membrane that is being crossed. The 
joint capsule and synovium may be an easier barrier to traverse for EPA and combined 
with the decrease in ketoprofen permeation, would indicate that the nature of the barrier 
is more lipophilic. The skin barrier is designed to keep out exogenous molecules and is 
therefore expected to have a greater barrier function. The internal barrier of the joint 
capsule has no such function and permeation through to underlying tissue is important 
to allow adequate nutrition.
The difference may be due to the sampling method of the experiment. Samples from 
the same joint were not taken throughout the time period as this would have punctured 
the joint capsule. The size of the joints used in the experiment did differ slightly and as
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a consequence the thickness of tissue between the surface and the synovial fluid within 
the joint capsule also differed. This made it very difficult to keep consistency within 
the experiment and could explain the permeation profiles becoming similar. However 
this slight inconsistency is representative of the variation between human joints and 
between individual patients that would be seen during in-vivo experiments.
Recently comparisons between routes of administration of nimesulide, a COX-2 
inhibitor were made by studying the concentration of the drug within synovial fluid. It 
was found that nimesulide did indeed permeate into the synovial fluid from topical 
application and achieved a concentration of 19.7 ± 8.6 ng m l'1. This was compared to 
1958.8 ± 397.5 ng ml'following oral therapy. (Erdogan et al., 2006). They also found 
that a repeated dose, using one week of three times daily application, provided a 
significant improvement in all WOMAC Osteoarthritis Index parameters.
5.5 Conclusions
The delivery of EPA and ketoprofen through a typical joint capsule and into synovial 
fluid has been demonstrated after only 3 hours. The permeation through the joint 
capsule is itself a fundamental discovery for determining the efficacy of a topical fish 
oil / ketoprofen formulation. If both compounds can permeate this barrier then both 
compounds can act upon the barrier and exert their anti-inflammatory effects.
It has been shown that the solubility of these compounds within synovial fluid is an 
important factor in determining this delivery. This need not present a significant 
problem as the joints in this experiment were without a skin barrier. The rate of 
permeation combined with the uptake of EPA into the systemic circulation and the use 
of EPA by inflammatory mediators as it permeates the inflamed tissues would limit the 
concentration of these compounds reaching the joint and so saturation of the synovial 
fluid is unlikely. Also of note is the solubilisation of both compounds within synovial 
fluid. As in all mechanisms there must be a driving force for permeation and in most
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cases this lies with the ability of the underlying tissues to accept / solubilise the 
permeating compounds. If this did not happen the compound would not permeate.
Despite the imperfections of the model, combining these findings with those of Chapter 
4 demonstrates the potential of a formulation such as this. The ability of the 
formulation, even in such a basic form, to deliver both EPA and ketoprofen has been 
shown.
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Chapter 6 Incorporation o f EPA into ex -vivo bovine cartilage following in-vitro transcutaneous delivery
6.1 Introduction
Chapters 3 and 4 demonstrated that the simultaneous transcutaneous permeation of 
NSAID and essential fatty acids from fish oil across excised pig skin using a fish oil 
vehicle was possible. Chapter 5 examined the permeation through the joint capsule into 
synovial fluid. This was found to be possible, indicating the potential value of such a 
formulation in RA and OA. It was considered important to ascertain if the permeated 
EPA could be incorporated into cartilage using an in-vitro model. Following this, the 
possibility that incorporated EPA could inhibit the production of the potent 
inflammatory mediators and hence reduce or halt the degradation of cartilage was 
studied.
To establish the potential of EPA to exert-an anti-inflammatory and anti-degenerative 
effect in both rheumatoid arthritis and osteoarthritis the pathology of the disease states 
must first be examined. As the two diseases are different in many ways, the plausibility 
of EPA being able to treat symptoms of both and to prevent further deterioration is a 
fundamental factor to consider. There are certain similarities between the two and these 
are discussed in the following sections and an insight to treating both diseases with EPA 
is established.
6.1.1 Cartilage metabolism
The subchondral bone is covered by articular cartilage that consists of chondrocytes 
embedded in a specialised ECM containing collagens and proteoglycans that are unique 
to cartilage. As there are no blood vessels, nerves, or lymphatics within such tissue, 
chondrocytes derive their nutrition in two ways. Firstly by passive diffusion from the 
blood supply in the subchondral bone and, secondly, from diffusion from the synovial 
fluid (Goldring and Goldring, 1999). Under normal conditions, chondrocyte production 
is limited and penetration of other cell types from the joint space or subchondral bone is 
restricted. Thus the chondrocytes actively maintain a stable equilibrium between 
synthesis and degradation of matrix components (Poole, 1993). During aging and in 
inflammatory and degenerative joint diseases, such as RA and OA, this stable 
equilibrium is disrupted and the rate of loss of collagens and proteoglycans from the
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matrix exceeds the rate of deposition of newly synthesised molecules (Poole, 1993) 
This metabolic imbalance leads to a progressive loss of articular cartilage and disruption 
of normal joint function.
6.1.2 Cartilage loss in RA
Cartilage destruction in RA occurs primarily in areas connected with the proliferating 
synovial pannus (Kobayashi and Ziff, 1975; Woolley et al., 1977) and to some extent at 
the cartilage surface exposed to the synovial fluid (Kimura et al., 1977; Dodge and 
Poole, 1989) due to the release and activation of proteinases from the synovial cells and 
polymorphonuclear leukocytes, respectively. In early RA, loss of proteoglycan occurs 
throughout the cartilage matrix and is not limited to the synovial-pannus junction 
(Mitchell and Shepard, 1978).
Destruction and loss of cartilage is triggered by the release of IL-1, a primary regulator 
of inflammatory response, both within cartilage chondrocytes and cells in the 
surrounding synovial fluid. This in turn causes the stimulation of potent inflammatory 
mediators, namely prostaglandins and leukotrienes by increasing COX-2 levels as 
detailed in Chapter 1. These mediators inhibit proteoglycan synthesis and initiate the 
release of MMPs which are involved in the breakdown of collagen and other proteins 
within the cartilage ECM.
6.1.3 Cartilage loss in OA
Cartilage loss in osteoarthritis is a direct consequence of the disease and both primary 
(idiopathic) or secondary (caused by major trauma) OA result in a breakdown of 
articular cartilage. This is caused by an imbalance of applied mechanical stress and the 
inability of the cartilage to overcome this stress. (Aigner et al., 2006) The resulting 
osteoarthritis ensues from the destruction of the ECM and the inability of the 
chondrocytes present in the cartilage to respond to such stimuli. Kurz et al., (2005) 
have suggested that, when exposed to a large mechanical force, the chondrocytes appear 
to switch from a state of low metabolic activity to that of one that stimulates production
86
Chapter 6 Incorporation o f EPA into ex-vivo bovine cartilage following in-vitro transcutaneous delivery
of the many inflammatory mediators, including IL-1. When coupled with the lipid 
based mediators, PG and LT, the chondrocytes serve to increase their own catabolic 
activity resulting in the release of proteolytic enzymes (such as aggrecanses and 
MMPs), culminating in the destruction of the ECM (Loeser, 2006).
6.1.4 Efficacy of EPA treatment
As discussed in detail in Chapter 1, the main mechanisms behind the anti-inflammatory 
action of EPA lies in its ability to actively compete against AA. This results in the 
production of less potent inflammatory mediators via the COX and LOX pathways and 
inhibition of the expression of inflammatory cytokines, namely IL-1, TNF-a and COX- 
2 itself. Both RA and OA disease states are facilitated by the production of these 
mediators and the further expression of cytokines in the form of an auto-catalytic 
production cycle. Abramson and Yazici (2006) state that at the molecular level joint 
tissue, including synovium, joint capsule and cartilage are the site of production of the 
aforementioned molecules which are associated with inflammation and perpetuate joint 
damage and inevitably destruction. Figure 6.1 illustrates the main characteristics of RA 
and OA. Studies have shown that the metabolism of AA by COX-2 and 5-lipoxygenase 
(5-LOX) yielding these inflammatory mediators can be inhibited by the long chain n-3 
polyunsaturated fatty acids such as EPA. Substantial work that highlights the 
effectiveness of NSAIDs in inhibiting the COX enzyme has also been carried out. 
Coupled with the knowledge that the presence of an NSAID, in this case ketoprofen, 
also enhances permeation of EPA the rationale for a system containing both n-3 fatty 
acids and an NSAID is justified.
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Figure 6.1 Disease progression of RA and OA
Curtis et a l, (2002) have provided evidence supporting supplementation with n-3 fatty 
acids. This study, carried out using well established culture models from normal bovine 
and human osteoarthritic cartilage, showed a dose-dependent reduction in the 
expression and activity of aggrecanases and the expression of inflammation-inducible 
cytokines, IL-1, TNF-a and COX-2.
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In a study by Bousserouel et al., (2003) EPA and DHA were shown to abolish the 
production of the prostaglandin PGE2 by inhibiting the IL-1 (3 induced production of 
COX-2 mRNA. They concluded that EPA and DHA act in opposition to AA by 
altering different steps of the inflammatory process induced by IL-1 p. In another study 
investigating the possible anti-inflammatory effects of EPA on the brain of aged rats via 
an IL-1 p modulatory pathway, Lynch et al. (2003) showed EPA to exert an effect upon 
the IL-1 p mRNA expression itself and thus prevented the age-related increase of the 
resulting IL-ip protein.
The aim of this chapter was to develop a novel in-vitro system for modelling the effect 
of fish oil on a sample of live cartilage following delivery across full thickness skin and 
further indicate the plausibility and efficacy of a transcutaneous fish oil formulation.
6.2 Development o f‘model joint’ system
To determine whether topically delivered EPA could be incorporated into a sample of 
viable cartilage, a ‘model joint’ system was developed. Ideally, this system would need 
to mimic a typical human joint (see Figure 6.2) undergoing topical treatment with an 
EPA formulation and must include the following:
1) A skin barrier overlying the model joint beneath.
2) Synovial fluid or an in-vitro substitute to determine the possibility of 
diffusion through the joint space and into the cartilage.
3) Ex-vivo viable cartilage ex-plant
Figure 6.2 A normal joint indicating, (1) skin membrane, (2) synovial fluid and (3) cartilage
89
Chapter 6 Incorporation o f  EPA into ex-vivo bovine cartilage following in-vitro transcutaneous delivery
An appropriate model would allow determination of EPA permeation through skin, 
diffusion through a model synovial fluid and subsequent incorporation into ECM of 
cartilage.
The model joint pictured in Figure 6.3 is the most representative in-vitro model 
attainable in this work. Ligament and synovial membrane tissue is lacking from the 
model joint due to the inability to obtain viable tissue samples. Also absent is the 
process of dermal clearance. The absence of these tissues and process limits the model 
joint to a certain degree, however during rheumatoid and, to a lesser extent 
osteoarthritis, the synovial membrane is swollen and stretched which should allow 
greater permeation of both EPA and ketoprofen. Modelling the joint without these 
tissues should not detract from results gained from the system as the major components 
of the joint are still present. The presence of EPA and ketoprofen in the swollen 
synovial membrane will also allow the compounds to ease the pain and inflammation 
occurring within the tissue.
'onor chamber
Skin membrane
Cartilage ex-plant
Figure 6.3 The model joint indicating, skin m em brane, model synovial fluid and cartilage ex-plant
6.3 Materials and Methods
Viable bovine articular cartilage was obtained from the metacarpophalangeal joints of 
1-2 week old calves. Ex-plant cultures of 1-2 mg wet weight of cartilage were 
established as described Little et al., (1999) and maintained for 4 days in approximately 
10ml filtered bovine foetal calf serum. They were then washed with 4 x 10ml of filtered 
serum free medium containing 10% gentamicin. This section of work was carried out
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under supervision by Dr. Clare Hughes and Prof. Bruce Caterson of the Cardiff School 
of Biosciences whose work on cartilage destruction has been well documented, 
Caterson et al., (2000); Curtis et al., (2000); Curtis et al., (2004).
6.3.1 Preparation of formulations
Each formulation was prepared as a 2.5% w/w formulation of ketoprofen in fish oil. 
The required mass of fish oil was weighed and BHA (0.05%w/w) added. The 
appropriate weight of ketoprofen was added and the formulation vortex mixed until full 
dissolution had occurred. An n-3 (EPA) formulation was also prepared by the addition 
of 240 pi (approximately 120mg) to 1ml of receptor phase solution (Dulbeccos serum 
free medium containing 10% gentamicin). The same receptor phase solution was used 
as a control formulation containing no n-3 fatty acids.
6.3.2 In-vitro skin permeation and cartilage incorporation study
Skin permeation experiments were carried out using glass Franz type diffusion cells as 
Chapter 2, Section 2.1. After sufficient culture time and rinsing protocol a sample of 
cartilage approximately 2mm x 2mm was added to each receptor phase compartment 
using sterile forceps within a laminar flow cabinet. The receptor phase chamber was 
then filled with receptor phase ensuring no air was present beneath the skin. The donor 
chambers were then filled with an infinite dose of formulation (1ml, approximately
0.8g) and the chamber occluded with perforated laboratory film. The complete cells 
were incubated at 37°C. A total of six replicates were carried out for the fish oil 
formulation and six replicates for the n-3 fatty acid formulation. Three cells of each 
formulation were removed after 48 hours incubation. The receptor phase was removed 
and frozen for analysis. The cartilage was stored separately, also at -20°C. The 
remaining cells were left to incubate until 72 hours when the receptor phase and 
cartilage were removed and stored as above. Three control cells were also analysed 
utilising the receptor phase solution as a control formulation. These cells were removed 
after 72 hours and the receptor and cartilage again stored as above.
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6.3.3 Extraction of EPA from bovine cartilage ex-plant
To analyse any incorporated EPA the cartilage sample was first comminuted. This 
breaks down the cartilage to cellular level and allows extraction of the EPA. The 
cartilage was first frozen with liquid nitrogen and then added to the comminution 
chamber with a solid steel ball. After 5 minutes comminution at 9000 rpm, PBS (1ml) 
was added to the powdered cartilage. To this solution, chloroform / methanol (1:2) 
(3.75ml) was added and this mix vortexed and left at room temperature for 30 minutes. 
Chloroform (1.25ml) and Garbus solution (2M potassium chloride in 0.5M potassium 
phosphate buffer, pH 7.4) (1.25ml) were then added and the solution once again 
vortexed. The chloroform phase, containing the phospholipid, was then removed and 
evaporated to dryness under nitrogen. The remaining solid was then derivatised as 
detailed in Chapter 2, Section 2.2.2. The fatty acid methyl esters were then analysed by 
HPLC as described in Chapter 2, Section 2.2.2.1.
6.3.4 Initiation of IL-1 degradative response
After incubation for 72 hours the receptor phase was removed for analysis and the 
cartilage washed with 3 x 10ml Dulbeccos serum free medium. An appropriate aliquot 
of IL-1 was then added to 2ml of the chosen samples in a 24 well plate and incubated 
for a further 72 hours. The media was then analysed for lactate concentration (an 
indication of metabolism of the cartilage) and for GAG (indicative of cartilage 
degradation).
6.3.4.1 Lactate assay
A vial of lactate reagent was dissolved in water (10ml) with gentle inversion. The 
lactate reagent (250pi) was then added to a sample of media (5pl) from each well. The 
solutions were then placed in a spectrophotometer and analysed at 540nm. A standard 
curve of 25-400pg/ml was employed. Increased lactate is indicative of a higher 
metabolic activity and conversely decreased lactate shows a reduced metabolic activity.
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6.3.4.2 Dimethylene methyl blue (DMMB) GAG assay
DMMB solution (200|l x 1) was added to each well in a fresh well plate containing the 
sample media (40pl) and water (20pl). Analysis was carried out by spectrophotometry 
at 540 nm employing a standard curve of 0 - 40pg/ml GAG.
6.4 Results and Discussion
6.4.1 Transcutaneous delivery and incorporation of EPA into cartilage - 1
Table 6.1 shows the average mass of EPA detected in the receptor phases of all samples 
after 48 and 72 hours, indicating the average mass of EPA permeated after both time 
points.
Table 6.1 Average mass of EPA permeated into the receptor phase
Formulation Time point Average mass of EPA (pg) ± 
S.E.M.
Fish oil 48 hours 3.16 ±0.004
Fish oil 72 hours 3.53 ± 1.5948
n-3 control dose 48 hours 2.64 ±0.1154
n-3 control dose 72 hours 2.68 ± 0.9606
Table 6.2 illustrates the average mass of EPA present in the comminuted cartilage. This 
is indicative of the mass of EPA incorporated into the chondrocyte cells within the 
cartilage.
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Table 6.2 Average mass of EPA incorporated
Formulation Time point Average mass of EPA (pg) ± 
S.E.M.
Fish oil 48 hours 0.71 ±0.0451
Fish oil 72 hours 0.44 ±0.1796
n-3 control dose 48 hours 0.30 ± 0.0306
n-3 control dose 72 hours 0.37 ± 0.0337
As previously demonstrated EPA has been transcutaneously delivered when using a fish 
oil vehicle. The permeated values are slightly less than those achieved in the previous 
study; however this could be due to a difference in receptor phase or a difference in 
incubation technique. It was shown that the fish oil formulation delivered a greater dose 
of EPA than the n-3 control dose. This can be expected, as the amount of EPA present 
in the fish oil formulation is greater than that of the n-3 control dose. As more EPA was 
seen to permeate it would be logical to assume a greater mass of EPA to be incorporated 
into the cartilage. This was found to be the case.
Interestingly, it was found that several of the receptor phases changed colour during the 
investigation and this was found to correspond with decreased metabolic activity and 
ultimately the death of the viable cells of the cartilage. For this reason a number of the 
cells were discarded and the receptor phase and cartilage samples were not used for 
further analysis. Due to this low number of repeats the investigation was repeated and 
the results are shown in Section 6.4.2.
6.4.2 Transcutaneous delivery and incorporation of EPA into cartilage — 2
Repetition of the same experiment produced a greater number of replicates but differing 
results. Only a limited number of cells appeared to be unusable and fewer problems 
were encountered. The average mass of EPA that permeated the skin membrane had 
increased by approximately ten fold as seen in Table 6.3.
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Table 6.3 Average mass of EPA permeated into receptor phase
Formulation Time point Average mass of EPA (pg) ± 
S.E.M
Fish oil 48 hours 43.41 ± 5.6272
Fish oil 72 hours 66.12 ± 14.4272
n-3 control dose 48 hours 48.55 ±4.3517
n-3 control dose 72 hours 48.11 ± 10.1966
Analysis of the receptor phase has shown that after 48 hours the permeation of EPA 
from fish oil and from the control formulation is comparable. However, after 72 hours, 
the permeation of EPA from the fish oil vehicle is approximately 1.4 times that of the 
control formulation. This is probably as a result of the higher dose present in the fish 
oil formulation.
The results of the cartilage analysis, Table 6.4, indicated an approximate level of 
saturation of EPA incorporation into the cartilage of 40 -  50pg. This is consistent 
between the fish oil formulations and the n-3 control dose. A plateau of EPA 
incorporation was anticipated as the masses of the cartilage are approximately the same.
Table 6.4 Average mass of EPA incorporated within bovine cartilage ex-plants
Formulation Time point Average mass of EPA (pg) ± 
S.E.M.
Fish oil 48 hours 40.81 ±5.6620
Fish oil 72 hours 46.35 ± 4.5378
n-3 control dose 48 hours 39.58 ±5.8198
n-3 control dose 72 hours 44.08 ± 9.9862
Table 6.5 shows the average percentage of EPA incorporated into the cartilage ex-plant 
from the applied dose. These results support the saturation of the cartilage as 
demonstrated above and it would appear that the cartilage can incorporate
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approximately 2% of its mass within 72 hours. An encouraging factor is the dose that 
it is possible to incorporate within the cartilage. Curtis et al., (2002) when 
demonstrating the effects of EPA, used a concentration of EPA of between 50-70pg ml"1 
which mimics human plasma levels of free fatty acids. The levels that were 
transcutaneously delivered in these experiments fall between these levels after 72 hours 
and fall just short after 48 hours. This would not cause a problem as re-application of a 
dose would occur approximately every 12 hours. Chapter 4 demonstrates a Q48 value 
through skin into a cetrimide receptor phase of approximately 28pg cm' , which again 
would increase after multiple dosing providing that saturation is not reached.
Table 6.5 Average percentage of EPA incorporated
Formulation Time point Average % of EPA from 
applied dose
Fish oil 48 hours 0.30
Fish oil 72 hours 0.38
n-3 control dose 48 hours 0.28
n-3 control dose 72 hours 0.42
These results differ from the previous analysis which again could be due to a difference 
in incubation from previous permeation experiments. However, this does not explain 
the discrepancy seen between the two studies and suggests that the life span of the 
cartilage could be an issue.
6.4.3 Stimulation of cartilage degradation by IL-1 and determination of the effect 
of permeated EPA
The results for both the lactate and DMMB analysis proved inconclusive. They were 
expected to confirm the initial degradation of the cartilage with an increase in metabolic 
activity and an increase in the GAG release. With EPA present these values would have 
been expected to be reduced.
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Neither assay showed any difference between cartilage dosed with IL-1 and cartilage 
without IL-1 or between different formulations. In fact the results indicated a lower 
than normal metabolic activity within the cartilage indicating cartilage cell necrosis.
During the experiments it was noted that the colour of the receptor phase changed from 
red to cloudy yellow. It was concluded that this was due to a build up of waste material 
within the receptor phase and consequent change in pH which would have a debilitating 
effect on the cartilage and in this case caused cell death. This may explain the lack of 
metabolic activity seen after 72 hours. Another possible reason for this could be the 
incompatibility of the porcine skin with bovine cartilage. Enzymes leached from the 
porcine skin could contribute to the death of the bovine cartilage by being incompatible 
with the normal physiological function of the cartilage cells as these cells need optimum 
sterile conditions in which to stay alive.
6.4.4 Dialysis membrane
To determine if the porcine skin was having an effect upon the bovine cartilage a 
dialysis membrane was used in place of the porcine skin. This allowed permeation of 
EPA from the fish oil into the receptor medium and incorporation into cartilage without 
producing enzymes which may have been affecting the cartilage growth. Unfortunately 
no clear result could be gained from this experiment. The receptor medium once again 
appeared yellow after a short period of time. Loss of receptor fluid from the chamber 
was also apparent indicating a build up of pressure and the expulsion of fluid via the 
sampling arm of the chamber. As a result of continued negative results this area of 
work was postponed while other investigations were carried out.
As the receptor fluid changed colour when using the dialysis membrane, it would 
appear unlikely that incompatibility of the porcine skin with the bovine cartilage caused 
the necrosis. It is possible that unknown components present in the fish oil lead to the 
necrosis, but this hypothesis does not adequately explain the cartilage death seen when 
using a formulation of an EPA solution. It is thought that residual cleaning agents on 
the Franz cells (left after washing and rinsing) may be the cause, but further 
experiments are required to determine the true cause of cartilage death.
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Since this work has been carried out a similar model joint has been developed by 
Kreiselmeier et al., (2005). They investigated a diffusion chamber for the analysis of 
the diffusion of a matrix metalloproteinase inhibitor through articular cartilage. The 
work employed a modified diffusion chamber with a sample of cartilage between the 
donor and receptor chambers but no skin membrane or model synovial fluid. For the 
investigation into permeation of compounds into the joint and incorporation within 
cartilage the work carried out in this chapter demonstrates a better model for joint 
delivery.
6.5 Conclusions
Incorporation of EPA into the cell membrane of the ex-plant appears to plateau after 48 
hours but can be expected due to size limitations of the cartilage ex-plants and the 
unexplained necrosis of the cartilage during the experiment.
A novel system has been developed to determine uptake of free fatty acids into cartilage 
and has been used to prove EPA can be delivered transcutaneously via a fish oil vehicle. 
This EPA can then diffuse through a model synovial fluid and be incorporated into 
bovine cartilage ex-plants within approximately 48 - 72 hours and these concentrations 
were almost equivalent to test conditions where the anti-inflammatory effects of EPA 
have been investigated. Sample time points before 48 hours and after 72 hours could 
elucidate more information on the saturation of the ex-plant with EPA and also indicate 
a life span of the cartilage under these conditions. This “model joint” system could then 
be used to further study other formulations containing fish oil.
The results of this chapter in combination with Chapters 4 and 5 demonstrate the 
efficacy of a fish oil / ketoprofen topical formulation. It has been proven that both EPA 
and ketoprofen can permeate through the SC, epidermis and dermis and then permeate 
through the joint capsule (comprising of fibrous joint capsule and inner synovium 
lining) and into synovial fluid. Under the right conditions the EPA can then become 
incorporated into cartilage ex-plants. Under in-vivo conditions all of these actions 
would occur sequentially and the route of EPA and ketoprofen would be a lot more 
arduous. However repeated dosing of the compounds would allow a constant supply to 
the inflamed tissues and make a significant difference in joint pain and inflammation 
associated with RA and OA.
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Chapter 7 Metabolism o f fish oil within full thickness porcine skin
7.1 Introduction
The transcutaneous delivery of EPA and ketoprofen from a fish oil vehicle was 
demonstrated in Chapter 3, where the data also seemed to indicate that an inter­
relationship existed between the permeation of EPA and ketoprofen. Ketoprofen 
permeation was shown to be enhanced by EPA in Chapter 4, but it was difficult to 
explain the enhancement of EPA by ketoprofen using regular skin permeation theory. It 
was thought that epidermal metabolism or inhibition of such metabolism may go some 
way to rationalize the data.
The fate of polyunsaturated fatty acids following topical application to the skin has been 
discussed in several papers and is summarised in Williams and Barry, (2004). The 
general consensus is that the fatty acids become incorporated within keratinocytes and 
are subsequently converted to ceramide derivatives (Nugteren et al., 1995). 
Incorporation of EPA into cells plays an important role in inflammation as the 
replacement of AA results in a decrease in inflammatory mediators, as described in 
Chapter 1. One study showed that after 6 weeks of ingestion of 3.6g EPA daily, a 
decrease of AA composition of neutrophil membranes of 33% was induced 
(Simopoulos, 2002). This incorporation would also be expected to occur in 
keratinocytes.
However, the fact that EPA has been demonstrated to traverse skin intact (Thomas and 
Heard, 2004) indicates intercellular permeation occurs such that incorporation of the 
applied dose into keratinocyte membranes does not exclusively take place.
Fatty acids when used as penetration enhancers have been shown to pool in the stratum 
comeum and even form discrete lipid domains within bilayer lipids in the SC (Tanojo et 
al., 1997). From these pools within the SC it is plausible that the fatty acids could cause 
saturation of enzymatic pathways as opposed to a small constant supply which the 
metabolic processes can deal with efficiently. However, with high local bioavailability
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of EPA it is probable that metabolism takes place to a certain degree possibly to an 
initial saturation limit before the production of further catabolic enzymes.
It has been proposed that, from oral doses, EPA is metabolised within the skin via 
epidermal 15-lipoxygenase to its monohydroxy lated metabolite, namely 15- 
hydroxyeicosapentaenoic acid (15-HEPE) (Miller and Ziboh, 1988). It has also been 
reported that these metabolites accumulate in the epidermis of guinea pigs after 
ingestion of fish oil ethyl esters (Miller et al., 1991). 15-HEPE is also a non-potent 
inflammatory mediator with the ability to actively compete with AA and thus inhibit the 
production of the 2-series prostaglandins and the 4-series leukotrienes via the COX and 
LOX pathways. Interestingly, it was found that the 15-HEPE is more potent than EPA 
at inhibiting cellular growth and AA metabolism in human prostatic cancer cells in 
culture (Vang and Ziboh, 2005). It is for this reason that 15-HEPE has been studied, as 
converted esters or ceramide derivatives have little or no benefit in the eicosanoid 
cascade.
The co-permeation of molecules across skin is a recently probed phenomenon and the 
effect on metabolism exerted by a co-permeant has had little examination. With EPA 
and ketoprofen acting on the COX enzymes, whether the two actives will act 
synergistically or competitively with relation to COX in the skin and the extent to which 
one would enhance or retard the metabolism or function of the other was unknown. If 
an EPA-ketoprofen complex co-permeates then this also may play a part in the 
utilization of the two compounds.
To investigate the metabolism of compounds within the skin it is a vital pre-requisite 
that the skin be as fresh and as metabolically active as an in-vivo experiment would 
allow. The viability of the skin for the duration of normal skin permeation experiments 
has been investigated using a range of different receptor phases. Haberland et al., 
(2005) found that when using minimum essential medium Eagle (MEME) 
supplemented with PBS + 0.1% glucose as receptor fluids, the viability of the skin 
equivalents used, compared to keratinocyte medium, was reduced by 10-50%. The 
viability of the skin is paramount when investigating the metabolism or breakdown of
101
Chapter 7 Metabolism offish oil within full thickness porcine shin
the drug / compound of interest. This issue is also of major importance when delivering 
co-drugs via the transdermal pathway as the co-drug requires metabolism to release the 
active compound locally or systemically. It is important, when designing such 
investigation, either into the metabolism of a drug or delivery of a co-drug, to ascertain 
whether the enzyme activity within freshly excised skin, using a non growth media 
receptor phase, is equivalent to the activity profile of growth media sustained skin. The 
simplest way of providing the growth media to the skin is utilising the growth media as 
the receptor phase solution in a normal Franz cell permeation experiment.
This chapter describes the investigation into the metabolism of EPA by 15-LOX as it 
permeates through the skin from a fish oil vehicle. The effect of the incorporation of 
ketoprofen into the formulation on the permeation and conversion of EPA to its 15- 
LOX metabolite is also examined, to observe if ketoprofen modifies 15-LOX 
metabolism in any way and to try and explain the increased permeation of EPA seen 
previously when incorporated within the same formulation. Additionally this 
metabolism will be examined when using both growth media sustained skin (GMS) and 
a non growth media (NGM) receptor phase solution, cetrimide. In this case the relative 
metabolite production will be an indication of the viability of the skin under the 
different conditions.
7.2 Materials
Fish oil capsules lOOOmg (Boots Super Strength, batch number: 30446M) were 
purchased from a local store. Ketoprofen, butylated hydroxyanisole (BHA) and 
cetrimide BP were obtained from Sigma -  Aldrich Company Ltd., Poole, UK. High 
vacuum grease was from Dow Coming, Barry, UK. Methanol (HPLC grade) was 
obtained from Fisher Chemicals, Loughborough, UK. All other reagents were of 
analytical grade or equivalent. D-Squame® Stripping Discs were obtained from 
CuDerm Corporation, Dallas, Texas. Freshly excised pig ears were obtained from a 
local abattoir prior to steam cleaning, cleaned under running water and the hair removed 
using electric clippers. The time interval between slaughter and commencement of 
experimentation was approximately 1 hour. Full thickness skin was then removed from
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the dorsal side of the ear, cut into approximately 2cm x 2cm sections and used within 
two hours of excision.
7.3 Preliminary investigation into the metabolism of fish oil in full 
thickness porcine skin
A simple preliminary study was carried out to demonstrate that fish oil was metabolised 
in porcine skin following topical delivery. Fresh full thickness pig skin was prepared as 
described in Section 7.2, cut into approximately 3mm squares, placed in a screw top 
glass vial and ground for 30 seconds with a glass rod. After application of dose (see 
Table 7.1), the skin was again ground for a further 30 seconds and the glass vial sealed 
and placed in temperature-regulated oven at 37°C for 24 hours. The samples were then 
removed and stored at -20°C until needed. Each sample was prepared in duplicate. 
The samples containing cetrimide solution were freeze dried and then all samples were 
derivatised as per FAME method.
Analysis of the FAME'S was carried out as Section 2.2.2.1.
Table 7.1 Metabolism sample preparations
Sample name Skin Fish oil1 Cetrimide2
Fish oil and skin 2cm x 2cm lOpl X
Fish oil, cetrimide, skin 2cm x 2cm lOpl 3 ml
Fish oil X lOpl X
Fish oil and cetrimide X lOpl 3 ml
Skin 2cm x 2cm X X
Skin and cetrimide 2cm x 2cm X 3 ml
1 1 Ojul fish oil equates to approximately lOmg. This in turn equates to 3.3mg EPA and
2.1 mg DHA using values quoted by Boots pic.
3ml was used to mimic the conditions during a skin permeation experiment i.e. the 
average volume of receptor phase is 3ml.
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7.4 Depth profile analysis of EPA and ketoprofen
7.4.1 Preparation of formulations
A fixed sub-saturated dose of ketoprofen (2.5% w/w) was used in each formulation as 
described in previous chapters. The appropriate masses of ketoprofen and fish oil were 
combined, in addition to BHA (0.05% w/w) to inhibit PUFA degradation, and the 
formulation vortex mixed. The formulations were stored at 2-4°C until required (< 24 
hours).
7.4.2 Receptor phase
Two different receptor phases were used during these experiments to determine the 
viability of porcine skin with and without the presence of growth media. In this case 
Hepes modified Hanks buffer solution (HHBSS) was the growth medium of choice as 
its use is well established. HHBSS was used as its use has been well documented in 
prolonging the viability of skin post excision (Mukhtar, 1992). HHBSS was prepared 
by the addition of 25 pM of HEPES and 50pg/ml of gentamicin sulphate to Hanks buffer 
solution, prepared as per manufacturers instructions. Degassed 30 mg ml-1 cetrimide 
solution was the second receptor phase solution utilised.
7.4.3 Depth profiling
Skin permeation experiments were carried out using glass Franz-type diffusion cells 
(see Chapter 2, Section 2.1) with the donor chambers of the cells dosed with either 1ml 
(approximately 0.8g) or 30pi (approximately 30mg) of each formulation +/- ketoprofen. 
The 30pl doses were applied to the skin then massaged into the skin ten times using a 
circular motion of a glass rod. A total of six replicates were carried out for each 
formulation. Samples were stored at -20°C prior to analysis. The skin was removed 
from the cell and excess formulation was removed from the top of the skin prior to tape 
stripping as detailed in Chapter 2 section 2.6.1.
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7.5 Analytical Methods
7.5.1 HPLC analysis
An aliquot of extraction fluid was taken from each vial and EPA, 15-HEPE and 
ketoprofen were assayed as Chapter 2, Section 2.2.3, 2.3 and 2.4 respectively.
7.5.2 Data analysis
HPLC area data was used to determine the concentration (pg cm' ) of compound and 
this data was plotted against tape strip number.
Statistical analyses were carried out using Instat 3 for Macintosh (GraphPad Software, 
Inc), where non-parametric Mann-Whitney tests were employed to determine 
differences between specific pairs of formulations.
7.6 Results and Discussion
7.6.1 Preliminary study
Table 7.2 shows the average mass of both EPA and DHA following incubation under 
different conditions. Following incubation with skin the levels of EPA and DHA 
detectable were markedly reduced, by up to approximately 0.5mg, demonstrating that 
fish oil permeating porcine skin is susceptible to metabolism and or cell incorporation.
Table 7.2 Average EPA and DHA content from skin metabolism study
Sample Average EPA content 
(mg)
Average DHA content 
(mg)
Fish oil and skin 1.066 0.979
Fish oil, cetrimide, skin 1.070 0.944
Fish oil 1.686 1.648
Fish oil and cetrimide 1.570 1.493
Skin not detected not detected
Skin and cetrimide not detected not detected
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7.6.2 Depth profile analysis of EPA -  cetrimide receptor phase
The depth profile analysis for EPA using freshly excised porcine skin and the cetrimide 
receptor phase (non growth media (NGM)) is seen in Figure 7.1. Typical profiles were 
produced, whereby the amounts of EPA localised diminished with increasing depth 
(Heard et al 2003b). The profile shows the mass cm' (± S.E.M) extracted from the 
groups of tape strips 1 - 3 0  and the remaining heat separated epidermis and dermis of 
the skin section.
It must be noted that no 15-HEPE was detected, suggesting either that the skin had 
ceased to be viable before the experiment or the cetrimide receptor phase solution was 
adversely affecting metabolic processes within the skin. The results show a slight 
difference in permeation of the formulations containing ketoprofen and those which do 
not. A lower concentration of EPA can be expected when ketoprofen is present as there 
is 2.5% less EPA in the applied dose. The difference in the 30pl dose and 1ml dose is 
as expected, in that the 1ml dose shows significantly greater permeation (p=0.0387). 
This is a common feature of finite versus infinite dosing. However the presence of 
ketoprofen in the formulation in the 30pl dose enhances the permeation of EPA through 
the skin to the lower levels of the epidermis compared to that of the formulation 
containing no ketoprofen, as illustrated by the increased concentration of EPA in strips 
10 to the epidermis. This enhancement, however, is deemed not significant (p=0.5899).
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Figure 7.1 Comparison o f NGM samples (n=6 ± s.e .m .)
A clearer comparison of doses can be made when examining the percentage of the 
applied dose that permeated (see Figure 7.2). This takes into account the presence and 
the true effect of the ketoprofen upon the permeation of EPA.
11 ml +2.5% Keto NGM B 30ul + 2.5% Keto NGM
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Figure 7.2 Percentage of applied dose comparison o f  NGM samples (n=6 ± s.e.m.)
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When considering percentage values, it can be seen that proportionately more EPA 
localised from the 30pl dose containing ketoprofen than from the 1ml dose containing 
ketoprofen equating to an average of 0.6% of the applied dose. This may be related to 
the massaging protocol employed when applying the 30pl dose. Massaging enhances 
the uptake into skin, possibly assisted by mechanical erosion of the SC.
7.6.3 Depth profile analysis of EPA -  Growth media sustained skin
The results using the GMS skin show that there was no significant difference (p>0.10) 
between any of the doses (see Figure 7.3). There was however an overall reduction in 
the concentration of EPA detected. A direct comparison between the GMS and NGM 
samples, indicated that the amounts of EPA differed by up to 200pg cm' in the 1ml 
infinite doses compared to the same dose with the NGM samples, producing a 
difference of 0.05 - 0.1% of the applied dose thus indicating a significant breakdown of 
EPA during the permeation process. This is thought to be due to the greater metabolic 
activity in the skin as an effect of growth media sustaining the skin, as the other aspects 
of the experiment were identical.
The formulation which exhibited the greatest permeation was the infinite dose 
containing ketoprofen. This is to be expected as, if a ketoprofen-EPA complex exists, 
this would affect the metabolism of EPA by the LOX enzymes including, as in this case, 
the 15-LOX iso-form.
There does not appear to be much difference in the concentrations of EPA in the skin 
between the other formulations or doses. This could be due to a saturation of the LOX 
metabolic pathway of EPA, perhaps even at a 30|il dose. Once again a clearer trend can 
be seen when the percentage of the applied dose is compared. (Figure 7.4)
108
Chapter 7 Metabolism of fish oil within full thickness porcine skin
■ Wctee+GMS ■30Jd3e+GMS °  1ni+296ket>+GMS □ 30d+23fcketHGMS
60 - -
40 --
m m  I J  M m m u  m h,jirhlj Ihlii^
StjBlt>3 Stps4t>6 Stps7t>9 StpsKto Stps13t> Stps16t> Stjps19t> Stps22t> Stps25t> StiB28t> Epcfemis Demis
Tapestrpno.
Figure 7.3 Comparison of GMS skin sam ples (n=6 ± s.e.m.)
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Figure 7.4 Percentage o f applied dose comparison of GM S samples (n=6 ± s.e.m.)
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7.6.4 Depth profile analysis of ketoprofen
The depth profiles for ketoprofen in all doses are compared below in Table 7.3. The 
majority of the ketoprofen is found in the dermis of all samples after 24 hours of 
permeation (highlighted). It is clear that the greatest concentration of ketoprofen is 
present when a 1ml dose is used with the NGM cetrimide receptor phase solution. The 
GMS samples show a vastly reduced concentration of ketoprofen in remaining 
epidermis and dermis, indicating its utilization within the skin either from an EPA- 
ketoprofen complex or in its role as an inhibitor of COX enzymes.
Table 7.3 Depth profile of ketoprofen in all samples
------------------------------------------------------------------  -------
Concentration (pg cm ')
1ml GMS 30ul GMS 1ml NGM 30ul NGM
Strips 1 to 3 9.81 9.04 22.42 3.25
Strips 4 to 6 2.97 2.28 6.10 1.27
Strips 7 to 9 2.25 1.61 4.09 1.01
Strips 10 to 12 2.00 1.44 3.15 0.85
Strips 13 to 15 1.66 1.20 2.24 0.73
Strips 16 to 18 2.00 0.70 1.86 0.57
Strips 19 to 21 1.61 0.52 1.95 0.47
Strips 22 to 24 1.71 0.51 1.63 0.46
Strips 25 to 27 1.74 0.67 1.87 0.53
Strips 28 to 30 1.33 0.50 1.42 0.31
Epidermis 3.60 2.66 42.96 8.24
Dermis 29.83 26.21 206.16 28.57
Figure 7.5 shows the molar ratios of EPA:ketoprofen as a function of depth within the 
skin. The average molar ratios for 1ml GMS, 30pl GMS and 1ml NGM samples was 
approximately 10:1. This increases sharply in the 30pl NGM sample to approximately 
34:1. This may be due to the readiness and ease of permeation through less 
metabolically active skin to the dermis, leaving a greater proportion of EPA in the 
epidermal layers. The molar ratio of EPA:ketoprofen within the formulation was 
approximately 6:1 which is less than that found within the skin. This may be due to the 
metabolism of the fish oil triacylglycerols to free fatty acids possibly allowing greater 
association.
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Figure 7.5 Molar ratios o f EPA:ketoprofen as a function of depth 
7.6.5 Analysis of 15-HEPE -  Growth media sustained skin
Unlike with NGM, Figure 7.6 shows that 15-HEPE was being generated in the skin 
when GMS was used as receptor phase. This suggests:
1. The skin was indeed viable during the experiment
2. The cetrimide receptor phase may have had an adverse affect upon the skin in 
the NGM samples.
The presence of this metabolite is itself indicative of a high metabolic activity within 
the GMS skin samples. The distribution of 15-HEPE is consistent with the hypothesis 
that the presence of ketoprofen is one reason for the increased permeation of EPA, i.e. 
as a consequence of forming a permeation complex and thus inhibiting the metabolism 
of EPA by 15-LOX.
As expected the greatest formation of 15-HEPE was seen with 1ml of fish oil. The 
change to a finite dose resulted in less metabolite being produced, again as expected. 
The addition of ketoprofen into the formulation resulted in an even lower concentration 
of metabolite being produced. As only ketoprofen, fish oil and BHA (fixed at 0.05%
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w/w) were present, this reduction in metabolism of EPA from fish oil must have been 
due to the ketoprofen as BHA was present in all formulations. The slight increase in the 
overall production of 15-HEPE as the tape strip number increased was due to the 
proximity of the EPA to the highly metabolically active basal layer of the epidermis. It 
also appears that there was a reservoir effect in the remainder of the epidermis after strip 
number 30 and a higher proportion within the dermis, implying that permeation of 15- 
HEPE through the epidermis into the dermis occurred. It is possible that some 
metabolite was generated in the dermis, although it is more likely that 15-HEPE was 
accumulating at the skin / receptor phase interface.
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Figure 7.6 Concentration of 15-HEPE as a function o f depth (n=6 ± s.e.m.)
The production of 15-HEPE was clearly dependent on the concentration of EPA within 
the skin. Figure 7.7 illustrates the concentration of 15-HEPE as a percentage of the 
EPA present at that particular point within the skin. It is, in effect, the percentage of 
EPA converted to 15-HEPE at that point within the skin. The shape of the profile 
corresponds well with the activity of the layers of the epidermis. A greater conversion 
of EPA to 15-HEPE is seen as the proximity to the highly metabolic basal layer of the 
skin is increased. The presence of ketoprofen was also seen to exhibit an inhibitory 
effect upon the metabolism of EPA to 15-HEPE up to the remainder of the epidermis
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and the dermis. This difference between the upper layers of the epidermis and 
remainder of the skin may be explained by the permeation and accumulation of 15- 
HEPE within the lower layers of the skin. The inhibited permeation of 15-HEPE into 
the receptor phase may result in a reservoir of the compound within the dermis and 
remaining epidermis. However, the action of ketoprofen in the metabolically active 
layers of the epidermis is significant, especially when comparing infinite doses of the 
formulation. As ketoprofen is known to act on the COX enzymes and not LOX this is a 
surprising inference when considering the reduction seen in concentration of LOX 
produced 15-HEPE. It is likely that some degree of complexation takes place between 
EPA and ketoprofen leading to less free EPA available to be metabolised. 15-HEPE 
does not account for all the metabolised EPA however as other catabolic enzymes such 
as COX are present and will also be metabolising EPA.
Also evident during the permeation process is a plateau of metabolism. After the first 
three strips the values for both infinite and finite formulations, + ketoprofen and the 
formulations -ketoprofen, appear to have become similar and not significantly different 
(p>0.10 in all comparisons) indicating a metabolic saturation level within the skin. 
Once reached, the permeation of EPA exceeds the metabolism and a constant 
concentration of metabolite and EPA is seen. Such flooding of the particular metabolic 
pathway, COX or LOX, permits the permeation of further molecules of EPA in an 
unconverted state. The concentration of ketoprofen present in the formulations plays an 
important role in flooding the COX pathway, as if the pathway is competitively 
inhibited by ketoprofen, this creates the opportunity for EPA permeation.
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Figure 7.7 Concentration o f 15-HEPE as a percentage o f EPA at specific depth (± s.e.m.)
It is not appropriate to compare finite and infinite dosing, as the thermodynamic effects 
are different, introducing an extra factor in permeation and leading to iniquitous 
comparisons being made. Figure 7.8 shows the comparison of the 1ml doses of both 
formulations with both receptor phase solutions.
Both NGM results show an increased percentage of EPA. It is evident that the presence 
of ketoprofen is having an effect on the permeation of EPA, be it in the GMS samples 
as explained or in the NGM samples. This alludes to the possibility of another 
mechanism in operation within the formulation that enables ketoprofen to enhance the 
permeation of EPA. This phenomenon is examined in Chapters 8 and 9.
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The data from the finite doses are compared in Figure 7.9. The finite dose comparison 
shows a logical pattern of permeation. The lowest permeation was seen with the 30pl 
dose without ketoprofen with the viable, metabolically active, GMS skin. When 
ketoprofen was added inhibition of metabolism by 15-LOX was increased permitting 
more EPA to permeate unchanged. With the NGM skin, a greater concentration of EPA 
permeated as the skin was not viable. The presence of ketoprofen once again enhanced 
the permeation of EPA as in the 1ml doses.
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f
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Figure 7.9 Comparison o f percentage o f applied dose of 30pl form ulations, GMS and NGM  (± 
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7.7 C onclusions
Several conclusions can be drawn from this investigation. Firstly, it has been shown 
that metabolism within the skin (in this case via 15-LOX) is unfavourable to the 
transcutaneous permeation of EPA. The ability of ketoprofen to enhance the 
permeation of EPA through the skin does negate this to a certain degree, but it must still 
be considered when designing further EPA permeation experiments. However, 
metabolism of EPA in the transcutaneous treatment of arthritis does not detract from the 
system, as 15-HEPE has also been shown to be a highly effective anti-inflammatory.
Evident within this chapter is the importance of ketoprofen for enhanced EPA 
permeation in both growth media sustained skin and growth media absent skin. The 
data from this study has suggested a further explanation for the enhancement 
demonstrated in Chapter 4 and by Thomas and Heard, (2005). The presence of 
ketoprofen in the formulation appears to decrease the 15-LOX metabolism of EPA and 
resulting conversion to its metabolite, 15-HEPE. However, if ketoprofen is inhibiting 
the action of COX then more EPA is left in an unaltered state upon which the LOX
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enzymes can act. This should then cause an increase in 15-HEPE production, but this 
was not seen to be the case. If the metabolism of COX is hindered and the 15-LOX 
pathway becomes saturated, more EPA is left free to permeate. This would explain 
greater overall permeation but not the influence of ketoprofen on the metabolism by 15- 
LOX as seen in this chapter.
An additional explanation for the enhancing ability of ketoprofen is therefore required. 
15-LOX is just one enzyme prevalent in the epidermis and it may be the case that other 
enzymes are just as important in the metabolism of EPA. Thus the link between 
ketoprofen, enzyme pathways and transdermal permeation of EPA appears to be only 
part of the solution as even in non-viable skin ketoprofen has a beneficial enhancing 
effect.
A possible complexation between ketoprofen and EPA could go some way to 
explaining the result. This complexation could cause a drag effect by ketoprofen on 
EPA allowing greater permeation. The co-permeation of drugs and of drug / solvent 
complexes is a phenomenon currently under scrutiny (Heard et al., 2006) and this data 
could be another example of such an occurrence.
The third conclusion is that the choice of receptor phase solution in skin permeation and 
specifically skin metabolism studies is a crucial aspect when designing and carrying out 
such an experiment. As stated in Haberland et al., (2005) the slightest change of 
receptor phase constituents can have a drastic effect on the viability of the skin cells. 
This study demonstrates that cetrimide, a widely used receptor phase, is not a good 
choice for this category of work and that a growth medium should be used in the 
majority of skin diffusion experiments to try and mimic in-vivo conditions as closely as 
possible. That said, this issue must be balanced alongside the necessity to provide sink 
conditions in skin experimentation.
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8.1 Introduction
The co-permeation of compounds is a common feature of topical formulations 
containing more than one active ingredient, although the ability of one compound to 
enhance the other’s permeation has not been fully investigated. It can be hypothesised 
that drugs within a formulation are not distinct entities in discrete solvation cages and 
that some degree of complexation takes place depending on the nature of the 
compounds and solvent in question. The nature of solvation itself is the complexation 
of solvent and solute (Figure 8.1) and hydrogen bonding between molecules and water 
is the fundamental factor of water being one of the most widely used solvents for 
organic molecules.
5+
Figure 8.1 Hypothetical solvation of a polar com pound by water
The complexation that could occur between molecules within a solution would have a 
follow-on effect on the permeation of these molecules through the skin, both 
thermodynamically and physically. This is on the proviso that complete dissociation 
does not occur beforehand. The permeation enhancement of compounds by chemical 
means and by careful selection of solvents is a field that has had more attention but still 
leaves certain aspects of permeation unanswered. For example, the implicit assumption 
made by many that a drug will permeate leaving the solvent behind in the vehicle or 
stratum comeum has recently been shown to be inaccurate (Thomas and Heard, 2004; 
Heard et al., 2006). It is assumed that either the solvent would have, or should have 
evaporated if volatile enough or, the stratum comeum has been efficient enough to stop 
any further permeation into the underlying dermis. It has been shown that ethanol and 
1,8-cineole used as enhancers can permeate the skin in a dose dependent manner and 
enhance permeation of solute in a similar manner (Heard et al., 2006). Such
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considerations highlight the importance of understanding the fate of enhancers and 
solvents. Mechanisms of enhancement are often the subject of publications Williams 
and Barry, (2004), Williams et al, (2006), Yamane et al., (1995) but the fate of solvents 
and enhancers is discounted or it is assumed that the enhancer has no further effect on 
the skin or upon permeation and is “washed out” of the stratum comeum leaving the 
skin to return to its original state (Williams and Barry, 2004).
In Chapter 4, the in-vitro transcutaneous delivery of EPA and ketoprofen from a series 
of formulations containing a fixed 2.5% ketoprofen and various concentrations of the 
enhancer 1,8-cineole was examined. It was found that the dose dependent enhancement 
of ketoprofen by 1,8-cineole was not replicated with EPA. A hypothesis for this 
apparent enhancement was stated in that ketoprofen may have been preferentially 
solvated by 1,8-cineole and that the loss of solvent from the formulation 
thermodynamically aided ketoprofen permeation. The permeation of EPA was 
enhanced by the presence of ketoprofen and similarly the permeation of ketoprofen was 
enhanced by the presence of fish oil. This synergistic enhancing effect was again 
demonstrated throughout Chapter 6 leading to the proposal of an EPA / ketoprofen 
complex forming within the formulation and permeating through the dermis.
Chapter 7 discussed the inhibition of COX by ketoprofen, which could provide a 
mechanism for a greater concentration of EPA to permeate. It was shown that the 
presence of ketoprofen in a formulation increased the presence of the EPA throughout 
the skin and conversely lowered the presence of the 15-LOX metabolite of EPA, 15- 
HEPE. This suggests two main hypotheses concerning the permeation enhancement of 
EPA by ketoprofen:
1. Formation of an EPA-ketoprofen complex and corresponding drag effect of 
ketoprofen on EPA
2. Inhibition of enzymes that act upon EPA by ketoprofen resulting in the less 
demanding passage of EPA through the skin, investigated in Chapter 9
In this chapter the formation of an EPA-ketoprofen complex is investigated using NMR 
to determine complexation involving possible tc-tc interactions between EPA and the
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aromatic regions of ketoprofen. As a further insight into possible complexes, a series 
of molecular models were constructed and binding energies of these complexes were 
calculated.
8.2 Probing n - n  Interactions
8.2.1 Molecular orbitals and n-n interactions
A molecular orbital is the discrete energy and region of space around the nuclei of the 
atoms in a molecule in which an electron is found. The four prominent electron orbitals 
that can exist on individual atoms are s, p, d and f  orbitals. The shapes of these orbitals 
are shown in Figure 8.2. The number notation signifies the energy of orbital and also 
corresponds to the distance of the electron from the nucleus of the atom with 1 being the 
highest energy and closest to the atom.
1 s 2p 3d 4f
Figure 8.2 s, p, d and f  atom ic orbitals (http://en.w ikipedia.org/w iki/C hem istry)
These orbitals give rise to distinct molecular orbitals including sigma (a) and pi (7r). Of 
importance in this chapter’s work are n molecular orbitals which are commonly found 
between alkene carbons. A n orbital is a molecular orbital formed by side-by-side 
overlap of atomic p orbitals (see Figure 8.3), in which the electron density is found 
above and below the bond axis. As EPA is a polyunsaturated fatty acid, several alkene 
bonded carbons exist and similarly several n molecular orbitals.
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p orbitals overlap to  form  
a 77 bond
H3C
h 3c
Figure 8.3 n m olecular orbital form ed by ethene  
(http://wps.prenhall.com /)
Once these n molecular orbitals are formed it is possible to achieve n molecular orbital 
interactions between different molecules, i.e. two n molecular orbitals on different 
molecules interact and loosely bond.
Examination of the structures concerned in this thesis, EPA and ketoprofen, indicated 
that the complexation of the two compounds could involve 71-71 orbital interaction or 
attraction via hydrogen bonds as opposed to a reaction forming a single compound as, 
during HPLC analysis of tape strips and receptor phase solution, the appearance of a 
complex is not seen. This means the complex must disassemble relatively easily under 
HPLC conditions and indicates that a n-n / hydrogen bond interaction is likely. 
Attractive interactions between n systems represent a significant factor within biological 
systems (Heard et al., 2003). To date the main focus of such research has been the 
benzene dimer due to its ease of analysis (Harris et al., 2003). The interaction energies 
of this dimer configuration are comparable to weak hydrogen bonds at approximately 
10-15 kJ mol'1 (Harris et al., 2003). In this thesis the interactions of much bigger 
molecules are examined, namely the unsaturated regions of EPA and the aromatic 
regions of ketoprofen. The theory of similar interactions have been investigated by 
Hunter and Sanders who have published a significant work on 7c-7t interactions and 
established several rules when considering such attractions. They also illustrate how n- 
n interactions are fundamental to DNA helix formation and to the intercalation of drugs 
into a DNA helix via face to face tt stacked complexes with the aromatic DNA bases 
(Hunter and Sanderson, 1990).
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The nature of the molecular interactions involved in two structurally similar compounds 
to this work has recently been examined (Heard et al., 2005): tamoxifen, a hormonal 
treatment for oestrogen receptor positive (ER+) cancer, and GLA, an n-6 
polyunsaturated fatty acid with anti-cancer properties. From the structures of the 
illustrated compounds (Figure 8.4 and 8.5) it is apparent that there is the possibility of 
n-n orbital attraction between the aromatic moieties of ketoprofen and regions of 
unsaturation that exist in polyunsaturated fatty acids, as exemplified by Heard et al. 
(2005) when examining the addition of borage oil (a natural oil containing a high 
percentage of GLA) to tamoxifen in Miglyol 812N (a synthetic oil containing purely 
saturated fatty acids used as control). Using a similar method, *H NMR spectroscopy 
was used to probe modulation of ketoprofen aromatic proton signals in the presence of 
varying concentrations of fish oil. As this thesis involves the study of EPA from fish oil 
(a blend of different PUFAs), standards of EPA and DHA free acids, the main 
constituents of fish oil, were analysed to examine the effect of individual fatty acids.
To further elucidate if any interactions took place a series of molecular modelling 
experiments were carried out by Dr. Jamie Platts, Department of Chemistry, Cardiff 
University. These models simulate the formation of the most stable and therefore 
thermodynamically favoured complex that could be found within a given system 
between two compounds. By examination of such models the atoms within the adjacent 
molecules that are most affected by any complexation can be deduced.
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Figure 8.4 (A) y-linolenic acid, (B) tamoxifen
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(A) cis, 5 ,8 ,1 1 ,1 4 ,17-eicosapentaenoic acid (EPA), (B) ketoprofen
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8.3 Methods
Detailed methods for NMR spectral modulation are found in Chapter 2, Section 2.8. 
Ketoprofen proton assignments are illustrated in Figure 8.6 (assigned using the Spectral 
Database for Organic Compounds, (SDBS).
Figure 8.6 Structure of ketoprofen with assigned protons
Figure 8.7 is an example of the aromatic region of the ketoprofen spectrum produced 
from 2.5% ketoprofen in Miglyol 812N with the assigned protons and their relevant 
positions within the spectrum.
As the region affected by t i - t l  bonding is the aromatic region of ketoprofen, this is the 
region which has been the focus of these studies. Assignments (J) and (K) represent a 
single proton and a methyl group respectively (three equivalent protons). Neither signal 
is in the aromatic region having shifts of approximately 3.8 and 1.5ppm respectively 
and has therefore been omitted from analysis.
8.3.2 Molecular Modelling
The detailed method for the molecular modelling and binding energy calculations can 
be found in Chapter 2, Section 2.9.
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Figure 8.7 NMR spectrum of ketoprofen aromatic region showing proton assignments
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8.4 R esu lts an d  D iscussion
8.4.1 Fish oil and Miglyol Formulations
NMR spectra have been shown to be highly sensitive to local chemical environment and 
the technique has been used previously to probe n-n interactions where such processes 
are manifested as up or downfield shifts depending on the magnitude of shielding / 
deshielding modulation (Kelly et al., 2001). Figure 8.8 shows the modulation of the 
ketoprofen aromatic protons signals in the different formulations prepared in Section
8.3 and it is clear that addition of fish oil to ketoprofen in Miglyol 812N resulted in 
dose-dependent downfield chemical shifts of signals from aromatic protons on the 
ketoprofen structure. The data shown is a result of several ]H NMR experiments 
involving these compounds and the shift data, although seemingly minor, represents a 
significant, reproducible pattern.
0.008
0.003
-0.012
-0.017 Fol M:F 20:1
M:F 1:1 NtF 1:10 - h— M:F 1:20
-0.022
-0.027
Proton
Figure 8.8 Chemical shifts o f ketoprofen aromatic protons in fish oil / Miglyol formulations
From examination of the NMR spectra it would appear that the proton most susceptible 
to shift when in the presence of fish oil or Miglyol is proton (F), which are meta to the
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carbonyl group on the unsubstituted phenyl ring -  this susceptibility is logical as the 
carboxylic acid group would cause more steric and chemical hindrance to a potential 
n-ii interaction. A single EPA molecule or EPA present on a triacylglycerol would 
experience difficulty in bonding in any way to the carboxylate side whereas the free 
benzene ring, which is also likely to be in a different plane, represents a more attractive 
option for any possible interaction.
8.4.1.1 Molecular modelling of EPA triglyceride /  ketoprofen complex
Figure 8.9 shows the lowest energy geometry located for the complex of an EPA 
triglyceride with ketoprofen, which would have a molecular weight of approximately 
1163. The highlighted protons (F) are the most noticeably affected in the NMR spectra. 
This is unexpected as these protons appear to be furthest away from the triglyceride 
structure and would have the least attractive / repulsive force applied of all the 
ketoprofen protons. This complex contains a hydrogen bond between the carboxylic 
acid group of ketoprofen and a carbonyl of the triglyceride, contributing to the 
calculated binding energy of 95.4 kJmol'1. This is nearly a ten fold increase compared to 
the benzene dimer and indicates that this complex is very strongly bound and highly 
likely to form. This large binding energy and resulting stability makes it understandable 
how this complex could permeate the skin as a whole, as there is no obvious mechanism 
in the passage through the skin that could supply sufficient energy to cause dissociation. 
These results strengthen the hypothesis of permeation enhancement of EPA by 
ketoprofen stated in earlier chapters.
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Figure 8.9 EPA triglyceride / ketoprofen complex
8.4.2 EPA and Miglyol formulations
'H NMR was carried out using differing concentrations of pure EPA free fatty acid and 
dose-dependent downfield shifts were again observed (Figure 8.10). As with fish oil, 
proton (F) appeared to be most susceptible to shifting, indicating that this effect may be 
due to individual fatty acids within the fish oil.
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Figure 8.10 Chemical shifts o f ketoprofen arom atic protons in EPA / M iglyol form ulations
The main difference between the free fatty acid and the triacylglycerol appears to be the 
effect upon the (B) proton of ketoprofen. This proton lies on the opposite ring to proton 
(F), ortho- to both carbonyl and carboxylic acid groups. This difference in the shifts 
may be due to the lesser steric hindrance of the free fatty acid, allowing it to approach 
closer to ketoprofen and hence exert a greater effect on other protons, specifically (B). 
Alternatively, free EPA may be susceptible to dimerisation between pairs of carboxylate 
groups unlike in the triglyceride, which may be partly responsible for the differences in 
the spectra.
8.4.2.1 Molecular modelling o f  EPA /ketoprofen complex
The molecular modelling in Figure 8.11 once again supports the evidence of 
complexation provided by the NMR spectra. The closest protons to the EPA structure 
are protons (F) (Figure 8.11 (a)) and also highlighted are the carbon atoms most likely 
to be involved in this n-% bonding. The binding data for an EPA free fatty acid and 
ketoprofen (molecular weight approximately 556) is 157.0 kJ mol'1, a substantial 
complexation energy much greater than the triglyceride / ketoprofen complex. The
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orientation of the groups involved in this interaction is such that jr... jt stacking seems 
unlikely, and this might be better described as C—H...jr contact. Proton (B) is 
highlighted (Figure 8.11 (b)), and can be seen to be within a region of electronegativity 
where the carboxylic acid group of both ketoprofen and EPA and the carbonyl group are 
present. This could explain the difference in shift of the proton not seen with the 
triglyceride as the complex differs in shape in this area.
(a)
Figure 8.11 EPA free fatty acid / ketoprofen com plex, (a) protons (F) with likely interaction, (b) 
proton (B) in electronegative environm ent
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8.4.3 DHA and Miglyol Formulations
The formulations containing DHA and Miglyol follow a similar trend, with a large shift 
difference seen on protons (B) and (F) (Figure 8.12). DHA at a level of 6.25mg m l'1 
also effects proton (E). As DHA has an additional two carbon atoms within the alkene 
chain it is possible that they are responsible for the effect on this proton. At higher 
concentrations DHA is not able to fit as easily around the ketoprofen molecule due to 
competition for space and so the affect is not as marked.
—«— Mig DHA25 DHA 12.5 -X -  DHA 6.125
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Figure 8.12 Chemical shifts of ketoprofen aromatic protons in DHA / Miglyol formulations
As EPA has been the main focus of this thesis molecular modelling using DHA was not 
carried out.
8.4.3.1 Miglyol /  ketoprofen molecular modelling
To compare the binding energies and structures of the EPA / ketoprofen complex and 
the control formulation, the Miglyol / ketoprofen complex was also modelled, 
approximate molecular weight 764, (Figure 8.14). The binding energy for the synthetic 
triglyceride is 109.1 kJ mol"1. This also represents a high energy binding complex and
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indicates that even in the presence of such a strongly bound complex EPA as a free fatty 
acid or triglyceride can displace another compound to form a stronger complex thus 
further providing evidence of an EPA / ketoprofen complex able to permeate skin intact.
Figure 8.14 Miglyol / ketoprofen complex
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8.5 Conclusions
It is clear that the ketoprofen !H NMR shifts are distinctly different in the presence of 
fish oil and Miglyol. Also clear is the difference between the test and the control media, 
containing no unsaturated moieties. Furthermore, the same general pattern of shifts is 
observed when pure EPA and DHA were used in place of fish oil.
The binding energies of the complexes are also indicative of a strongly bound complex 
that could possibly endure the rigours of permeation through the skin. The 
enhancement of EPA by ketoprofen can also be attributed to the complexation process. 
It was seen in Chapter 4 that very little EPA permeated from a fish oil vehicle alone, 
underpinning the need for ketoprofen in the formulation. The results explain these 
findings and those of Chapter 7. If the complex forms within the formulation then a 
dual enhancing effect could be at work. The lipophilic EPA triglyceride / fatty acid 
permeates the lipophilic SC taking the more hydrophilic ketoprofen with it. Then in the 
more hydrophilic layers of the viable epidermis and dermis the reverse occurs. 
Ketoprofen permeates taking its n bound EPA with it. The Log P values for the 
complexes could not be determined, however if calculated, they could indicate a further 
explanation for the synergistic enhancement as well as the likely form of the complex 
that is able to permeate the skin.
It appears that the molecular weights of the complexes have no significant effect upon 
their binding energies and but it is the unsaturation of the EPA chains that has the over­
riding effect, again supporting the notion of bonding by a n-n / C-H....7C interaction. 
The binding energy of tamoxifen and GLA has also been found to be considerably 
greater than the benzene dimer structure at 91.2kJ mol'1. This binding energy is also 
considerable and has implications in for further work using these two compounds.
The possibility of the complex permeating the skin intact has been shown by the 
magnitude of the binding energies of the complexes. However, interactions with fatty 
acids and other molecules in the skin are likely but these interactions must be studied to 
determine their individual binding energies and to determine whether these possible
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complex energies are stronger than those of the EPA / ketoprofen complex. The issue 
of the complex dissociating when in contact with epidermal enzymes is investigated and 
discussed in detail in Chapter 9.
In summary, the geometries of these complexes show strong O—H ...0  hydrogen bonds 
in all cases, and in the case of ketoprofen complex with free EPA there is also some 
evidence of C—H. . .7T and/or n - n interactions, giving rise to regiospecifically solvated 
complexes. Permeation of these intact complexes across skin could, at least in part, 
account for increased permeation reported for mixtures of ketoprofen with fish oils, 
EPA or DHA.
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Probing the phenomenon of 
permeation enhancement of fish 
oil/EPA by ketoprofen
in. Influence of fish oil /  ketoprofen 
on epidermal COX-2 and LOX
Chapter 9 Influence o f fish oil /  ketoprofen on epidermal COX-2 and LOX
9.1 Immunocytochemistry (ICC) of epidermal COX-2 and LOX enzymes
The epidermis is the main site for metabolism and chemical conversion processes when 
considering the permeation of drugs / molecules through the skin. Once the barrier of the 
SC has been overcome permeating molecules then encounter the epidermal enzymatic 
systems. Most phase 1 and phase 2 reactions, including oxidation, hydrolysis and 
methylation can occur within the epidermis, though discussed in Williams, (2003) at a level 
of less than 10% of the liver. Inflammatory processes such as psoriasis and psoriatic 
arthritis require and are propagated by the same enzymes involved in other arthritic 
conditions, namely COX-2 and 5-LOX. This provides a good model for arthritic conditions 
in deeper tissue as well as indicating the fate of the compounds as they permeate the skin.
Chapter 6 demonstrated that when using viable skin metabolism of EPA to its 15-LOX 
metabolite 15-HEPE did indeed occur. A clear pattern was also seen as the metabolism of 
EPA to 15-HEPE increased as EPA neared the basal layer. The addition of ketoprofen to 
the formulation impeded this conversion. Chapter 8 indicated that an EPA / ketoprofen 
complex is possible and this may be the reason for the decrease in metabolism. The study 
in Chapter 8 showed the relationship between EPA and ketoprofen in a formulation and 
possibly throughout permeation. The interaction of EPA and ketoprofen with the main 
inflammatory enzymes, however, was still unknown and the effect of EPA on ketoprofen 
and vice versa when in the presence of these enzymes was still unclear.
This chapter investigates the effect of EPA and ketoprofen on the COX-2 and LOX 
enzymes within porcine skin. Incorporated with the data from Chapters 7 and 8 this should 
then elucidate mechanism of EPA permeation enhancement by ketoprofen and also show 
the ability of such a formulation to inhibit these enzymes and thus indicate the efficacy of 
such a formulation.
Immunocytochemistry (ICC) is a method employed to qualitatively determine the activity 
of particular enzymes in a given system. In this case the skin will be set, cut and stained to
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show the presence and activity of COX-2 and LOX enzymes at given time points 
throughout a normal skin permeation experiment.
9.2 Methods
The method for the staining process is described in Chapter 2, Section 2.7.
9.3 Results
9.3.1 ICC analysis for COX-2
The primary antibody used for this analysis was COX-2 antibody #4842 (purchased from 
Cell Signalling Technology) which was specific for endogenous levels of total COX-2.
9.3.1.1 Analysis of formulation containing 2.5% ketoprofen
Figure 9.1 illustrates the staining seen at the specified time-points. It is very clear that the 
presence of a ketoprofen and EPA formulation dramatically reduced the stain at all time- 
points. This is indicative of a large reduction in the COX-2 enzyme present in the skin. 
(A) is the control sample where no formulation had been applied. The darkness of the 
epidermis is in stark contrast to the lower dermis which is almost transparent due to the 
lack of metabolically and enzymatically active cells. The small amount of staining in the 
epidermis is to be expected as the skin had recently been removed from the ear and small 
amounts of COX-2 have already been expressed in response to trauma.
At 8 hours the skin with no formulation applied (B) shows heavy staining, especially in the 
more biologically active basal layer of the epidermis. After removal of the skin from the 
ear it is apparent that an inflammatory response had been triggered. The damage to the skin 
upon removal from the ear would initiate this inflammatory response with the production of 
cytokines and COX-2 and eventually the metabolism of AA to continue the inflammatory 
cascade. The stratum comeum is labelled.
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It can be seen in (D) that 8 hours after administration of the formulation the staining is 
significantly less than the control. It also appears to be less than the 0 hour control 
indicating a substantial inhibition o f COX-2. The formulation is likely to be acting in two 
ways; inhibition of the induced COX-2 by ketoprofen, followed by a down regulation of 
inflammatory cytokines caused by the increase in ratio of anti-inflammatory to pro- 
inflammatory mediators as a result of COX-2 metabolism of EPA instead of endogenous 
AA. The active basal layer also appears to be subdued in its COX-2 production suggesting 
the rapid permeation of ketoprofen through the rest of the epidermis.
After 24 hours (C) the COX-2 production would seem to have reached a maximum as the 
stain throughout die epidermis is of an equal distribution. The top layers of the epidermis 
appear to be the darker regions of the skin. This could be due to the progression and 
accumulation of active COX-2 generated by the lower layers of die epidermis, through to 
the upper stratum spinosum and stratum granulosum.
Even after 24 hours the staining seen after formulation application (E) is noticeably 
reduced, compared to die equivalent control sample (C). Some staining can be seen in the 
top layers of the epidermis. After 24 hours the skin is likely to be nearing a necrotic state 
and a slight darkening of the stain, compared to control, is to be expected. The difference 
between the test and control confirms just how extensively ketoprofen and EPA inhibit and 
even cause a decrease in the induction of COX-2 enzymes. The considerable effect seen by 
the formulation is also an indication of what would occur after transcutaneous permeation 
through to the joint synovium and then within the synovial fluid. If this effect is repeated 
within these tissues, the benefit of such a formulation is self-evident.
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Figure 9.1 COX-2 staining from a formulation containing 2.5% ketoprofen w/w in a fish oil vehicle. (A) 0 hour control, (B) 8 hour control, (C) 24 
hour control, (D) 8 hour test sample, (E) 24 hour test sample
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9.3.1.2 COX-2 analysis o f fish oilformulation
Figure 9.2 shows the COX-2 staining for the formulation of fish oil alone. The 0 hour 
control sample (A) shows limited staining, similar to the 0 hour control of Figure 9.1. 
Again it is evident by the degree of staining that COX-2 has been induced in the short time 
post excision. The 8 hour control (B) was heavily stained compared to the 0 hour control 
(A) due to the inflammatory process occurring for 8 hours. In contrast, the 8 hour test 
sample (D) had much reduced staining compared to (B). A possible explanation is that 
EPA from the fish oil actively competed with AA, affecting COX-2 induction via its ability 
to inhibit cytokine release and COX-2 gene expression.
Samples (C) and (E) did not follow the trend seen thus far. The 24 hour control (C) showed 
a decrease in the staining due to decreased concentration of COX-2 present. The 24 test 
sample (E) is heavily stained, more so than the equivalent control sample (C). The 
decrease in the COX-2 staining seen in 24 hour control could be due to the short lifespan of 
the skin sample and after the initial peak at 8 hours the skin has become necrotic, the 
enzymes denatured and their activity and availability to interact with the antibody also 
ceased. Another cause could be the switch of inflammatory pathway to the LOX system. 
This would lead to a decrease in the production of COX-2 and in the reduced staining seen 
in the sample. The dark staining seen in the test sample (E) could be due to an increase in 
COX-2 production via the converse mechanism, inhibition of LOX enzymes causing a 
switch to the COX pathway. As EPA was limited within the skin due to other enzymatic 
processes this pathway may have become more active. When ketoprofen was present it 
was possible to inhibit the excess COX-2 produced and so explaining the difference in 
staining between ketoprofen containing and ketoprofen free formulations.
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Figure 9.2 COX-2 staining with fish oil formulation, (A) 0 hour control, (B) 8 hour control, (C) 24 hour control, (D) 8 hour test sample, (E) 24 
hour test sample
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9.3.1.3 COX-2 analysis of ketoprofen formulation
Figure 9.3 shows the test samples for 8 and 24 hours post application of a 2.5% ketoprofen 
in water solution, (A) and (B) respectively. In comparison to both the equivalent control 
samples in Figure 9.2, (B) and (C) it can be seen that the staining has been markedly 
reduced. At 24 hours post application of the ketoprofen solution the majority of the 
staining is nuclear and not in correlation with the basal layer of the epidermis. This 
suggests that the permeation of ketoprofen through the epidermis has significantly inhibited 
the proliferation of COX-2.
(A) (B)
Figure 9 3  COX-2 staining with ketoprofen solution, (A) 8 hour test sam ple, (B) 24 hour test sam ple
9.3.2 ICC analysis of LOX
The primary antibody used for this analysis was 5-lipoxygenase polyclonal antiserum 
(purchased from Cayman Chemical, USA) which had cross-reactivity for human, rat, 
murine, hamster and porcine 5-LOX, 12-LOX and 15-LOX.
1 AA
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9.3.2.1 Analysis of formulation containing 2.5% ketoprofen
The control sample shown in Figure 9.4 (A) shows a relatively high degree o f LOX present 
throughout the skin, again localised at the basal layer of the epidermis (highlighted). A 
certain concentration of LOX enzymes including 5-LOX and 15-LOX is likely to have been 
induced in response to the trauma caused by excision but the majority is likely to be due to 
endogenous enzymes. The degree of staining is due to all LOX enzymes being stained, not 
just a particular iso-form but this non-specificity is not a problem as 5-LOX is of particular 
interest due to the inflammatory connotations associated with its induction. 15-LOX is also 
of interest as this is said to be the most prevalent form of LOX within skin (Miller and 
Ziboh, 1998).
Eight hours post application of the 2.5% ketoprofen in fish oil formulation (C) the LOX 
enzymes present in the skin appear to have been inhibited relative to the 8 hour control (A). 
The degree of staining between the two 8 hour samples is very different. The EPA present 
appeared to diminish the stain of LOX either by inhibiting the staining because of its 
agonistic effect on the LOX enzyme or due to a negative feedback caused by reduced 
inflammatory mediators and cytokines. The presence of ketoprofen could have aided this 
negative feedback in its inhibition of COX. However, if a ketoprofen formulation was used 
alone, a greater degree of LOX induction would be expected to take place to compensate 
for one inflammatory pathway being inhibited. This would imply that EPA is having the 
greater effect in causing the reduction of LOX staining via its metabolism, as opposed to a 
reduction in inflammatory mediators assisted by ketoprofen. The basal layer was again the 
darkest region of staining and can be explained by the permeation rate of EPA as, after only 
8 hours, EPA would still be in short supply at this lower epidermal layer. After a further 16 
hours a difference between the test and control samples was again evident (B and D). 
Heavy staining in the control sample (B), particularly focused at the basal layer, was 
expected as, after 24 hours, the inflammatory process is in full progress. The test sample 
was slightly darker than the 8 hour test, again as expected as only EPA acts upon LOX and
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Figure 9.4 LOX staining o f formulation containing 2.5% ketoprofen w/w  
sample, (D) 24 hour test sample
in fish oil vehicle, (A) 8 hour control, (B) 24 hour control, (C) 8 hour test
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the inhibition of COX by ketoprofen and EPA would not only deplete available EPA but 
may also encourage LOX induction.
9.3.2.2 Analysis of fish oilformulation
Figure 9.5 shows the LOX staining for a fish oil formulation containing no ketoprofen. (A) 
represents the endogenous LOX enzymes present. After 8 hours (B) the staining became 
slightly darker indicating the production of LOX enzymes and was now more evident 
between the keratinocytes in the extra-cellular space. The addition of fish oil to the skin 
caused reduction in the concentration of LOX enzymes as illustrated by (D). The staining 
in (D) was comparable to that of the control section (A). It is apparent that the presence of 
fish oil, and in particular EPA from fish oil is having a marked affect upon the production 
of LOX enzymes.
After 24 hours (C) the degree of staining has increased and again evident was the dark 
staining in the basal layer of the epidermis. Post-application of a fish oil formulation (E) 
the staining was reduced. It is interesting that the staining was quite light until the basal 
layer where the staining became darker nearer the metabolically active cells. This pattern 
of staining seems to indicate the route of permeation of EPA through the skin and the 
inhibition of LOX along the way. Also of note is that the significant difference between the 
basal layer and the rest of the epidermis was not as noticeable in the equivalent time-point 
(D) in Figure 9.3. This signifies the permeation enhancement of EPA by ketoprofen 
through the epidermis to the basal layer within 24 hours: the enhancement allowed EPA to 
exert its effect on the LOX enzymes produced in the basal cells, supporting the theory of 
EPA permeation enhancement via formation of a ketoprofen / EPA complex discussed in 
Chapter 8. Once the ketoprofen-EPA complex has reached a potential site of action i.e. 
enzyme, the formation of the complex seems to have no detrimental effect upon the action 
of either EPA or ketoprofen. The ability of the EPA and ketoprofen to dissociate from this
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(A)
Figure 9.5 LOX staining with fish oil form ulation, (A) 0 hour control, (B) 8 hour control, (C) 24 hour control, (D) 8 hour test sam ple, (E) 24 hour 
test sample
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complex and act upon enzymes is a significant finding as this would need to occur 
throughout the permeation process when encountering inflammatory mediators.
9.3.2.3 LOX analysis o f ketoprofen solution
Figure 9.6 shows the 8 hour and 24 hour LOX analysis for the ketoprofen solution, (A) and 
(B) respectively. As ketoprofen was not expected to be active upon LOX the staining seen 
in both (A) and (B) can be expected. After 8 hours the intercellular space within the 
epidermis is very darkly stained and is comparable to the control (B) in Figure 9.5, 
interestingly after 24 hours the darker regions of staining are the keratinocyte nuclei. This 
suggests that after 24 hours the LOX present has permeated into the keratinocytes, possibly 
to further up-regulate its proliferation and that of other inflammatory mediators.
(A) (B)
Figure 9.6 Lox analysis for ketoprofen solution, (A) 8 hour test sam ple, (B) 24 hour test sam ple
9.4 Discussion
Examination of the data in this chapter alludes to several possible mechanisms concerning 
the possible action of EPA and ketoprofen upon inflammatory enzymes, namely COX-2
14Q
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and LOX. It has been shown that a formulation containing ketoprofen, along with fish oil 
(Figure 9.1) had a greater influence on COX-2 staining than either ketoprofen (Figure 9.3) 
or fish oil alone (Figure 9.2). A result that was expected as both compounds act as 
inhibitors of COX-2 within its active site. The synergistic action upon the overall COX-2 
staining by EPA and ketoprofen can be explained by their separate inhibitory actions. 
Ketoprofen blocks the enzyme and therefore inhibits its activity and inflammatory action. 
EPA acts as an agonist of COX-2 and so occupies the active site and prevents staining and 
also AA metabolism. EPA also utilises its ability to suppress the gene expression of COX- 
2 and so the COX-2 that would usually be expressed in such inflammatory conditions, is 
diminished resulting in reduced staining even after 24 hours.
The LOX staining was again as expected with ketoprofen (Figure 9.6) showing no effect on 
LOX staining / activity and EPA (Figure 9.5) diminishing the LOX stain up to 24 hours 
after application of formulation. With ketoprofen present the staining seen was not 
appreciably different. Within this formulation the inhibition of COX-2 by ketoprofen 
would allow a greater concentration of EPA available to inhibit LOX. This must also be 
balanced with the induction and up-regulation of the individual inflammatory pathways. If 
COX-2 inflammation is reduced it is likely that the LOX inflammatory pathway will 
compensate. EPA once again can slow this, by its inhibition of the expression of 
inflammatory cytokines and mediators which up-regulate LOX.
Chapter 8 demonstrated a strong possibility of a ketoprofen / EPA complex that may be 
strongly bound enough to permeate the skin intact. It appears that this complex does not 
stop the binding to enzymes within the skin as the presence of ketoprofen does not severely 
affect the ability of EPA to inhibit LOX. Chapter 7, however, indicates that the presence of 
ketoprofen inhibits the formation of the 15-LOX metabolite of EPA, 15-HEPE. This 
inconsistency could be explained by the difference in analysis of the chapters. The 
presence of ketoprofen was significant when quantifying 15-HEPE formation but not 
significant when qualitatively analysing the enzyme staining studying three possible LOX 
iso-forms.
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9.5 Conclusion
The anti-inflammatoiy action of a ketoprofen / EPA formulation has been demonstrated 
and the efficacy of such a treatment for inflammatory disorders has been shown. As 
ketoprofen and EPA permeate further through an inflamed joint the same inflammatory 
processes would be occurring and this chapter has shown that the formulation can 
adequately deal with such processes. The formulation has shown the ability to act on the 
two main inflammatory mediators over a period of 24 hours as it permeates the skin and 
this can be used as an inflammatory model for deeper tissues.
The formation of a ketoprofen / EPA complex appears not to interfere significantly with the 
anti-inflammatory action which is a requirement as the formulation permeates through 
inflamed tissue. This complex has been found to jointly enhance the permeation of 
ketoprofen and EPA through the skin (Chapters 3 and 4), so with the enhancement of 
permeation coupled with the apparent dissociation of the complex when required holds 
great promise for further development of the two-pronged dual action anti-arthritis therapy 
discussed in Chapter 1.
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10.1 General discussion
The objective of this thesis was to probe the development of a formulation that could 
deliver EPA (the major bioactive polyunsaturated fatty acid of fish oil) and ketoprofen, 
a non-steroidal anti-inflammatory drug transcutaneously to provide a dual action 
therapy to combat the two main mechanisms of inflammation seen in arthritic 
conditions. During this development investigations were carried out to assess the ability 
of these agents to permeate full-thickness skin and underlying tissues. The action of the 
formulation within skin during the permeation process was also investigated to 
determine if the two active compounds had an effect upon each other as they permeated.
The work showed that transcutaneous delivery of EPA and ketoprofen was possible 
although only as a basic formulation. The formulation used in Chapter 3 provided 
negligible amounts of EPA permeation across the skin; however these formulations 
contained a maximum of 20% (w/w) fish oil in a thickened gel formulation. It was 
found within this study that the presence of HPC as thickener had a retarding effect on 
the permeation of EPA from fish oil, but seemingly posed no such issues for ketoprofen. 
Chapter 3 also highlighted the permeation enhancement of ketoprofen by different 
concentrations of fish oil in the formulation. There was a direct correlation between the 
concentration of fish oil within the formulation and the permeation of ketoprofen and 
this enhancement was at first thought to occur by the disruption of the lipid bilayers 
within the SC, as previously described by Barry (1987). The un-thickened formulation 
employed in Chapter 4 used fish oil alone as the delivery vehicle for ketoprofen at 2.5% 
w/w. This was more successful as the permeation of both EPA and DHA from fish oil 
(in addition to ketoprofen) was observed. Included within these formulations were 
different concentrations of the terpene enhancer 1,8-cineole. Ketoprofen once again 
exhibited a concentration dependent increase in permeation whereas EPA and DHA 
from fish oil appeared to be impaired by its presence. In a fish oil/ ketoprofen 
formulation the presence of the fish oil seemed to enhance the permeation of ketoprofen 
compared to an aqueous control. However, an unexpected outcome from the 
permeation studies was that the presence of ketoprofen also enhanced the permeation of 
EPA and DHA from the fish oil vehicle. Perhaps most surprising is the data that
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indicated that the permeation of EPA and DHA was dependent upon the presence of 
ketoprofen within the formulation. This inference cannot be explained by conventional 
skin theory as the smaller less lipophilic ketoprofen would have been expected to 
permeate independently of the triglyceride-containing fish oil. The enhancement of 
ketoprofen by 1,8-cineole, whereas no enhancement of fish oil occurred, was explained 
by selective solvation within the formulation. As the 1,8-cineole selectively solvated 
ketoprofen, no enhancement of the permeation of EPA and DHA occurred, due to 
reasons that became clearer within Chapter 8.
Subsequent to the successful in-vitro permeation of EPA/DHA and ketoprofen through 
full thickness skin, it was demonstrated in Chapter 5 that these compounds were able to 
penetrate deeper, i.e. into the synovial fluid of a porcine joint capsule using the basic 
non-thickened formulation. In Chapter 6 a novel transcutaneous delivery model was 
developed and used to provide preliminary data for the uptake of EPA into an ex-vivo 
cartilage ex-plant post transcutaneous permeation. Unfortunately, this experiment 
didn’t provide any further information as to the efficacy of the formulation against the 
biological inflammatory response. However, Curtis et al., (2000) had proved the 
efficacy of EPA supplementation to arthritic cartilage employing treatments of a similar 
concentration to the ones found to have permeated into the receptor phase solution and 
incorporated within the cartilage ex-plant.
In summary, the early chapters (3-6) indicate that a simple ketoprofen in fish oil product 
could be beneficial for the treatment of arthritic conditions. When considered together, 
these in-vitro experiments have shown the formulation has the potential to deliver EPA 
and ketoprofen through the (whole) skin, the joint capsule and potentially taken up by 
joint cartilage. The prime factor that remains to be considered is dermal clearance from 
the skin into the systemic circulation. This could reduce the amounts of compound 
ultimately bioavailable to the cartilage, although of the proportion of compounds in the 
system following ‘inadvertent’ transdermal permeation a certain amount would be 
delivered to the capsule.
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A major outcome of the skin permeation data was the apparent enhancement of fish oil / 
EPA permeation by ketoprofen. Chapters 7, 8 and 9 can be considered as a collective 
investigation into this phenomenon and the two main hypotheses concerned firstly, the 
formation of a Ji-Jt ketoprofen / EPA complex -  the existence of which was strongly 
supported by the NMR/molecular modelling work of Chapter 8. Secondly, the 
ketoprofen inhibition of epidermal enzymes active upon EPA as discussed in Chapter 7 
and 9.
During the work it was found that both theories were plausible. Chapter 7 demonstrated 
that the presence of ketoprofen in both media sustained skin and skin with no growth 
media enhanced the permeation of EPA through the skin. This was thought in part to be 
due the inhibition of epidermal COX by the ketoprofen. Both EPA and ketoprofen act 
upon these enzymes and so if ketoprofen preferentially binds with COX then this leaves 
more EPA un-metabolised and free to permeate. It was also discovered that ketoprofen 
caused a decrease in the production of 15-HEPE, the 15-LOX metabolite of EPA. As 
ketoprofen does not act upon LOX enzymes another mechanism must be in action. The 
possible complexation of EPA with ketoprofen was then investigated in Chapter 8. The 
modulation of ketoprofen lH NMR spectra from different formulations containing 
varying concentrations of fish oil and a control saturated triglyceride enabled the 
hypothesis of the existence of a possible complex. Molecular modelling of the systems 
(the different formulations) discovered that complexes of considerable binding energies 
could indeed form. If this was the case then the previous results seen concerning the 
permeation enhancement of EPA by ketoprofen could be attributed to this complex. 
Once the complex is formed the triglyceride / free fatty acid could aid the permeation of 
its associated ketoprofen into the lipophilic SC via the drag effect. Once permeated the 
more hydrophilic ketoprofen could aid the permeation of the triglyceride / free fatty acid 
through the epidermis again via the drag effect. This could explain the synergistic 
permeation enhancement seen with these compounds. The formation of this complex 
however did not appear to reduce the effect the compounds can have upon inflammatory 
enzymes, as Chapter 9 demonstrated that the formulation is capable of inhibiting both 
COX-2 and LOX enzymes within the skin (either the complexes dissociate in situ, or
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bind to the binding sites intact). Such inhibition would also be seen throughout the 
inflamed tissue as the formulation permeates.
10.2 Future work
The development of a commercial formulation has been firmly supported by the data in 
this thesis. It may be possible to enhance the permeation of both ketoprofen and EPA 
via formulation modulation although the amount of fish oil within the formulation 
would need to be high -  however the optimum (target) dose within the joint capsule 
needs to be established. When considering a formulation the issue of odour arising 
from the use of fish oil must also be considered. The use of 1,8-cineole was found to 
have an odour masking effect however the effect on the permeation was not favourable. 
The ideal would involve a permeation enhancer which works for both EPA and 
ketoprofen with dual role of odour masking. The use of thickeners in any formulation 
would also need to be addressed as the use of HPC, a well recognised thickener in 
pharmaceutical formulations proved to retard the permeation of EPA.
In-vivo work on animals (e.g. arthritic rat) could also be undertaken to determine the 
efficacy of the formulation with an arthritic model. Ultimately, any clinical benefit 
would need to be established via an appropriate clinical trial.
10.3 Concluding remarks
The hypothesis that a novel dual-action, transcutaneous anti-arthritic formulation can be 
developed has been achieved. All major stages of the delivery into a joint have been 
investigated and at each stage the formulations have indicated success in its purpose. 
The theory of vehicle-drug complexation has also been developed with strong evidence 
that complexation and synergistic permeation enhancement can take place between the 
two actives, which may have major ramifications for currently accepted wisdom in the 
field of topical drug delivery.
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